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Abstract 
 
Pharmaceuticals that are intended for human use are frequently detected in the aquatic 
environment. This is predominantly from the excretion of pharmaceuticals by patients, in 
their urine and faeces, which subsequently enter sewage treatment plants. Sewage 
treatment provides a final opportunity for pharmaceutical removal, prior to discharge into 
the environment, however, removal is often incomplete. Once in the environment, 
pharmaceuticals have the potential to cause effects on aquatic organisms. Sewage 
treatment plants, that are designed to meet statutory discharge consents for nutrients, are 
increasing in number. These plants, capable of biological nutrient removal, are 
understudied for the removal efficiencies of pharmaceuticals. This thesis presents research 
findings on the behaviour, fate and removal of selected pharmaceuticals in a bespoke 
laboratory rig, and in operational biological nutrient removal sewage treatment plants.  
 
Pharmaceuticals possessing a broad range of physical and chemical properties were 
selected for this research, they included: salicylic acid, caffeine, propranolol, diclofenac 
and carbamazepine. Sensitive chromatographic methods were developed to quantify the 
analytes in a laboratory sequencing batch reactor rig and in operational plants. 
Radiolabelled 
14
C isotopes of salicylic acid, caffeine, propranolol and diclofenac were 
dosed into the laboratory rig. The compounds exhibited different behaviours during a 
simulated sewage treatment process. Salicylic acid and caffeine produced the highest 
amount of biodegradation, with 25.2% and 14.5% of the radiolabel mineralised to 
14
CO2 in 
the rig. However, parent degradation is likely to have been higher, since neither compound 
could be detected in the effluent by specific chemical analysis. These findings were 
replicated in the operational sewage treatment plants, with > 97% removal of both 
pharmaceuticals, in all three plants investigated. Propranolol and diclofenac were less 
affected by biodegradation processes, and produced 3.7% and 0.2% mineralisation, 
respectively, in the laboratory rig. Furthermore, 33.8% of the radioactivity associated to 
14
C-propranolol was detected in the rig solids. These compounds showed insignificant 
removal from two operational plants; -6.8% and 20.9% (propranolol) and -0.9% and 
-39.4% (diclofenac).  
 
Monitoring of operational plants showed that concentrations of propranolol were highest in 
the activated sludge tanks at all three sites. This supports the findings from the rig, that 
propranolol interacts with the sludge, which might be more significant in plants with lower 
sludge wastage rates, such as sequencing batch reactors. This could have implications for 
the terrestrial environment, and therefore, terrestrial risk assessments should be refined 
accordingly. Monitoring of the operational sewage treatment plants highlighted the 
widespread presence, and recalcitrant behaviour, of carbamazepine during biological 
sewage treatment. Future work should focus on investigating the mechanisms of removal, 
of this pharmaceutical in the laboratory sequencing batch reactor. This work highlighted 
the problems biological systems face in effectively removing recalcitrant pharmaceuticals. 
Advanced wastewater treatment should be considered, if complete removal is desired.  
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1.1 Pharmaceutical consumption 
Pharmaceuticals are natural or manufactured products containing active ingredients that are 
intended to prevent, diagnose, or treat health problems in humans and animals 
(Wennmalm, 2011). As a class, pharmaceuticals possess characteristics that make them 
different to conventional industrial pollutants (Cunningham, 2008). These attributes 
include a typically large and chemically complex structure, containing multiple ionisation 
sites spread throughout the molecule (Cunningham, 2008). They cannot be categorised as a 
homogenous group of compounds, since they vary widely in properties, such as molecular 
weight, structure, functionality, salt forms and polymorphs (Cunningham, 2008). 
Additionally, their entry into the environment is usually subsequent to metabolism in the 
body (Daughton and Ternes, 1999).  
 
1.1.1 Human pharmaceutical consumption in the UK 
The consumption of active pharmaceutical ingredients (APIs) for medicinal uses in 
industrialised countries is estimated to be between 50 and 150 g per person per year (Watts 
et al., 2007), with less than 50 compounds making up 95% of total API consumption 
(Ternes and Joss, 2006). In 2004 there were approximately 3,000 pharmaceuticals 
registered for use in the UK. Consumption patterns tend to vary between different 
countries and over time, depending on regulations and approvals, prescribing practices and 
health care systems (Watts et al., 2007). Between 2001 and 2002 there were 538 million 
prescription items dispensed by community pharmacies in the UK, but between 2010 and 
2011 it had increased to over 850 million items (NHS, 2011).  
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Consumption data for APIs in the UK can be obtained from the NHS prescription cost 
analysis (PrCA) reports that are published annually. However, data on API consumption by 
weight is not forthcoming and requires lengthy manipulation of the data. The 
Intercontinental Medical Statistics (IMS) holds data on all the APIs sold in the UK, but it is 
available, only at a substantial cost. However, in 2007 the Drinking Water Inspectorate 
published a review on the current knowledge of pharmaceuticals in drinking water. The 
report contained data from the IMS on the top 50 consumed UK pharmaceuticals in 2004. 
This information is shown in Table 1.1 for the top 20 pharmaceuticals. 
 
Table 1.1  The top 20 consumed pharmaceuticals in the UK in 2004 (Watts et al., 2007). 
Compound Name Therapeutic class 
IMS figure of the active 
ingredient used in 2004 (t) 
Paracetamol (acetaminophen) NSAID 3,535 
Metformin Antidiabetic 497 
Ibuprofen NSAID 330 
Aspirin (acetylsalicylic acid) NSAID 178 
Amoxicillin Antibiotic 141 
Valproic acid Antiepileptic 73 
Mesalamine NSAID 65 
Sulfasalazine NSAID 61 
Flucloxacillin Antibiotic 58 
Carbamazepine Antiepileptic 52 
Atenolol Beta-blocker 50 
Erythromycin Antibiotic 49 
Gabapentin Antiepileptic 49 
Ranitidine Anti-ulcer 48 
Codeine Narcotic 42 
Povidone-iodine Antiseptic 38 
Salicylic acid NSAID 37 
Diclofenac NSAID 35 
Naproxen NSAID 34 
Dextropropoxyphene Opioid 33 
 
Whilst Table 1.1 is useful for showing the highest ranking APIs in the UK, the data is 
outdated. The consumption patterns in today’s society are almost certainly misrepresented 
by these figures. It was possible to obtain more recent consumption figures for a selection 
of widely used APIs in the UK. These figures were obtained by AstraZeneca from the 
IMS. The figures, reported in Table 1.2, offer a comparison of the consumption patterns in 
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2004 and 2011. The APIs included are a selection, and do not comprise a list of the highest 
ranked APIs. 
 
More than half of the pharmaceuticals in Table 1.2 were more extensively used in 2011 
than 2004. Furthermore, the increase in consumption was more sizeable than the decrease, 
observed during the same period. The API with the largest increase in weight was 
metformin, which almost doubled in seven years from 497 to 967 t. Metformin is an 
antidiabetic drug used to treat type 2 diabetes.  
 
Table 1.2  A comparison of UK consumption figures in 2004 and 2011 (IMS). 
Compound name 
IMS figure of the active 
ingredient used in 2004 
(t) 
IMS figure of the active 
ingredient used in 2011 (t) 
Paracetamol (acetaminophen) 3,539 3,472 
Metformin 497 967 
Ibuprofen 278 258 
Aspirin (acetylsalicylic acid) 175 130 
Amoxicillin 147 198 
Carbamazepine 52 48 
Atenolol 50 28 
Salicylic acid 37 28 
Diclofenac 35 28 
Naproxen 34 111 
Simvastatin 15 54 
Omeprazole 5 22 
Atorvastatin 10 18 
Ciprofloxacin 16 15 
Quetiapine 4 13 
Citalopram 5 13 
Amitriptyline 9 12 
Propranolol 10 11 
Isosorbide mononitrate 12 9 
APIs were only included if one or more weights in 2004 and 2011 were above 10 tonnes. The 
weights shaded in grey have increased from 2004. 
 
The consumption of naproxen, increased more than three-fold in 2011, from 34 t consumed 
in 2004. A number of non-steroidal anti-inflammatory drugs (NSAIDs) including 
paracetamol, ibuprofen, aspirin, salicylic acid and diclofenac have seen a fall in 
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consumption levels during this time. However, this decline is relatively small and is quite 
variable during the intervening years.   
 
1.2 Occurrence in the environment 
1.2.1 Veterinary pharmaceuticals 
Veterinary pharmaceuticals enter the environment via a number of different pathways 
including; application to surface water during aquaculture, wash-off from topical 
treatments to animals, and in the excreta of treated animals either directly or during manure 
spreading (Capleton et al., 2006). Runoff from fields will lead to the contamination of soil 
and surface water (Kim et al., 2008; Kümmerer, 2008). Soil biota can also be affected by 
the application of manure containing high concentrations of veterinary pharmaceuticals 
(Halling-Sorensen et al., 1998). Veterinary pharmaceuticals can also enter the environment 
during the manufacture and formulation process, but this is considered less relevant, 
compared with entry into the environment via treatment of animals (Boxall, 2003). 
Veterinary pharmaceuticals are considered non-point source pollutants unlike human 
pharmaceuticals, the latter largely entering the environment as a result of sewage treatment 
plant (STP) discharges (Kim et al., 2008). Since veterinary pharmaceuticals do not enter 
STPs, they will not be considered further in this literature review. 
 
1.2.2 Human pharmaceuticals 
The use, disposal, manufacture, processing and distribution, are all potential sources of 
human pharmaceuticals (Ternes et al., 2004b). The latter three are regulated processes in 
developed countries that are thought to contribute little to the overall level of 
environmental contamination (Kümmerer, 2008). However, the production of 
pharmaceuticals may be moved to countries where costs are lower, but emission controls 
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may be lacking, such that significant entry into the environment could result (Wennmalm, 
2011). 
 
The use and disposal of APIs are the two most important sources of environmental 
contamination (Fent et al., 2006; Ternes et al., 2004b). The disposal of unused medication 
can occur by patients flushing unwanted drugs down the toilet, which is a practice still 
recommended in some countries (Wennmalm, 2011), and disposing medication with 
household wastes (Santos et al., 2010). These practices will lead to the contamination of 
STPs and landfills. Pharmaceuticals that reach STPs will be discharged to surface waters if 
they are not removed, whilst leachate from landfill sites could contaminate the surrounding 
soil and groundwater (Santos et al., 2010).  
 
1.2.2.1 Metabolism  
By far the most important cause of environmental contamination is the ingestion and 
subsequent excretion of APIs by patients, either in the community or hospitals (Ternes et 
al., 2004b). After ingestion pharmaceuticals can undergo phase I and phase II metabolism. 
The phase I reaction usually consists of oxidation, reduction or hydrolysis and this adds 
reactive functional groups to the molecule. Phase II is referred to as the conjugation 
reaction; this involves the addition of glucuronic acid, sulphate, acetic acid or an amino 
acid to make the molecule hydrophilic and more excretable. Substances usually undergo 
both phase I and phase II metabolism (Daughton and Ternes, 1999). Depending on the 
patient and the drug pharmokinetics, the parent compound and an array of metabolites will 
be excreted (Daughton and Ternes, 1999). 
  
These processes yield polar hydrophilic metabolites that are easily excretable; primarily in 
the urine, but also in faeces, which normally exhibit insignificant pharmacological activity. 
However, this is not always the case and some drug substances produce active metabolites 
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that contribute to the overall pharmacological profile (Flanagan et al., 2007) and can even 
be more bioactive than the parent compound (Daughton and Ternes, 1999). Once excreted 
by the patient, these substances enter the sewage system. Metabolites, in addition to the 
parent compound, could be relevant when investigating the environmental fate of a 
compound (Fatta-Kassinos et al., 2011; Jones et al., 2005). 
 
Once pharmaceuticals enter the sewer system there is the opportunity for removal (Vieno 
et al., 2007). Readily biodegradable compounds will be removed by microorganisms 
present in the sewage treatment process (Jones et al., 2005); however, hydrophilic APIs 
that are resistant to degradation will remain in the aqueous phase where they are 
discharged to receiving water bodies (Ternes and Joss, 2006). Once discharged, APIs are in 
the environment and can potentially cause toxic effects on the flora and fauna. 
Hydrophobic pharmaceuticals may be removed from the aqueous phase through 
partitioning to the solids (Drewes, 2007).   
 
The growing population, which is also an aging one, has undoubtedly increased the 
frequency and volume of pharmaceuticals in our waterways (Arnold et al., 2013). Sadezky 
et al. (2010) concluded that more than 180 pharmaceutical products have been detected in 
the environment.  
 
1.2.3 Analytical techniques 
Pharmaceuticals, unlike conventional priority pollutants, received comparatively little 
attention until the late 1990s. Some of the first studies using gas chromatography-mass 
spectrometry (GC-MS) demonstrated that many pharmaceuticals are not completely 
removed during the sewage treatment process, and were consequently detected in sewage 
effluents (Hignite and Azarnoff, 1977; Richardson and Bowron, 1985).  
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The main reason for the lack of research until the 1990s was the inadequacy of the 
available analytical techniques. Sufficient separation of pharmaceuticals from the plethora 
of other substances could not be readily achieved (Daughton and Ternes, 1999). 
Furthermore, detection limits to the ng l
-1
 range were not commonly available, and it is 
these concentrations that many pharmaceuticals are found at in the environment. 
  
A number of approaches have been used to analyse APIs in the environment, including 
GC-MS, gas chromatography-tandem mass spectrometry (GC-MS/MS), liquid 
chromatography-ultraviolet (LC-UV), liquid chromatography mass spectrometry (LC-MS) 
and liquid chromatography tandem mass spectrometry (LC-MS/MS). LC-MS/MS is one of 
the most powerful tools for API quantification in complex environmental matrices, 
resulting from its sensitivity and selectivity (Al-Odaini et al., 2010; Kasprzyk-Hordern et 
al., 2010). LC-MS/MS allows the separation and detection of compounds, having the same 
molecular mass, but different product ions even if they co-elute (Fatta et al., 2007). The 
limit of detection (LOD) achieved by LC-MS/MS is only slightly higher than GC-MS, 
however, the latter is not suitable for the analysis of hydrophilic, thermally labile and/or 
high molecular mass compounds (Flanagan et al., 2007).  
 
The main drawbacks with LC-MS/MS analysis of pharmaceuticals in ‘dirty’ samples, are 
the matrix effects which can cause ion enhancement or suppression during electrospray 
ionisation (ESI). This can reduce the sensitivity, linearity, accuracy and precision of the 
method (Fatta-Kassinos et al., 2011). Matrix effects can be reduced by effective sample 
clean up techniques, external calibrations using matrix-matched samples, standard addition 
or internal standard (IS) addition using structurally similar unlabelled pharmaceuticals, or 
isotopically labelled standards and the dilution of sample extracts (Fatta-Kassinos et al., 
2011). 
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A sample preparation procedure is an essential part of micropollutant analysis in 
environmental samples. It is required to clean-up matrix components in dirty samples and 
to pre-concentrate the target analytes in order to reach the limit of quantification (LOQ) for 
instrumental analysis (Fatta-Kassinos et al., 2011). The physical and chemical properties of 
the target analytes will affect the applicability of different sample preparation techniques 
and analytical methods (Pavlović et al., 2007). Figure 1.1 is a summary of the typical 
processes used to analyse pharmaceuticals in aqueous samples. The first step usually 
involves filtering samples through glass fibre filters usually with a pore size < 1 µm. This 
is to avoid lowered extraction efficiencies by the presence of suspended solids. This 
method will therefore, only detect the freely dissolved molecules rather than the total 
concentration in the aqueous phase, which might include fractions that are sorbed to 
suspended particles or to dissolved organic matter (Tolls, 2001).  
 
The next step involves the extraction of the APIs from the sample matrix into a small 
volume of solvent. The most common technique to achieve this is solid phase extraction 
(SPE) since it overcomes many of the disadvantages of liquid-liquid extraction; these being 
its labour intensiveness, difficulty to automate, and requirement of large portions of high-
purity solvents (Jones-Lepp et al., 2009; Kot-Wasik et al., 2007). Also used are solid phase 
microextraction, liquid phase microextraction and lyophilisation (Zhang et al., 2009).  
 
SPE cartridges are packed with a wide-variety of sorbents; the most widely used are 
hydrophobic-lipophilic balanced (HLB) cartridges, C18, Oasis MCX (mixed-mode cation 
exchange) and Strata-X (Gros et al., 2006). The selection of an appropriate sorbent is 
difficult, particularly in the case of methods that simultaneously determine several classes 
of pharmaceuticals, in these cases there needs to be a compromise between the solid-
phases providing the best recoveries for each class of compounds (Fatta et al., 2007). It is 
important to obtain data on a compounds physical and chemical properties such as pKa and 
Chapter 1 Literature Review 
9 
 
Aqueous sample 
Filtration (pH 
amendment) 
Extraction 
Derivatisation LC-MS 
LC-MS/MS 
GC-MS 
GC-MS/MS 
log Kow (n-octanol-water partition coefficient), since they will help determine whether a 
compound will concentrate under a specific condition (Pavlović et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  The procedure for analysis of pharmaceuticals in aqueous matrices (Fatta et al., 2007). 
N.b. pH amendment depends on the physical and chemical properties of analytes. 
 
Most pharmaceuticals have acidic and/or basic functionalities and are therefore present as 
cations, anions or zwitterions; their ionisation rate depends on the type of functional 
group(s) present, and the pH of the surrounding environment (Boxall and Ericson, 2012). 
Therefore, pH amendment of samples prior to extraction may be necessary. For instance, 
lipophilic sorbents such as C18 cartridges will require acidification of acidic 
pharmaceuticals, because at neutral pH the target analytes exist in their ionised form, 
therefore, they will be poorly retained by the sorbent. Developing multi-residue methods is 
difficult, often requiring a compromise, which sometimes results in the selection of sub-
optimum conditions for analytes (Togola and Budzinski, 2008).  
 
Since the development of these sensitive and selective analytical techniques, there have 
been a prolific number of papers published on pharmaceutical concentrations in a variety 
of environmental matrices (Comeau et al., 2008; Heberer, 2002; Jones et al., 2007; Kolpin 
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et al., 2002; Radjenović et al., 2009; Ternes, 1998; Ternes and Hirsch, 2000; Vulliet and 
Cren-Olivé, 2011; Xu et al., 2007; Yoon et al., 2010). In a recent review of pharmaceutical 
residues in environmental waters and wastewater, Fatta-Kassinos et al. (2011) reported that 
in 2000 there were approximately 500 publications on the occurrence of these pollutants in 
environmental water matrices, but by 2010 this had increased to over 2500.  
 
1.2.4 Hospital wastewater 
Hospitals have for some time been identified as contributors of APIs to STPs (Ternes et 
al., 2004b). Hospital waste discharges are a concentrated source of a whole host of 
undesirable constituents, including X-ray contrast media, antibiotics, anaesthetics, 
disinfectants, adsorbable organic halogens, cytostatic drugs and possibly a range of 
antibiotic resistant bacteria (Kümmerer, 2001). Furthermore, hospital wastewater is usually 
discharged directly to sewers without any pre-treatment (Ort et al., 2010).  
 
A study conducted by Langford and Thomas (2009) investigated the contribution of two 
hospital discharges to the load of APIs entering a STP. They found that for some 
compounds, hospital effluent is an important point source, however, for others the 
contribution is much smaller. The concentration of propranolol originating from hospital 
effluent contributed 11.5% of the total load entering the STP. Atorvastatin and atenolol 
contributed just over 2% each. For some compounds such as tamoxifen and ibuprofen their 
contribution was below 1%.  
 
Ort et al. (2010) found that for 28 of the 59 investigated compounds, over 85% of the 
pharmaceutical residue loads, did not originate from hospital wastewater. The remaining 
pharmaceuticals were not detected frequently, or were below the LOD. Only trimethoprim 
and roxithromycin had loads over 15% originating from hospital wastewater. They suggest 
that the treatment of hospital wastewater would not reduce the overall load of APIs, since 
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many of the pharmaceuticals are also taken at home, and many of the APIs administered in 
hospitals are likely to be excreted by patients at home.  
 
1.2.5 Biosolids and contaminated soil 
Biosolids is a term given to sludge generated during the sewage treatment process 
(LeBlanc et al., 2008). Biosolids applies to the sludge once it has undergone biological, 
chemical, heat or any other form of treatment, to reduce its hazardous properties (European 
Commission, 2012). Biosolids are composed of organic and inorganic solids, with between 
50% and 85% dry weight (dw) constituting organic matter. The organic fraction is where 
most of the synthetic organic compounds are located (Rogers, 1995; Wang et al., 1993). A 
large proportion of this organic matter is composed of live and dead microorganisms, 
which provide a large surface area for organic residues to adsorb (Wang et al., 1993).  
 
There are large disparities in the amount of biosolids produced around the world, which is 
influenced by the standards of wastewater treatment in each country. There is a strong 
correlation between the wealth of a nation and the development of its sanitation, 
wastewater, and wastewater sludge management systems (LeBlanc et al., 2008). China 
produces 2,966,000 t y
-1 
(dry solids), whilst the USA with a population size of less than a 
quarter of that of China, produces over 6,514,000 t y
-1
 (dry solids) (LeBlanc et al., 2008).  
 
Since the implementation of stricter guidelines for the treatment of wastewater in the form 
of the Urban Wastewater Treatment Directive (UWWTD 91/271/EEC), all 27 EU member 
states are increasing the amount of sludge they produce. Italy, UK, France, Spain and 
Germany all produce over 1 million t y
-1
 (dry biosolids) (European Commission, 2010b). 
Europe as a whole produces over 10 million t y
-1
 (dry biosolids). The Sewage Sludge 
Directive 86/278/EEC encourages the use of sludge in agriculture. Europe as a whole 
recycles 39% of biosolids to agriculture. However, this figure is much higher in countries 
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such as the UK, Spain and Ireland, where more than 60% of biosolids are recycled to 
agricultural land (European Commission, 2010b). In the UK in 2010, 1,100,000 t (dry 
solids) were reused on soil and agriculture. This was 79% of the total sludge produced 
(Defra, 2012). For other countries, disposal to landfill and incineration are still the main 
outlets (European Commission, 2012). In the UK in 2010, disposal to landfill comprised 
less than 1%, and incineration 18%, of the total biosolids produced (Defra, 2012). Figure 
1.2 summarises these sludge re-use and disposal pathways in the UK. 
 
Figure 1.2  A summary of the sewage sludge re-use and disposal routes in the UK in 2010 (Defra, 
2012). 
 
A nationwide reconnaissance study was carried out by the United States Environmental 
Protection Agency (EPA) in 2001. They determined the average concentration of 72 
pharmaceuticals and personal care products (PPCP) in 110 biosolid samples. They found 
that in at least one composite sample, 38 (54%) of the 72 analytes were detected. The 
antibacterial compounds triclocarbon and triclosan were the most abundant analytes, with 
maximum concentrations of 48,100 µg kg
-1
 and 19,700 µg kg
-1
, respectively. The second 
most highly detected PPCPs were the antibiotics. Ciprofloxacin had the highest maximum 
concentration of all the antibiotics detected, at 10,800 µg kg
-1 
(McClellan and Halden, 
2010). This is similar to the finding by Walters et al. (2010). They looked at the 
Re-use: Soil 
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Re-use: 
Others
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Landfill
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pharmaceutical residues present in their biosolid/soil mixture prior to starting their outdoor 
mesocosm experiment. They observed the highest initial concentrations for triclocarban 
and triclosan at 2,715 and 1,265 µg kg
-1
, respectively.  
 
The wide variety of PPCPs found in biosolids could present a problem for the terrestrial 
environment. Topp et al. (2008) investigated the runoff of PPCPs following the application 
of liquid municipal biosolids to an agricultural field. The results showed that when the 
spiked biosolids were applied by subsurface injection, there was less contamination of 
adjacent subsurface or surface waters compared to broadcast application. The authors 
conclude that this is because during broadcast application there is more material on the soil 
surface for rainfall to interact with and form runoff. Therefore, this work highlights the 
importance of using different management practices for the spreading of biosolids to lessen 
contamination of the surrounding environment.   
 
Edwards et al. (2009) conducted research into the mass loads of PPCPs in tile drainage, 
after the application of dewatered municipal sludge by two different methods i.e. direct 
injection below the soil surface and surface spreading. They found that for the dewatered 
municipal sludge, it took a rain event for the PPCPs to be above the detection limits in the 
tile drainage. The authors found there was no significant effects at the p = 0.05 level, of the 
dewatered municipal sludge land application method on PPCPs tile mass loads. In a study 
by Gottschall et al. (2012) PPCPs were monitored in groundwater, tile drainage, soil, 
dewatered municipal biosolid aggregates incorporated into the soil post-land application, 
and in the grain of wheat grown on the field for a period of approximately one year 
following application. The authors found that despite the 22 Mg dw ha
-1
 of dewatered 
municipal biosolids applied to the site, there was no significant impact on the quality of 
either tile drainage or groundwater. This is despite the fact that PPCPs were detected in 
dewatered municipal biosolid aggregates incorporated in soil up to one year post-
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application. Furthermore no PPCPs were detected in the grain of wheat, planted post-
application on the field.  
 
Walters et al. (2010) conducted a mesocosm study with biosolid-amended soil to 
investigate the fate of 72 PPCPs over a period of three years. They observed no noticeable 
loss over the three years for the four compounds: diphenhydamine, fluoxetine, 
thiabendazole and triclocarban. Even those compounds that could be fitted to first-order 
loss rates had decidedly high half-lives. Ciprofloxacin was estimated to have a half-life of 
1,155 to 3,466 d. The shortest half-life was 182 to 193 d for triclosan. Furthermore, 
environmental half-lives determined in this study are higher than comparable values 
obtained in laboratory experiments or those generated with computer models (Walters et 
al., 2010).  
 
Kinney et al. (2008) reported that soils contaminated with organic chemicals, as a result of 
biosolid or manure spreading, can be transferred to earthworms. However, out of the five 
pharmaceuticals monitored, only the antibiotic trimethoprim was detected in the worms 
themselves, at 61 and 127 µg kg
-1
. Across all three sampling sites the biogenic sterols (3-
beta-coprostanol, cholesterol, beta-sitosterol and stigmastanol) had the highest 
concentration in the earthworms, soil and biosolids or manure. This demonstrates there is a 
potential for pharmaceuticals, but particularly other organic pollutants to impact upon 
terrestrial organisms as a result of sludge spreading. 
 
1.2.6 River, groundwater and drinking water  
Vulliet et al. (2011) analysed surface and groundwater samples for 52 pharmaceuticals and 
hormones in France. Their results demonstrated that none of the sampling locations were 
free of these pollutants. Out of 28 target pharmaceuticals, 21 were detected. Most drugs 
were found at concentrations below 25 ng l
-1
, with the exception of oxazepam and 
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metformin, the latter had a maximum concentration of 735 ng l
-1
. Acetaminophen, 
salicyclic acid and carbamazepine were the most commonly detected pharmaceuticals, and 
were present in 90% of samples. The groundwater was less contaminated than the surface 
water, since the concentrations and frequency of detection for the pharmaceuticals and 
hormones were reduced. An approach was taken by the authors to evaluate the potential for 
adverse human effects, by quantitative estimates of potential indirect exposure to 
pharmaceuticals. This was achieved by calculating an exposure value based on the 
ingestion of 2 l d
-1
 of water, using the maximum measured values as the basis for estimates 
of intake, assuming no removal during drinking water treatment. These values were then 
compared with the minimum daily therapeutic dose, typically taken by an adult. It was 
concluded that there was no risk for the adult French population. However, the authors 
concluded, risks due to the presence of synthetic hormones could not be dismissed (Vulliet 
et al., 2011).  
 
Heberer et al. (2002) also found that pharmaceuticals are a common occurrence in surface 
water, groundwater and even in drinking water at low levels. There was a direct correlation 
between STP discharges and the presence of APIs in the surface water. Clofibric acid and 
diclofenac were detected at 500 and 1000 ng l
-1
, respectively, in surface water samples 
downstream of Berlin. Carbamazepine was similarly detected at maximum concentrations 
of 1000 ng l
-1
 in surface water samples. The following APIs: clofibric acid, phenazone, 
propyphenazone and salicylic acid were found at μg l-1 concentrations in groundwater 
samples.   
 
The occurrence of X-ray contrast media was investigated in STPs, rivers, creeks and 
groundwater by Ternes and Hirsch (2000). The X-ray contrast media, as a group, have 
received less attention than other therapeutic classes. They are designed to have extremely 
high chemical and biological stability, so are likely to exhibit persistence in the 
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environment. It is therefore not surprising that Ternes and Hirsch (2000) found their 
elimination during sewage treatment was very low. Their concentrations were high in the 
effluents of the STPs monitored, with at least one X-ray diagnostic present above 1 µg l
-1
. 
Therefore, rivers and creeks were also highly contaminated. Concentrations of 100 µg l
-1
 
and approximately 20 µg l
-1
 of diatrizoate were detected in two small creeks. Groundwater 
was also found to be contaminated, with maximum concentrations as high as 2.4 µg l
-1
 for 
iopamidol. This demonstrates environmental waterways were heavily contaminated by X-
ray contrast media, which might persist for several years (Ternes and Hirsch, 2000). In a 
review of pharmaceuticals in surface water, groundwater and drinking water, Mompelat et 
al. (2009) reported that a number of pharmaceuticals have been detected in drinking water 
albeit at low concentrations. These include pharmaceuticals from the following therapeutic 
classes: NSAIDs, antibiotics, antiepileptics, lipid regulators, antidepressants, 
antineoplastics, and stimulants. 
 
Drinking water treatment plants use a wide and technically more advanced range of 
processes, but like STPs these are not designed to specifically remove pharmaceuticals 
(Maycock and Watts, 2011). Huerta-Fontela et al. (2011) monitored the removal of 55 
pharmaceuticals during each step of a drinking water treatment plant, which employed the 
following treatments: prechlorination, coagulation, sand filtration, ozonation, granular 
activated carbon filtration and post-chlorination. Concentrations in the raw water entering 
the plant were relatively high, with an average of 685 ng l
-1
 for valsartan, and 670 ng l
-1
 for 
hydrochlorthiazide. They found that five compounds were detected in the finished water: 
atenolol (12 ng l
-1
), sotalol (2 ng l
-1
), hydrochlorthiazide (3 ng l
-1
), carbamazepoxide 
(1 ng l
-1
) and phenytoin (9 ng l
-1
).  
 
Boleda et al. (2011) carried out an interesting study on the presence of drugs of abuse in 
tap water in Spain, and a number of other countries around the world. They found the 
Chapter 1 Literature Review 
17 
 
quantity of illicit drugs consumed, is at similar concentrations to prescription drugs 
(Boleda et al., 2011). The most frequently detected compounds were: caffeine, nicotine, 
cotinine, cocaine, and its metabolite benzoylecgonine, methadone and its metabolite 
EDDP. In Spain, caffeine had the highest concentration with an average detection of 
50 ng l
-1
, followed by nicotine (13 ng l
-1
), and cotinine (3.4 ng l
-1
). In the remaining 
countries, again the three non-controlled drugs had the highest concentrations. A number 
of studies have shown that drinking water can be contaminated with pharmaceuticals, 
albeit at low ng l
-1
 concentrations. The general consensus is that pharmaceuticals do not 
pose a health risk for humans (Boxall et al., 2011). 
 
1.3 Environmental impact 
1.3.1 Ecotoxicology  
Although a human health risk has not been identified, concerns have been raised over 
environmental threats to wildlife. This is a result of the bioactive nature and pseudo-
persistence of pharmaceuticals in the environment; the latter being the result of continuous 
discharge from STPs (Williams, 2005). The intake of exogenous drugs of any type in 
sufficient quantity, by any species, may interfere with the regulation of metabolic systems, 
and induce adverse or even fatal effects (Jones et al., 2004). Many non-target species could 
have similar drug-binding sites to those present in humans, which could interfere with wild 
populations (Williams, 2005).  
 
Due to the low levels pharmaceuticals are present at in the environment, acute toxic effects 
are unlikely, and testing exclusively for these is seen of little environmental relevance 
(Jones et al., 2004). Instead chronic affects occurring over a longer period of time are to be 
expected (Jones et al., 2004). However, due to the long-term nature of these effects, studies 
may take several years to complete, and thus there is a definitive lack of data on the 
chronic toxicity of pharmaceuticals. The available chronic toxicity data often does not 
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investigate the effects in a range of species, or over different life stages (Fent et al., 2006). 
This is mainly because toxicity experiments are usually performed according to established 
guidelines (Fent et al., 2006). Furthermore, the endpoints measured in these tests vary, and 
since it is likely that an organism’s sensitivity or insensitivity is dependent on the endpoint 
measured, the importance of test organism selection is crucial (Kümmerer, 2009a).  
 
1.3.1.1 Aquatic ecotoxicology 
Exposure of aquatic organisms to human pharmaceuticals, is most likely to occur from 
STP point source discharges (Fent et al., 2006). The clearest and most extensive evidence 
for potential adverse effects on aquatic wildlife is for the natural and synthetic steroids 
(Crane et al., 2006). Environmental estrogens are chemical pollutants that can disrupt the 
endocrine system of animals by binding to, and activating estrogen receptor(s). As well as 
natural and synthetic steroid estrogens, they include a variety of estrogen-mimicking 
chemicals, such as 4-nonylphenol and bisphenol-A (BPA) (Jobling et al., 2003).  
 
17α-ethinylestradiol (EE2) has been shown to have detrimental effects on the male fathead 
minnow (Pimephales promelas) (Lange et al., 2001; Parrott and Blunt, 2005). Lange et al. 
(2001) reported that the fathead minnow’s sexual reproduction was impaired at the low 
ng l
-1
 range. Similarly Parrott and Blunt (2005) exposed fathead minnows to EE2 and 
detected a decrease in egg fertilisation and a sex ratio skewed towards females, both of 
which were significantly affected at the lowest EE2 concentration of 0.32 ng l
-1
. These 
concentrations are environmentally relevant with EE2 detected in surface water at 
concentrations of 4.3 ng l
-1
 in the river Rhine, Germany (Belfroid et al., 1999). 
 
Burki et al. (2006) investigated the vitellogenin (VTG) biomarker response in brown trout 
(Salmo trutta) under conditions of low and fluctuating activities of environmental 
estrogenicity. VTG is used as a biomarker to detected exposure to fish exogenous, 
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estrogen-active substances. Caged and feral fish were exposed to a small river, which 
received effluents from a single STP. Fish were sampled upstream and downstream of the 
STP, and two different methods for quantifying VTG were employed (enzyme-linked 
immunosorbent assay and real-time reverse transcription-polymerase chain reaction). The 
authors found that males in cages downstream of the STP had significantly (p = 0.04) 
higher VTG mRNA levels than males from cages upstream of the STP, but site-specific 
differences were not detectable at the VTG protein level. In contrast the plasma VTG 
levels of feral males were above the detection limit, and showed males downstream had 
significantly (p = 0.01) higher VTG protein levels than males upstream, however, the VTG 
mRNA showed no site-specific differences.  
 
In another study investigating the effects of estrogenic activity on the intersex of brown 
trout, Körner et al. (2005) found that on examination of the gonads, there was 
spematogenic activity in ovarian tissue of 13 out of 64 and 14 out of 57 macroscopically 
classified females caught at two rivers in Switzerland. The proportion of intersex fish at 
these two locations ranged from 4.5 to 26.7%.  
 
It is not only fish that experience reproductive effects as a result of exposure to estrogenic 
compounds. A study by Jobling et al. (2003) investigated the effects of embryo production 
in the prosobranch mollusc, Potamopyrgus antipodarum by exposing them to EE2, BPA 
and 4-tert octylphenol, and a mixture containing these compounds (treated sewage 
effluent). Changes in embryo production were observed with exposure to all compounds 
and the treated sewage effluent. Exposure to EE2 induced similar reproductive responses 
in the snails, as it did in the fathead minnow (P. promelas), stimulating egg/embryo 
production at low doses (up to 1 ng l
-1
 in the minnow and 25 ng l
-1
 in the snail) and causing 
inhibitory effects at higher doses. This raises the point that egg production in prosobranch 
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snails, may potentially be used as a sensitive end-point for testing estrogenic compounds, 
with relevance to vertebrates.   
 
Pharmaceuticals other than the estrogens, can exhibit ecotoxicological effects on aquatic 
species. Propranolol has been shown to exhibit toxic effects in aquatic vertebrates, due to 
the similar beta-adrenergic receptors present in some fish (Huggett et al., 2002). Huggett et 
al. (2002) found that in a four-week follow-up exposure to propranolol, the total number of 
eggs and the viable number of eggs were lowered in medaka (Oryzias latipes) at 
concentrations as low as 0.5 µg l
-1
. Diclofenac can produce histopathological effects in the 
kidney and gills of rainbow trout after a 28 d exposure period. At the lowest observed 
effects concentration (LOEC) of 5 µg l
-1
, renal lesions and alterations of the gills occurred 
(Schwaiger et al., 2004).  
 
In a study by Heckmann et al. (2007) the chronic effects of ibuprofen on Daphnia magna 
were investigated. Population growth rate was significantly reduced at all ibuprofen 
concentrations (0, 20, 40 and 80 mg l
-1
) although survival was only affected at 80 mg l
-1
. 
Reproduction, however, was affected at lower concentrations (14 d EC50 of 13.4 mg l
-1
) 
and was completely inhibited at the highest test concentration of 80 mg l
-1
. The authors 
concluded that the long-term crustacean population consequences of a chronic ibuprofen 
exposure at environmentally realistic concentrations (ng l
-1
 and μg l-1) would most likely be 
of minor importance.  
 
De Lange et al. (2006) assessed the effect of three pharmaceuticals: fluoxetine, ibuprofen 
and carbamazepine on the activity of Gammarus pulex. When exposed to 10 and 100 ng l
-1
 
of fluoxetine, time spent on activity by G. pulex was reduced from 55% in the control to 
< 20%. However, exposure to the other concentrations did not affect the percentage of time 
spent on activity. This was similar to the effects seen during exposure to ibuprofen. There 
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was a decrease in activity from 65% in the control to 30% at concentrations of 1 and 
10 ng l
-1
, but exposure to other concentrations did not result in different activity. The 
activity of G. pulex was slightly reduced when exposed to 1 and 10 ng l
-1
 of 
carbamazepine, but this was not significant, and the activity at higher concentrations was 
similar to the control. The authors suggest that the reduced activity at lower concentrations 
only could show a biphasic effect, which may be the result of (1) a reduced activity which 
starts at low concentrations and (2) an increased activity as flight or stress response, which 
starts at higher concentrations.  
 
1.3.1.2 Terrestrial ecotoxicology 
Terrestrial ecotoxicology plays a minor role in the evaluation of pharmaceutical “side 
effects” as compare to aquatic toxicology (Schmitt and Römbke, 2008). This is mostly 
caused by the typical exposure pathways of human pharmaceuticals, which tend to be 
discharged into the aquatic environment (Schmitt and Römbke, 2008). 
 
One of the most infamous studies into the terrestrial toxicity of pharmaceuticals is that of 
the NSAID diclofenac, and its fatal effects on Indian vultures. The Oriental white-backed 
vulture (Gyps bengalensis) has seen a decline of over 95% starting in the 1990s (Oaks et 
al., 2004). Oaks et al. (2004) linked the NSAID diclofenac to renal failure in these 
vultures. The vultures were exposed to diclofenac after eating carcasses of cattle that had 
been given the veterinary drug by farmers.  
 
Liu et al. (2009) assessed the impact of six antibiotics (chlortetracycline, tetracycline, 
tylosin, sulfamethoxazole, sulfamethazine and trimethoprim) on seed germination, plant 
growth, soil respiration and phosphate activity of three plant species (sweet oat, rice and 
cucumber). The tetracyclines and sulfonamides were most toxic to seed germination (end-
point measured as root length) with the lowest EC50 values for each antibiotic and plant 
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species as follows: 16 mg l
-1
 (chlortetracycline and oat), 57 mg l
-1
 (tetracycline and oat), 
141 mg l
-1
 (tylosin and oat), 8 mg l
-1
 (sulfamethoxazole and rice), 37 mg l
-1
 
(sulfamethazine and oat) and 86 mg l
-1
 (trimethoprim and oat).  The sweet oat was the most 
sensitive plant to the six antibiotics in terms of seed germination. In the plant growth tests, 
only sulfamethoxazole and sulfamethazine strongly affected rice growth in soil. 
Tetracycline, chlortetracycline and tylosin had little effect on soil microbial respiration 
measured as CO2. In contrast, the sulfonamides and trimethoprim were found to cause 
significant decreases in soil respiration at increasing concentrations. All the antibiotics 
tested inhibited phosphatase activity to some degree at concentrations of between 1 and 
300 mg kg
-1
 during the 22 d exposure period.  
 
1.3.1.3 Antibiotic resistance 
The intensive use of antibiotics for human, veterinary and agricultural purposes, results in 
their continuous release into the environment (Rizzo et al., 2013) and this combined with 
their misuse, has resulted in strong selection pressures for the emergence, enrichment and 
spread of various resistant mechanisms in pathogenic bacteria (Andersson and Hughes, 
2012). This is of concern due to the development of resistant genes and bacteria, which 
reduce the therapeutic potential of antibiotics used to treat bacterial infections in humans 
and animals (Rizzo et al., 2013). The temporal and spatial dynamics and driving forces of 
these processes are complex, and only now are scientists beginning to understand how 
resistance genes, resistant bacteria and the selective agents (antibiotics, environmental 
pollutants etc.) move between different ecosystems and exert their effect (Andersson and 
Hughes, 2012). 
 
Resistant genes, resistant bacteria and antibiotics will flow between different 
compartments and environments, including humans, animals, and the environment 
(wastewater, soil, rivers etc.), creating situations where resistant bacteria may emerge, 
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become enriched and spread between hosts and various natural environments (Andersson 
and Hughes, 2012). It is difficult to assess the relative contributions of various 
environments and selection, to the spread of antibiotic resistance (Andersson and Hughes, 
2012; Kümmerer, 2009). 
 
1.4 EU environmental legislation 
In the last six years there has been a move towards regulating APIs in the environment. 
There are three key pieces of environmental legislation concerning the environmental 
control of APIs in the environment. The central piece of environmental legislation comes 
from the EMA (European Medicines Agency), formerly the European Agency for the 
Evaluation of Medicinal Products (EMEA). It outlines the environmental risk assessment 
(ERA) procedure, each new drug must undergo prior to entry onto the market. This is so 
the fate and effects in the environment can be quantified. The Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) regulates the production of every 
chemical manufactured in quantities > 1 t. It does not specifically regulate 
pharmaceuticals, but will control the chemicals used in their manufacture. Pharmaceuticals 
were proposed for inclusion on the Water Framework Directive (WFD) priority substance 
(PS) list. This requires monitoring of PSs in surface waters and requires action if 
concentrations are above environmental quality standards (EQS). However, their inclusion 
was rejected and instead they have been placed on a ‘watch list’ (Water UK, 2013).  
 
1.4.1 Environmental risk assessment (ERA) 
In the EU, the ERA for animal and human pharmaceuticals, as part of product 
authorisation, was first established in the 1990s (European Commission, 2010a). Currently 
the ERA for human pharmaceuticals is based on the Guidelines of the EMA (EMEA, 
2006). It states that an ERA will accompany an application for marketing authorisation for 
all new medicinal products destined for human use. Additionally, an ERA is required for 
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applications requesting major changes or extensions to existing authorisations, which 
would result in increased environmental exposure to the API. The ERA involves the 
generation of data on the environmental exposure and ecotoxicity of APIs. However, for 
human pharmaceuticals, if an impact is detected this will not constitute a basis for refusal 
of a marketing authorisation. 
 
The ERA involves a step-wise, phased procedure, consisting of two phases. The first phase 
estimates a preliminary conservative exposure of the environment to the drug substance. 
This estimate is called the predicted environmental concentration (PEC) and is calculated 
based on a worst case scenario from Equation 1.1 (EMEA, 2006): 
 
P CS RF C   T R   
  S ai   Fpen
  ST  inhab       T    
 
(Equation 1.1) 
Where: 
DOSEai = maximum daily dose consumed per inhabitant (mg inh
-1
 d
-1
)  
Fpen = percentage of market penetration 
WASTEWinhab = amount of wastewater per inhabitant per day (l inh
-1
 d
-1
) 
DILUTION = dilution factor 
PECSURFACEWATER = local surface water concentration (mg l
-1
) 
 
If the PEC is below 0.01 µg l
-1
 then this signals the end of the procedure, however, if the 
calculated value exceeds this concentration then the pharmaceutical continues onto phase 
two.
 
In the second phase, information regarding the fate and effects in the environment is 
obtained and assessed. Phase two is split into two parts; tier A and B. Tier A involves 
evaluating the PEC/PNEC (predicted no effects concentration) ratio. The tier A screening 
dataset provides information on the APIs physical and chemical properties and fate in the 
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environment. To investigate the fate of an API during sewage treatment, a ready 
biodegradability test is prescribed. If the API is not readily biodegradable, then its fate 
should be investigated in a water sediment study. A compound with a high Kow value is 
assumed to remain within the STP and reach the terrestrial environment. In this case 
assessments of the effects in the terrestrial compartment need conducting, unless the 
compound is readily biodegradable.  
 
To generate the PNEC a standard long-term toxicity test set on fish, Daphnia and algae 
should be conducted (EMEA, 2006). The purpose of these toxicity studies is to predict the 
concentration of the API for which adverse effects are not expected to occur. The PNEC is 
calculated by applying an assessment factor (AF) to the no observed effects concentrations 
(NOEC) from relevant effects studies. The AF is an expression of the degree of uncertainty 
in the extrapolation from the test data, on a limited number of species, to the actual 
environment. The PNECWATER is based on the lowest NOEC result from the long-term 
toxicity tests (EMEA, 2006). If the ratio of the PEC/PNEC is < 1, then further testing in 
the aquatic compartment is not necessary, and the drug substance is unlikely to represent a 
risk to the aquatic environment. However, a PEC/PNEC > 1 requires further evaluation 
centred on the fate of the drug substance in tier B (EMEA, 2006). 
 
If a potential risk has been identified in tier A, then a tier B assessment should be 
conducted. This requires an extended ecotoxicity dataset, which should reduce uncertainty. 
Tier B is the final step of the ERA, and involves a process of continuous PEC and PNEC 
refinement. The PEC can be refined with extended fate data through STP modelling, using 
metabolite data, and refined sales figures (EMEA, 2006). 
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1.4.2 Registration, evaluation, authorisation and restriction of chemicals  
REACH was adopted by the EU in 2006 and came into force in 2007. Its goals are to 
produce fewer industrial chemicals and to understand the possible human and 
environmental hazards in order to preempt and prevent any possible threat (Williams et al., 
2009). With the adoption of REACH any business that manufactures or imports > 1 t of a 
chemical per year must register it before it can be marketed. The regulation contains broad 
exemptions for human and veterinary pharmaceuticals because they are covered under the 
EMA guidelines; however, there remain some important regulatory obligations. REACH 
guidelines are still applicable to pharmaceutical industries because the substances that are 
used in production within the EU, but not contained in the finished product are not 
included in the exemption (Covington and Burling, 2007).  
 
1.4.3 Water Framework Directive (WFD) 
The WFD (2000/60/EC) is concerned with achieving good chemical and ecological status 
for surface and groundwater bodies, and the prevention of deterioration. The WFD has 
identified a list of chemicals that pose a significant risk to, or via, the aquatic environment. 
This list of PSs is reviewed every four years along with their EQSs for surface water, 
sediment or biota. To meet good chemical status, water bodies must meet EQSs set for the 
priority pollutants. Member states are required to monitor the priority substances and 
report exceedances of the EQSs. 
 
Three pharmaceuticals (diclofenac, EE2 and E2) were proposed for inclusion on the PS 
list, however, this action was reviewed in 2012, and it was decided not to include them, but 
to place them on a ‘watch list’ instead. This involves monitoring and collecting data from a 
network of monitoring sites across Europe, to assess their suitability for future inclusion on 
the PS list (Water UK, 2013).  
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1.5 Sewage treatment technologies 
Every day in the UK the sewers collect over 11 billion litres of wastewater and this is 
treated at about 9,000 STPs (Defra, 2012). Sewage treatment in the UK, and the rest of 
Europe, is influenced by the UWWTD. The directive protects water bodies that are 
adversely affected by STP discharges. STPs with agglomerations over 10,000 population 
equivalents (PE), discharging to water bodies designated as sensitive areas, must employ 
more stringent treatment. A reduction in the pollutant(s) must be seen within seven years 
of the sensitive area designation. The stringent treatments employed are disinfection to 
protect bathing or shellfish waters, and nutrient removal to protect water bodies from 
eutrophication caused by nitrate (NO3
-
-N) and phosphorus in STP effluents. 
 
The effluent quality requirement for STPs discharging wastewater to eutrophic areas 
depends on the size of the agglomeration. STPs with a population equivalent of between 
10,000 and 100,000 must achieve a total nitrogen (total-N) concentration of 15 mg l
-1
 
and/or a total phosphorus (total-P) concentration of 2 mg l
-1
 in the final effluent. STPs with 
a population equivalent of > 100,000 have to meet stricter consents at 10 mg l
-1
 and/or 
1 mg l
-1
 total-N and total-P, respectively (91/271/EEC). 
 
1.5.1 The conventional activated sludge (CAS) process 
The activated sludge process (ASP) is a type of secondary treatment that uses a microbial 
biomass to treat the influent wastewater by removing organic matter. The typical 
configuration consists of a primary clarifier, aeration tank, a secondary clarifier and a 
process for returning a portion of the secondary sludge. Preliminary treatment at the head 
of the treatment plant is also required to remove larger particulate material. Figure 1.3 
shows the flow of wastewater through a typical STP. In the aeration tank the wastewater is 
mixed and aerated with the microbial suspension. Secondary treatment is characterised by 
short hydraulic retention times (HRT) i.e. the length of time the wastewater remains in the 
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reactor and solid retention times (SRT) i.e. the length of time the sludge/solids remain in 
the reactor. Once the sewage leaves the aeration tank it then flows to a clarifier where the 
microbial suspension is settled and thickened. Some of this settled biomass is returned to 
the aeration tank, to continue biodegradation of the influent organic material. Whilst a 
portion of settled activated sludge is removed regularly to maintain the SRT. This wasted 
sludge will receive additional treatment usually in an anaerobic digester (Metcalf and 
Eddy, 2003). 
 
Figure 1.3  The treatment processes in a typical conventional activated sludge plant. 
 
1.5.2 Biological nutrient removal (BNR) 
BNR is a secondary treatment that utilises the ASP. The wastewater is subject to a higher 
level of treatment compared to the conventional aeration only activated sludge treatment. 
The wastewater passes through aerobic, anoxic and anaerobic zones, where the processes 
of nitrification, denitrification and biological phosphorus (bio-P) removal are encouraged. 
The SRT of plants operating with nitrogen removal is higher compared with CAS plants, 
which are designed for biochemical oxygen demand (BOD) removal only. 
 
The removal of nutrients by biological means, as opposed to the use of chemicals, is 
preferential, if a higher quality, and lower quantity sludge are desired (Oldham and 
Rabinowitz, 2002), and with the growing global urbanisation of society, coupled with 
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increasingly stringent sludge reuse/disposal regulations and increasing public pressure, this 
is an important consideration for the industry (Liu and Tay, 2001). The activated sludge 
process is the most common type of treatment for BNR (Seviour and Nielsen, 2010).  
 
1.5.2.1 Microbiology of BNR 
Activated sludge systems become more complex when plant configuration is adapted for 
BNR. This is because three broad groups of microorganism are required to remove 
nitrogen and phosphorus; they are nitrifying autotrophs (aerobic conditions), denitrifying 
heterotrophs (anoxic conditions) and polyphosphate-accumulating organisms (PAOs) 
(anaerobic-aerobic conditions) (Barker and Dold, 1997). These bacteria require certain 
environmental conditions in order to flourish. Figure 1.4 is a summary of the biochemical 
processes involved in BNR and the STP reactors where they occur. 
 
Figure 1.4  The main biochemical processes involved in biological nutrient removal and the full-
scale reactors where they occur. The reactions shown are the enhanced biological phosphorus 
removal process, this occurs under intermittent anaerobic and aerobic conditions. The process of 
nitrification occurs in the aerobic reactor and denitrification occurs in the anoxic reactor. VFA = 
volatile fatty acids; PHB = polyhydroxybutyrate; poly-P = polyphosphate. 
 
Nitrification is a two-step process involving two groups of autotrophic bacteria. In the first 
stage the genus of microorganisms known as Nitrosomonas oxidise ammonium (NH4
+
-N) 
to nitrite (NO2
-
-N). Whilst in the second stage, NO2
-
-N is oxidised to NO3
-
-N by a group of 
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microorganisms called Nitrobacter. Both these processes occur in the aerobic reactor. 
Species from both genera are commonly isolated from most nitrifying activated sludge 
(NAS) samples (Daims et al., 2006). Their carbon for cell growth is obtained from CO2. 
Therefore, organic substrate is not essential for the growth of nitrifiers (Jeyanayagam, 
2005).  
 
Denitrification is an essential part of nitrogen removal, where facultative heterotrophic 
bacteria reduce NO3
-
-N to N2 under anaerobic/anoxic conditions. This process requires a 
source of rapidly biodegradable organic matter (Jeyanayagam, 2005). 
 
Enhanced biological phosphorus removal (EBPR) is generally achieved, by recycling PAO 
enriched sludge and wastewater, through alternating anaerobic and aerobic spatial or 
temporal stages, in which various chemical transformations occur (Gebremariam et al., 
2012). During anaerobic conditions i.e. a zone free of NO3
-
-N and dissolved oxygen (DO), 
carbon is taken up in the form of volatile fatty acids (VFA) and stored as the organic 
polymer polyhydroxyalkanoate (PHA), more specifically known as polyhydroxybutyrate 
(PHB). Glycogen and polyphosphate are codegraded and orthophosphate (PO4
3-
-P) is 
released into the bulk liquid (Mino et al., 1998; Zuthi et al., 2013). The anaerobic zone is 
followed by an aerobic zone where the organic polymer is oxidised, glycogen is 
synthesised, and PO4
3-
-P is assimilated to synthesise polyphosphate (EPA, 2009; 
Gebremariam et al., 2012; Mino et al., 1998).  
 
EBPR can succeed with or without nitrification, however, when nitrification occurs in the 
aeration basin the return activated sludge (RAS) will contain NO3
-
-N, resulting in some 
metabolism of the VFA before storage, thereby reducing the amount available to the 
PAOs. Consequently some form of denitrification must be employed to reduce/remove the 
NO3
-
-N from the RAS. The right carbon source is essential for EBPR and this comprises 
Chapter 1 Literature Review 
31 
 
acetates and propionates. It is said that a ratio of at least 40:1 COD:TP in the influent is 
needed to reduce effluent phosphorus to less than 1.0 mg l
-1
 (EPA, 2009). Some of this 
chemical oxygen demand (COD) should consist of short chain VFAs. While the anaerobic 
zone serves mainly as a contact zone for PAOs with VFA, some fermentation, of easily 
biodegradable compounds to acetate and propionate, may take place (EPA, 2009). MeOH 
and similar compounds are not suitable carbon sources for bio-P removal (Oleszkiewicz 
and Barnard, 2006). 
 
1.5.2.2 Types of BNR treatment 
Nitrogen removal 
Most conventional nitrogen removing systems are single sludge processes; i.e. a single 
microbial community is employed for both nitrification and denitrification (Seviour and 
Nielsen, 2010). The most widely applied anoxic reactor type is a primary anoxic zone. 
Ludzack and Ettinger (1962) were the first to place the anoxic zone before the aerobic 
reactor, allowing the denitrifiers a source of organic material (influent wastewater), and 
reducing the active heterotrophic community in the aerobic zone, thus reducing 
competition for nitrifiers (Seviour and Nielsen, 2010). However, the zones were not 
separated, and the lack of control over mixing gave variable plant performances. Barnard 
(1975; 1976) considered it necessary to separate the anoxic and aerobic zones, and create 
recycles between them, mixing the RAS with the influent entering the anoxic zone. The 
redesigned plant was called the modified Ludzack-Ettinger process (Seviour and Nielsen, 
2010). 
 
Barnard went on to develop the Bardenpho process by adding another anoxic reactor after 
the aerobic zone, present in the modified Ludzack-Ettinger process. This increased the 
denitrification rates and produced an effluent with no NO3
-
-N (Seviour and Nielsen, 2010). 
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A re-aeration reactor was incorporated after the secondary anoxic zone to allow air 
stripping of N2 (Seviour and Nielsen, 2010). 
 
Nitrogen and phosphorus removal 
Barnard (1994) was the first to effectively eliminate both nitrogen and phosphorus from 
wastewater, by modifying the Bardenpho process. This was achieved by adding an 
anaerobic zone ahead of the primary anoxic selector, to produce the five-stage Bardenpho 
process (also known as the Phoredox process). This process was subsequently simplified, 
by increasing the size of the primary anoxic reactor and removing the re-aeration zone. 
This gave rise to the three-stage Phoredox process. Even simpler still is the Phoredox, 
designed for EBPR only. This system consists of an anaerobic zone at the head of the 
aeration basin. The RAS is pumped from the clarifier to the anaerobic zone. The process 
has a low SRT to avoid nitrification (EPA, 2009). 
 
The Johannesburg process was developed from the Phoredox system, with the aim to 
reduce the negative effects of NO3
-
-N on EBPR (Seviour and Nielsen, 2010). It has a pre-
anoxic tank ahead of the anaerobic zone to allow denitrification (EPA, 2009). The 
Westbank process is a modification of a five-stage Bardenpho, but without the secondary 
anoxic zone and the re-aeration zone. The process uses a step-feed arrangement for 
distributing primary effluent and VFA, generated from fermenting primary sludge, to the 
anaerobic and anoxic zones. The process consists of a small pre-anoxic zone, followed by 
an anaerobic zone, an anoxic zone, and an aerobic zone. The primary effluent is directed 
between the pre-anoxic zone, the anaerobic zone and the anoxic zone. The fermentation 
supernatant, containing VFAs, is fed directly to the anaerobic zone (EPA, 2008). The 
University of Cape Town process was designed with the same aim as the Westbank to limit 
NO3
-
-N in the anaerobic zone. It is a variation of the Phoredox process consisting of 
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anaerobic, anoxic and aerobic zones. NO3
-
-N are recycled from the aerobic zone to the 
head of the anoxic zone (EPA, 2008).  
 
1.5.3 Membrane bioreactors (MBRs) 
MBR technology is a combination of the ASP with a micro- or ultrafiltration membrane 
system (Mutamim et al., 2012). The activated sludge treatment is responsible for the 
biodegradation of the organic waste compounds, and the membrane system physically 
separates the solids from the liquid (Hoinkis et al., 2012). The membrane acts like the 
clarification tanks in the CAS process. The pore diameter of the membrane is in the range 
of 0.01-0.1 µm, so that particulates and bacteria can be kept out of the permeate (Hoinkis 
et al., 2012). MBRs are a promising technology for municipal and industrial wastewater 
treatment (Cirja et al., 2008). MBRs can be used in conjunction with BNR activated sludge 
as the final sedimentation process.  
 
1.5.4 Sequencing batch reactors (SBRs) 
The ASP originated in the early 20
th
 century from batch operated systems, however, as 
technology advanced, continuous flow processes superseded these batch systems (Shaw et 
al., 2009). However, there has been a resurgence of interest in batch systems, with SBRs 
successfully treating both municipal and industrial wastewater in Europe, China and the 
United States, particularly in areas characterised by low or varying flow patterns (Al-
Rekabi et al., 2007).  
 
The biological reaction processes, and separation of solids from the liquid, takes place in 
one tank during well-defined phases of a continuous cycle. The typical stages of a SBR 
cycle are designated fill, react, settle, draw and idle (Figure 1.5):   
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Supernatant
MLSS
Settled solids
(3) Settle(4) Draw
(5) Idle
(1) Fill
(2) React
(anaerobic/anoxic/
aerobic)
1. Fill: The influent to the tank can be raw wastewater or primary effluent. The length 
of the fill stage depends on the number of tanks, the volume in the SBR, and the 
flow rate of the effluent (Singh and Srivastava, 2011). 
2. React: The microbial biomass consumes the substrate during this stage, breaking 
down organic and inorganic matter. The flow of wastewater into the tank is 
terminated. SBRs are suitable for BNR, with the option to incorporate anaerobic, 
anoxic and aerobic phases. Excess sludge can be wasted at the end of the react 
phase, settle, draw or idle phases, and this maintains constant mixed liquor 
suspended solid (MLSS) concentrations and controls the SRT in the reactor. 
3. Settle: The microbial flocs are allowed to settle out, and the clear treated 
wastewater becomes separate from the sludge. 
4. Draw (decant): The treated supernatant, which is now separate from the solids is 
removed from the tank as effluent. 
5. Idle: The period between draw and fill is the idle period, which can be used for 
sludge wasting and dead time, where there is a multi-tank system in place.  
  
 
 
 
 
 
 
 
 
Figure 1.5  The five main sequential phases of a sequencing batch reactor cycle: (1) fill – addition 
of fresh wastewater to the reactor, (2) react – treatment of the wastewater by the microbial 
suspension, can contain aeration on and off phases targeted at the removal of different wastewater 
constituents, (3) settle – separation of the solid material from the treated supernatant by gravity 
settling, (4) draw – removal of the treated supernatant and (5) idle – period before the next cycle 
begins. 
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SBRs offer a number of benefits over the CAS process; they are cost-effective due to lower 
operating costs, have a reduced operator input owing to online control, a reduced demand 
for site space, and the dynamic nature of these systems can be adapted to suit variable 
wastewater compositions and flow rates (Al-Rekabi et al., 2007). Numerous laboratory 
studies have used SBRs to understand the processes involved during BNR, and now this 
application has been extended to full-scale STPs (Al-Rekabi et al., 2007). SBRs provide 
excellent control over oxygen and Eh (oxidation-reduction potential) conditions, leading to 
separate aerobic, anoxic and anaerobic phases.  
 
There are, however, certain factors which limit operational flexibility. Firstly, the SBR can 
only handle a volume of wastewater, that fills the difference between the lowest decant 
level, and the maximum fill level. If the peak flow exceeds this then the cycle time will 
have to be shortened. Secondly, there must be sufficient biomass in the reactor, with a 
sufficiently long react phase, to provide the substrate and nutrient removals required. 
Thirdly, the settling characteristics of activated sludge are difficult to predict. The settling 
rate has a direct impact, on the length of time needed for the settle and draw phases (Shaw 
et al., 2009). Table 1.3 highlights some of the typical operating parameters for SBRs. 
SBRs can operate at lower food to microrgansim ratios (F:M) than other types of ASPs and 
are operated at longer SRTs and HRTs, and higher MLSS concentrations than the 
complete-mix activated sludge or the conventional plug flow systems.  
 
Table 1.3  The typical design parameters for a biological nutrient removing sequencing batch 
reactor (Metcalf and Eddy, 2003). 
Design parameter Value Units 
SRT 10 – 30 d 
F:M  0.04 – 0.10 kg BOD-1:kg MLVSS d-1 
MLSS 2000 – 5000 mg l-1 
HRT 15 – 40 h 
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SBR complexity can range from single tank unified processes, to complex multi-tank 
systems, such as the 24 SBRs currently treating a large proportion of the wastewater from 
Dublin (Seviour and Nielsen, 2010). SBRs are not only suitable for small communities, but 
now, due to modifications and variations in design, they can treat wastewater from large 
populations. The SBRs at Ringsend, Dublin, serves a population equivalent of 1.7 million, 
making it the largest double-decker SBR in the world (Celtic Anglian Water, n.d.).  
 
Real-time control of SBRs 
SBRs have proven to be a viable alternative to the continuous flow systems, for achieving 
BNR. The physical and chemical changes taking place due to microbial activity, can be 
detected through on-line monitoring (Singh and Srivastava, 2011). Shaw et al. (2009) 
suggested a number of online monitoring techniques for the advanced control of SBRs. 
This would enable adjustments of the reaction phase, to make the best use of the biomass, 
whilst the settle and draw phases could be adjusted depending on settling characteristics. 
Lee et al. (2001) found that real-time controlled SBRs, exhibited better performance in the 
removal of nitrogen and phosphorus, than SBRs with fixed-time operation.  
 
There is a number of parameters that can be measured and controlled, for example the 
oxygen uptake rate (OUR) can be measured to determine when aerobic treatment is 
complete, by detecting the drop in OUR, known as the nitrification shoulder. The Eh and 
pH indicate the completion of various stages of aerobic, anoxic and anaerobic treatment. 
Furthermore, online NH4
+
-N, NO3
-
-N and PO4
3-
-P analysers can indirectly measure 
nitrification and denitrification rates, as well as phosphorus release and uptake, to 
determine when the treatment phases are complete. These indirect analyses of microbial 
biomass activity can make the treatment process more efficient and save energy. 
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1.5.5 BNR in the UK and Europe 
There are significant regional differences in the treatment of wastewater in the EU, 
stemming from regulatory, financial considerations and geographical factors such as 
climate and hydrology. Richer countries in Northern Europe have been prompted to adopt 
stricter discharge consents, due to fees for failed discharges, and thus the overall effluent 
quality has improved (Oleszkiewicz and Barnard, 2006). 
 
In 1998 there were significant differences in the adoption of BNR between European 
countries. Germany had the highest compliance with 98% of its STPs employing tertiary 
treatment (i.e. BNR and disinfection treatment), whereas France was 86% compliant, and 
the UK had only 15% of STPs operating with tertiary treatment (Oleszkiewicz and 
Barnard, 2006). BNR treatment was slow to arrive in Europe because it had been 
discounted as unsuitable for cold climes. 
 
The dominant process in Europe is a one-sludge BNR system, consisting of a sequence of 
anaerobic, anoxic and aerobic stages (Oleszkiewicz and Barnard, 2006). The commonly 
used BNR processes in Northern Europe and the UK is the modified three-stage 
Bardenpho process, Johannesburg process and the alternating continuous flow processes 
such as Biodenitro and Biodenipho. Plants practicing EBPR tend to utilise a modified 
Bardenpho or the Johannesburg-type process, featuring a three-stage anaerobic-anoxic-
aerobic reactor with RAS pre-denitrification, similar to the Westbank process first 
developed in Canada. Others would employ a Phoredox-type configuration consisting of an 
anaerobic zone followed by an alternating simultaneous nitrification-denitrification 
process, with an oval configuration (Oleszkiewicz and Barnard, 2006). 
 
Due to the rising cost of chemicals and their associated environmental impact, many plants 
are turning to EBPR instead of chemical phosphorus precipitation (Manyumba et al., 
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2009). VFA production from primary sludge is becoming a popular method of substrate 
generation for EBPR. However, to achieve very low phosphorus levels (< 0.3 mg l
-1
), 
chemical precipitation is required. There is a growing attempt in the UK to adopt EBPR; 
however, many UK plants suffer from low carbon to nitrogen and phosphorus ratios in the 
wastewater. This has been overcome in the seven plants built by Thames Water (Maple 
Lodge, Reading, Slough, Little Marlow, Swindon, Wargrave, Aylesbury), which feature 
VFA production from primary sludge. The UK has adopted concepts developed in Western 
Canada, such as the Westbank process built at Slough and Reading.  
 
1.6 Fate and removal of APIs from STPs 
The most frequently detected classes of pharmaceuticals in wastewater are NSAIDs, 
antibiotics, beta-blockers, lipid-regulators, steroids, antiepileptics, X-ray contrast media 
and tranquilisers (Drewes, 2007). Within these classes there are certain APIs that are 
frequently reported in the literature, and as a consequence are known to occur in the 
environment worldwide. Carbamazepine is one such compound. There have been 
numerous reports of its presence in STPs, including in the USA (Spongberg and Witter, 
2008), Canada (Gagnon and Lajeunesse, 2008), China (Sui et al., 2010), Korea (Sim et al., 
2010), Taiwan (Lin et al., 2009), Australia (Ort et al., 2010), Greece (Kosma et al., 2010), 
Spain (Carballa et al., 2004), Germany (Ternes, 1998) and the UK (Kasprzyk-Hordern et 
al., 2009). The frequent detection of carbamazepine is due to its widespread use and 
persistent nature; the latter being the cause of its reported poor removal from STPs. 
Diclofenac, ibuprofen, acetaminophen, acetylsalicylic acid, its metabolite salicylic acid, 
gemfibrozil, naproxen, sulfamethoxazole, atenolol and propranolol are all commonly 
detected APIs in STPs.  
 
Unlike the antiepileptic drug carbamazepine, APIs such as caffeine, acetaminophen, and 
salicylic acid are well removed from the sewage treatment process (Monteiro and Boxall, 
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2010); however, these drugs are usually reported at the highest concentrations in the 
influent. Kosma et al. (2010) monitored an STP in Greece, and detected concentrations in 
the influent of 164 µg l
-1
 (salicylic acid), 25 µg l
-1
 (ibuprofen), 53 µg l
-1
 (acetaminophen) 
and 113 µg l
-1
 (caffeine). These APIs were removed significantly during wastewater 
treatment, resulting in maximum effluent concentrations of 10.1 µg l 
-1 
(salicylic acid), 
2.6 µg l
-1
 (ibuprofen), 1.7 µg l
-1
 (acetaminophen) and 13.9 µg l
-1
 (caffeine).  
 
Spongberg and Witter (2008) analysed 20 pharmaceuticals in influent, effluent and 
biosolids samples at three STPs in Northwest Ohio, USA. The antiepileptic drug 
carbamazepine, and clindamycin an antibiotic, were detected in every sample regardless of 
matrix or sampling date. Caffeine, salicylic acid, gemfibrozil and cotinine (a metabolite of 
nicotine) were all removed during wastewater treatment. However, concentrations of 
carbamazepine, clindamycin, diclofenac and sulfamethoxazole increased in the effluent by 
a factor of two or three in most cases.  
 
What is clear from the wealth of published works, is that the majority of APIs are not fully 
removed during sewage treatment. A study conducted by Gros et al. (2010) reported that 
removal efficiencies varied greatly between the individual APIs monitored, but overall, 
incomplete removal was observed. They attempted to link the removal efficiencies of the 
most representative APIs to therapeutic group. As a result, three different behaviours were 
documented: (1) an increase in concentration during sewage treatment, (2) no significant to 
medium removal, (3) high removal efficiency. Generally, macrolide antibiotics, the 
antiepileptic carbamazepine, and serotonin reuptake inhibitors showed either poor or no 
elimination. Lipid regulators, fluoroquinolone, tetracycline antibiotics, cholesterol 
lowering statin drugs, histamine H1 and H2 receptor antagonists, beta-blockers, beta-
agonists and the antidiabetic glibenclamide were partially degraded with removals between 
40% and 70%. However, two beta-blockers metoprolol and propranolol were poorly 
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removed from most of the STPs monitored (20%). The NSAIDs and the antihypertensive 
enalapril were the only APIs that exhibited high removal efficiencies. The only exception 
was the NSAID diclofenac, with a removal rate that varied from no elimination up to 
100%. By the author’s own admission, it was difficult to establish a link between 
therapeutic group and the removal efficiencies of the pharmaceuticals. Consistent with 
Gros et al. (2010), Lin et al. (2009) found the NSAIDs displayed the highest removal, in 
addition to estrogens and psychostimulants. Similarly, they found that the macrolide 
antibiotics were not removed, and were present at higher concentrations in the effluent, 
than the influent.   
 
In the study by Gros et al. (2010) the average removal efficiencies and the relative standard 
deviations (RSD) were reported for some of the most representative pharmaceuticals in 
each therapeutic group. Some APIs such as acetaminophen, salicylic acid, enalapril, 
naproxen and ibuprofen demonstrated high average removal efficiencies and low RSDs. 
This illustrates that these APIs had fairly consistent removal efficiencies over the whole set 
of STPs sampled. These APIs tend to be well removed during sewage treatment, which 
suggests it is their physical and chemical properties that are the reason for their removal. 
Alternatively, some APIs had very variable removal efficiencies, such as diclofenac; this 
suggests removal is dependent on other factors, not only chemical structure. STP 
configuration and operating conditions such as temperature, HRT, SRT, and Eh can also 
affect removal.  
 
It is often reported that some APIs are detected at higher concentrations in the effluent 
compared with the influent (Gros et al., 2010; Spongberg and Witter, 2008). This has been 
attributed to the deconjugation of glucuronide and sulphate conjugates during sewage 
treatment, due to the presence of the glucuronidase enzyme in the fecal coliform bacteria 
(Kümmerer, 2008). As a result, these metabolites entering STPs are converted back to the 
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parent compound during the STP process, and therefore, their concentrations increase in 
the effluent. Kümmerer et al. (2008) suggested that in instances where conjugates are the 
primary drug metabolite, they should be treated the same as the parent compound in 
environmental fate studies. 
 
The removal of organic chemicals from wastewater is determined by their biodegradability 
and physical and chemical properties, such as water solubility and hydrophobicity 
(Drewes, 2007). Many studies have reported that sorption to solid material, and 
biodegradation are the two main mechanisms for removing APIs from STPs. There is an 
obvious potential for biodegradation due to the high density of microorganisms present in 
STPs. Biodegradation primarily occurs during the secondary treatment step where the 
largest abundance of microorganisms are located. Removal of APIs from the sewage 
treatment process is an advantage of the process, since STPs are not designed to remove 
APIs. 
 
1.6.1 Biodegradation 
Biodegradation is highly dependent on the substrate’s chemical structure and initial 
concentration. Furthermore the activity of the degrading microbial population is also 
equally important to how and whether a substrate is biodegraded. It is determined by the 
species initially present in the inoculum, their relative population densities, the induction of 
their enzymes, and their ability to grow once exposed to a chemical. Environmental 
conditions, such as temperature, salinity, pH, oxygen concentration, Eh and concentration 
and nature of various substrates and nutrients also have an effect on the biodegradation of a 
chemical (Pavan and Worth, 2006). 
 
Organic compounds are used by microorganisms for energy and growth. However, 
pharmaceuticals are detected at low concentrations in STPs; these concentrations would be 
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unlikely to reach the lower limit of microbial enzyme affinity (Daughton and Ternes, 
1999). Therefore, pharmaceuticals are probably transformed coincidentally, provided there 
is another compound present that can supply the microorganisms with energy. This is 
known as cometabolism (Kümmerer, 2008).  
 
Microbial degradation can lead to transformation of the parent compound to lower weight 
degradation products (primary degradation) (Daughton and Ternes, 1999). Sometimes, 
these intermediate products can be more stable than the parent compound. They can vary 
in their toxicity and have a potential to accumulate (Kümmerer, 2008). Compounds may 
undergo complete mineralisation to CO2 and H2O (ultimate biodegradation); this is the 
only pathway that will fully remove the compound from the environment and render it 
harmless.   
 
The kinetics of biodegradation have been described by a variety of mathematical 
expressions, increasing in complexity in order to accommodate the numerous variables, 
which can affect the rate of biological removal, of an organic chemical in the aquatic 
environment (Battersby, 1990). First-order rate constants can be used to calculate half-lives 
for the disappearance of a chemical in batch systems (Equation 1.2):  
 
t1/    
ln 
k
 
(Equation 1.2) 
Where: 
t1/2 = the half-life 
k = constant  
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In the ERA of pharmaceuticals, the data generated in ready biodegradation tests, are used 
to calculate half-lifes for the fraction of parent compound remaining after sewage 
treatment. This is used as an estimate of environmental exposure, as a result of consumer 
use of the medicinal products and their subsequent release into the environment through 
STPs (Ericson, 2010).  
 
Care should be exercised when using half-lives to describe the biological removal of a 
chemical. This is because at low concentrations the rate of biodegradation is not constant 
during the entire reaction, because it can be limited by the rate of substrate entry into the 
cell (Battersby, 1990).  
 
If the concentrations of other components are also involved in biodegradation, the order 
normally changes to a higher order, e.g, second order, if the concentrations of two 
components are involved in the rate limiting step. If one of the two components is present 
in excess, and its change in concentration is negligible, the second order kinetic equation 
collapses to the pseudo-first order equation (FOCUS, 2006). In the literature, pseudo-first 
order degradation kinetics (Kbiol) have been used to describe the kinetics of API 
degradation (Joss et al., 2006). 
 
Joss et al. (2006) used Equation 1.3 to derive Kbiol rates for all pharmaceuticals with an 
experimental resolution limit of 0.1 l gSS
-1
 d
-1
. Accordingly, API removal can be described 
using the Kbiol calculation in Equation 1.3 (Joss et al., 2006; Ternes et al., 2004a): 
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 (Equation 1.3) 
Where: 
Ci = soluble substance concentration of the compound inside the reactor (µg l
-1
) 
Ki,biol = kinetic constant for pseudo-first order degradation (l gSS
-1
 d
-1
) 
SS = suspended solids concentration (gSS l
-1
). 
Based on the degradation rate constant, pharmaceuticals were fitted to the following three 
categories of removal from STPs (Joss et al., 2006; Ternes et al., 2004a). The kinetic rate 
constant units were expressed in l gSS
-1
 d
-1
. 
 
kbiol < 0.1   no substantial removal by biological degradation (< 20%) 
kbiol 0.1 < 10  degree of removal strongly dependent on reactor configuration 
(20% and 90%) 
kbiol > 10   more than > 90% removal by biological degradation.  
 
When comparing the Kbiol in a CAS system and MBR system Joss et al. (2006) observed 
significant variability in reaction rate constants. They identified three sludge characteristics 
that were of significant influence: (1) diversity of the active microbial biomass due to 
differences in microbial populations or the enzymatic activity (2) the fraction of active 
biomass in the total suspended solids and (3) the floc size of the sludge. 
 
1.6.2 Sorption 
Sorption is the process in which chemicals become associated with solid phases, in STPs 
these solids phases are MLSS. Sorption can be an important elimination process for APIs 
during sewage treatment (Ternes et al., 2004b). The sorption mechanisms of organic 
compounds on wastewater solids consist of two processes: (1) adsorption of the organic 
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compounds from the bulk liquid onto the surface of solids and (2) partitioning of the 
organic compounds between the aqueous phase and the organic matter within solids. A 
number of parameters have been used to attempt to predict the sorption behavior of 
pharmaceuticals.  
 
Jones et al. (2005) suggested that compounds with high Kow values are more likely to sorb 
to sludge, whilst compounds with lower values are known to stay in the aqueous phase. 
However, the Kow is not always the best indicator of sorption potential. Tolls (2001) found 
that prediction of log Koc (organic carbon partition coefficient) based on the 
hydrophobicity parameter log Kow leads to significant underestimation of log Koc and log 
Kd,DOM (solid-water distribution coefficient, dissolved organic matter) values. Furthermore, 
Tolls (2001) discovered the use of Koc is conceptually inapproapriate for veterinary 
pharmaceuticals, which suggests that mechanisms other than hydrophobic partitioning play 
a significant role in sorption. The lack of correlation between Kd, and Kow and Koc values 
was confirmed by Carballa et al. (2008) and Ternes et al. (2004a). A number of 
hydrophobicity-independent mechanisms such as cation exchange, cation bridging at clay 
surfaces, surface complexation, and hydrogen bonding appear to be involved. These 
processes are not accounted for by organic carbon normalisation (Tolls, 2001).   
 
Since log Kow values have been shown generally to be ineffective at describing sorption of 
negatively-charged, uncharged and positively-charged APIs during biological treatment, 
the n-octanol-water distribution coefficient (Dow) has been used to consider the effect, the 
current pH of wastewater has on the ionisation of APIs (Rosal et al., 2010). Sathyamoorthy 
and Ramsburg (2013) found that log Dow based models (pH corrected) offered a substantial 
improvement in prediction ability for negatively charged APIs, and marginal 
improvements for uncharged APIs. For positively-charged APIs the log Kow based model 
had significantly better predictive ability than the log Dow model. This can be explained 
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because both Kow and Dow are parameters which describe hydrophobic partitioning, while 
the positive charged species are also affected by electrostatic interactions with the typically 
net-negative surfaces of the sludge (Sathyamoorthy and Ramsburg 2013).  
 
Acidic pharmaceuticals such as the NSAIDs will be negatively charged at neutral pH, 
therefore, for polar APIs, sorption onto the sludge was found to be negligible (Ternes et 
al., 2004b). On the other hand beta-blockers will be positively charged at the pH of 
wastewater (pH 7), so it is likely that these cations may be prone to electrostatic 
interactions with negatively charged sludge material (Scheurer et al., 2010).  
 
Sathyamoorthy and Ramsburg (2013) concluded that Kow is not an effective predictor of 
API sorption in biological treatment plants, even when Kow is corrected to the experimental 
pH. The authors propose that specific characteristics of the sludge are required to enhance 
the predictive capability of such models. Hörsing et al. (2011) confirmed this by 
concluding that predicting sorption, based on Dow, is unsuitable since it does not consider 
the properties of the sludge. The Dow is more applicable to neutral industrial chemicals and 
pesticides since the main interactions would be hydrophobic.  
 
1.6.2.1 Sorption isotherms 
Sorption isotherms define the equilibrium between the concentration of a chemical in 
aqueous and solid phases (Schwarzenbach et al., 2003). The three most widely used 
environmental sorption isotherms are; linear (Equation 1.4), Freundlich (Equation 1.5) and 
Langmuir (Equation 1.7). 
 
Solid-water distribution coefficient 
The reversible sorptive exchange of chemicals between the water phase and solid phase 
sorbent is represented by the Kd. The Kd is defined as the ratio of the concentration in the 
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solid phase and in the aqueous phase at equilibrium. The Kd can be calculated from 
Equation 1.4 (Ternes et al., 2004a): 
 
 d   
 
S
 
(Equation 1.4) 
Where: 
Kd =  the solid-water distribution coefficient (l kg
-1
) 
X =  the concentration in the solid phase (µg kg
-1
) 
S =  the concentration in the aqueous phase (µg l
-1
). 
 
The coefficient takes into account the two main sorption mechanisms; absorption and 
adsorption. The assumptions of the Kd constant is that (1) only trace amounts of 
contaminants exist in the aqueous and solid phases, (2) the relationship between the 
amount of contaminant in the solid and liquid phases is linear, (3) equilibrium conditions 
exist, (4) the desorption rate is equal to the adsorption rate, (5) it describes contaminant 
partitioning between one sorbate (contaminant) and one sorbent (sludge), and (6) all 
adsorption sites are accessible and have equal strength (EPA, 1999). Some of these 
assumptions, however, are restrictive for use in natural heterogenous systems. For example 
competitive binding is likely to take place, between the contaminant of interest and other 
chemicals present (EPA, 2010).  
 
The Kd is the slope of the line of linear sorption, or the ratio of the equilibrium sorbed 
contaminant to the solution contaminant. This ratio can be significantly smaller at higher 
contaminant concentrations; if Kd is employed for concentrations outside the linear range 
then contaminant sorption will be underestimated. 
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Freundlich isotherm 
The nonlinear Freundlich isotherm is a commonly used isotherm, in which Kf and n are the 
Freundlich sorption coefficient and the linearity parameter, respectively. In the simplest 
case n = 1 and Kf is equivalent to the Kd. The Freundlich isotherm expressed as the 
adsorptive capacity (x/m) is described in Equation 1.5 (Metcalf and Eddy, 2003): 
 
 
 
       
 
    
(Equation 1.5) 
Where:  
x/m =  adsorption per unit mass of adsorbent. This is obtained by dividing the 
amount of adsorbate (x) by the weight of the adsorbent (m) (µg kg
-1
) 
Kf =  Freundlich capacity factor 
Ce   = equilibrium concentration of adsorbate in solution after adsorption (µg l
-1
) 
1/n = Freundlich intensity parameter. 
 
By taking the logarithms of the Freundlich isotherm, the linearised form can be obtained 
from Equation 1.6 (Metcalf and Eddy, 2003): 
 
log  
x
m
  log f   
1
n
log Ce 
(Equation 1.6) 
 
If the relationship of log x/m against log Ce is linear, it can be assumed that the Freundlich 
isotherm describes the adsorption characteristics of the compound. 
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Langmuir adsorption isotherm 
The Langmuir is an alternative sorption isotherm that may have the best fit in cases where 
the sorbent becomes saturated at higher API concentrations, i.e. sorbents with a finite 
number of sorption sites (Hörsing et al., 2011; Tolls, 2001). The Langmuir adsorption 
isotherm is defined in Equation 1.7 (Metcalf and Eddy, 2003): 
 
x
m
   
abCe
1   bCe
 
(Equation 1.7) 
Where: 
a, b =  empirical constants 
 
The Langmuir isotherm was developed by assuming: (1) a fixed number of accessible sites 
are available on the adsorbent surface, all of which have the same energy, and (2) 
adsorption is reversible. Equilibrium is reached when the rate of adsorption onto the 
surface is the same as the rate of desorption from the surface. The Langmuir sorption 
constants; a and b can be determined by plotting Ce/(x/m) versus Ce, Equation 1.7 can be 
rewritten as Equation 1.8 (Metcalf and Eddy, 2003): 
 
Ce
x m 
   
1
ab
  
1
a
 Ce 
(Equation 1.8) 
 
1.7 Sewage treatment technologies and API removal 
1.7.1 MBR treatment 
Many studies have investigated the potential of MBRs to remove APIs during wastewater 
treatment, by comparing these systems to other types of ASP including BNR and CAS. 
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MBRs can operate at high MLSS concentrations because the membrane separation step is 
not limited by sedimentation capacity, which will result in longer SRTs (Cirja et al., 2008). 
These conditions can be favourable for API biodegradation. A longer SRT will allow the 
development of a more diverse microbial population, because slower growing microbes 
such as nitrifiers have the opportunity to flourish. A diverse population will have broader 
physiological capabilities giving rise to different biodegradation pathways (Clara et al., 
2005b).  
 
Longer SRTs might improve the removal of APIs for reasons other than diversifying the 
microbial population. For example, adaptation may play a role in improving 
pharmaceutical removal, because the bacterial biomass has the opportunity to acclimate to 
certain xenobiotics. The extended contact time gives them the opportunity to broaden their 
enzymatic capabilities (Suarez et al., 2010). It might be possible that systems operating at 
high SRTs could promote the release of less specific enzymes due to cell lysis (Suarez et 
al., 2010), or as Ternes et al. (2004b) suggest, the microbial population may diversify their 
metabolic activity in response to the lower sludge loading rate at plants with high SRTs.  
 
The literature demonstrates that MBR treatment in some instances can improve 
pharmaceutical removal compared to ASP (Kimura et al.,  007; Radjenović et al., 2009), 
and at worst, these systems seem able to perform as well as activated sludge treatment 
(Clara et al., 2004; Joss et al., 2005). Some researchers have demonstrated a link between 
SRT and pharmaceutical removal (Clara et al., 2005a; Kimura et al., 2007), whereas others 
have observed no relationship (Bernhard et al., 2006). It is unlikely that SRT will exert a 
negative impact on pharmaceutical removal, and it is probable that there is an improved 
opportunity for pharmaceutical removal at increased SRT. 
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1.7.2 BNR treatment 
Many studies have taken samples from full-scale BNR STPs. In the majority of studies 
detailed operating conditions and plant configurations are not provided. This makes it 
challenging to understand the influence of operating conditions on the removal of APIs, 
and to compare removal between STPs.  
 
Tables 1.4 and 1.5 summarise a selection of the key papers that have looked specifically at 
the mechanisms involved in API removal during BNR treatment. BNR can affect 
pharmaceutical removal for a range of reasons; SRTs and HRTs are longer in BNR plants, 
the Eh will vary in aerobic, anoxic and anaerobic zones, and the collective effect of these 
operating conditions, is to diversify the microbial populations in the STP, this in turn will 
lead to a wider array of degradation pathways (Jones et al., 2007).  
 
The operating conditions and microbial populations present in BNR and CAS plants are 
different. APIs are affected by biodegradation; therefore, these characteristics could lead to 
contrasting removals in these systems. Many of the studies summarised in Table 1.4 
conclude that NAS elicits a positive outcome on the degradation of APIs (Andersen et al., 
2003; Batt et al., 2006; Suarez et al., 2010; Vader et al., 2000; Wick et al., 2009). 
 
Vader et al. (2000) suggests the removal of EE2 by NAS could be due to cometabolism 
occurring in the nitrifying tanks. Several bacterial strains such as N. europaea, an obligate 
chemolithotrophic ammonia-oxidising bacterium, produce monooxygenase enzymes that 
are known to aerobically cometabolise organic compounds (Vader et al., 2000). N. 
europaea is widespread in the environment, catalysing the oxidation of NH4
+
-N in soils, 
natural waters and NAS. Shi et al. (2004) investigated the degradation of estrogens with 
pure cultures of N. europaea, and found that these bacteria contribute to estrogen 
degradation by NAS. Ammonia oxidising bacteria are known to be capable of oxidising 
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various hydrocarbons (Shi et al., 2004), which suggests that this cometabolic activity 
might extend to APIs.     
 
Table 1.4  Key studies on the ability of nitrifying activated sludge to remove pharmaceuticals. 
Compound(s) 
investigated 
Type of sewage 
treatment 
Full, pilot and 
lab scale 
Main findings 
Literature 
reference 
E1, E2 and EE2 NAS, D and CP Full Removal of E1 and E2 was > 98% 
after two denitrification tanks. 90% 
of EE2 was eliminated from the STP 
due to aerobic biodegradation.  
Andersen et al. 
(2003)  
E1, E2 and EE2 NAS Full Removal rates of > 96% achieved for 
E1 and E2, whilst EE2 removal was 
poor at < 6%. 
Kanda and 
Churchley (2008)  
Iopromide and 
trimethoprim 
CAS and NAS Full and  
Lab 
Higher removal of both APIs in NAS 
compared to CAS in lab batch 
reactors and full-scale plants.  
Batt et al. (2006)  
Sulfamethazine, 
sulfamethoxazole, 
sulfathiazole and 
trimethoprim 
Primary 
sewage, CAS, 
NAS and final 
effluent batch 
experiments. 
Lab The three sulfonamides were 
removed from three matrices, except 
the final effluent. Trimethoprim was 
poorly removed from all matrices 
except from the NAS where it was 
completely removed in 3 d. 
Perez et al. 
(2005) 
EE2 NAS with high 
and low 
nitrifying 
capacity 
Lab NAS capable of oxidising NH4
+
-N at 
a rate of 50 mg NH4
+
 g
-1
 dw h
-1
 
degraded EE2 at a rate of  
1 µg g
-1
 dw h
-1
. No degradation of 
EE2 was measured in activated 
sludge with low nitrifying capacity. 
Vader et al. 
(2000) 
10 APIs* CAS and 
NAS 
Lab Higher removal of all APIs in NAS 
compared to CAS. The removal 
efficiency of APIs increased with the 
increase of initial NH4
+
-N 
concentration. 
Tran et al. (2009) 
16 PPCPs† Two activated 
sludge systems; 
(1) NAS and (2) 
D 
Lab Removal of all compounds was 
higher in the nitrifying system with 
faster rates of degradation for the 
majority of compounds.  
Suarez et al. 
(2010) 
D = denitrifying, CP = chemical phosphorus removal, dw = dry weight. 
*Clofibric acid, gemfibrozil, ibuprofen, fenoprofen, ketoprofen, naproxen, diclofenac, indomethacin, 
propyphenazone and carbamazepine. 
†Fluoxetine, citalopram, E2, EE2, ibuprofen, naproxen, diclofenac, carbamazepine, trimethoprim, 
roxithromycin, sulfamethoxazole, erythromycin, galaxolide, tonalide, celestolide and diazepam. 
 
The bacteria responsible for nitrification grow much more slowly than heterotrophic 
bacteria, therefore BNR plants have longer HRTs and SRTs than those plants designed for 
BOD removal only (Metcalf and Eddy, 2003). The literature summarised in Table 1.5 
suggests that API removal is improved at these extended HRT and SRTs. When 
denitrification and bio-P removal are also included, the HRT is extended further to ensure 
the removal of all the target nutrients. Longer HRTs will allow the microbial biomass an 
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extended contact time with the API; this may not only increase the rates of biodegradation, 
but also the sorption of APIs to the activated sludge. 
 
Other studies have focused on API removal under the varying Eh conditions present in 
BNR plants (Joss et al., 2004; Kujawa-Roeleveld et al., 2008). These studies have shown 
that reducing environments, i.e. anoxic and anaerobic conditions can lead to the partial 
degradation of APIs; however the majority of degradation occurs under aerobic conditions.  
 
Table 1.5  Key studies on the impact of hydraulic and solid retention time on pharmaceutical 
removal. 
Compound(s) 
investigated 
Type of 
sewage 
treatment 
Full, pilot 
and lab 
scale 
Main findings 
Literature 
reference 
Beta-blockers and 
psycho-active drugs 
NAS and D Full The reduction in API load was mainly 
limited to the activated sludge unit 
equipped for nitrification and 
denitrification rather than the tank 
employing BOD removal only. 
Additionally, it was the nitrifying 
tank, not the denitrifying tank that was 
responsible for the observed API 
removal. 
Wick et al. 
(2009) 
5 APIs CAS with CP Full Ibuprofen was well removed from two 
STPs, but had a low removal (27%) 
from the STP with the lowest HRT. 
Tauxe-Wuersch 
et al. (2005) 
9 APIs CAS, NAS, D 
and CP  
Lab and  
Full 
A minimum SRT of 10 d was 
necessary to achieve high removal of 
APIs, corresponding to the design 
criteria for nitrogen removal. Removal 
< 20% was observed for ibuprofen 
from a lab reactor operated at an SRT 
of 2 d and from two full-scale plants 
operated at SRTs of 0.6 and 2 d.   
Clara et al. 
(2005b) 
Ibuprofen, naproxen, 
carbamazepine, 
diclofenac and 
diazepam. 
NAS and D Lab The reactor operating at a HRT of 1 d 
and SRT of 60 d achieved 82% 
removal of ibuprofen and 68% 
removal of naproxen. The removal of 
carbamazepine, diazepam and 
diclofenac was < 20%. 
Suarez et al. 
(2005) 
Ibuprofen, naproxen, 
ketoprofen, diclofenac 
and clofibric acid.  
NAS and D Lab The reactor was operated at a HRT of 
48 h and a SRT of approx. 100 d. 
Removal of ibuprofen, naproxen and 
ketoprofen was > 87%, but diclofenac 
removal was between 49 and 59%. 
Kosjek et al. 
(2007) 
Tetracycline  SBR Lab Tetracycline exhibited significantly 
lower removal from the SBR 
operating at a lower HRT and SRT. 
Kim et al. 
(2005) 
D = denitrifying, CP = chemical phosphorus removal 
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1.8 Radiolabelled chemicals in laboratory studies 
Fate studies using radiolabelled chemicals, are often prescribed for regulatory tests, that 
use the data to refine PECs of pharmaceuticals in ERAs, and as part of the REACH 
guidelines to determine the persistency component of the persistence, bioaccumulation and 
toxicity (PBT) assessment for industrial chemicals. These tests are typically closed batch 
systems that are dosed with the radiolabelled or unlabelled chemical. The distribution of 
the chemical within the test system is then monitored by a number of analytical techniques. 
The OECD 301 ready biodegradability tests are the recommended tests for the phase II tier 
A fate assessments featured in the ERA. There are more complex OECD tests that can be 
prescribed to assess the fate of a chemical. These tests are referred to as simulation tests, 
and they are designed to represent more realistic environmental conditions in order to 
generate biodegradation kinetics. These tests include the inherent OECD 302 
biodegradation screens and the recently authorised OECD 314 tests. Simulation tests such 
as the 303A activated sludge laboratory simulation can also be requested under some 
circumstances (although these tests are not included in the ERA process). OECD 303 tests 
are less frequently used because they are very costly systems to operate, even though they 
offer the most realistic environmental conditions to assess a compounds fate.  
 
A number of published studies have investigated the fate of organic pollutants in 
radiolabelled laboratory experiments (Berg and Nyholm, 1996; Federle and Itrich, 1997; 
Shimp and Larson, 1996). A small fraction of these studies have looked at the fate of 
radiolabelled pharmaceuticals in activated sludge. Federle and Itrich (1997) produced a 
paper on the approach for assessing the kinetics of primary and ultimate biodegradation of 
chemicals in activated sludge. The radiolabelled test chemical was dosed at 
environmentally relevant concentrations, and samples were periodically removed and 
acidified to determine evolved 
14
CO2. Solid samples were also collected and extracted to 
recover parent and metabolites. As a result of the sampling regime the loss of parent, 
14
CO2 
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evolution and incorporation into biomass could be determined, and rates of decay or 
production fitted accordingly. All radiolabelled studies follow similar approaches to those 
used by Federle and Itrich (1997). 
 
Ericson (2010) evaluated a newly approved OECD 314B method for investigating APIs in 
activated sludge. It is a method that may be more suitable for phase II tier A testing and to 
the data needs of the ERA (Ericson, 2010). The test utilises realistic concentrations of test 
chemical and biomass, without the considerable costs and resources of the OECD 303 
tests. Samples from the mixed liquor were removed to measure the total amount of 
radioactivity remaining, dissolved radiolabelled 
14
CO2, parent compound remaining and 
the radioactivity sorbed to the solids. Samples were also taken from the CO2 traps to 
determine the amount of evolved 
14
CO2. The 314B system was compared to a 301B ready 
biodegradability test. In the 301B system, biodegradability was determined by measuring 
evolved CO2 from the unlabelled test compounds. None of the APIs met the criteria for 
ready biodegradability in the 301B test, which is defined as 60% mineralisation in a 10 d 
window. In the 314B tests more mineralisation was recorded and one compound passed as 
readily biodegradable. However, the additional sludge biodegradation data collected in the 
314B test demonstrated that all compounds were observed with loss of parent and the 
appearance of metabolites.  
 
Radioactivity can generate large quantities of detailed data, on the fate of a compound, if 
used to determine mineralisation, parent compound removal and metabolite production. By 
generating data on parent compound removal, PECs could be refined accordingly. This 
study also highlights the importance of designing tests that are environmentally realistic, if 
comparable fate in full-scale STPs is required. Furthermore, the authors suggest the 314B 
could progress the ERA data package from one that focuses on ready biodegradability, to 
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one that characterises elimination rate and extent of primary and ultimate biodegradation 
during sewage treatment (Ericson, 2010). 
 
Environmentally relevant and detailed fate data can be obtained by dosing radiolablled 
compounds into laboratory STP simulations. Only a handful of studies have examined this 
in the laboratory. The fate of 
14
C-diclofenac and its main human metabolite 4’-
hydroxydiclofenac (4’ H F) were investigated in a MBR by Bouju et al. (2011). The 
spiking solution consisting of  4.6% 4’ H F and 64.3% diclofenac, was administered as 
a single dose. The radioactivity was monitored in the permeate, biomass and gas traps over 
a period of 12 d. It was observed that the majority of radioactivity left the reactor in the 
permeate, whilst little radioactivity sorbed to the solids or was mineralised. An additional 
three compounds were detected in the permeate samples, which demonstrates that some 
primary degradation was occurring. The authors suggest these products originated from the 
degradation of 4’ H F. However, the study highlighted the poor biodegradability of 
diclofenac. 
 
In a similar study conducted by Cirja et al. (2007), two different 
14
C labelled isotopes of 
EE2 were dosed into an MBR. The runs with these compounds were carried out separately, 
and both were dosed continuously to the reactor. The authors used radiolabelled isotopes to 
overcome analytical difficulties, which were related to the quantification of low 
concentrations of xenobiotics in complex sludge matrices. The MBR had previously been 
fed with unlabelled EE2 before dosing with 
14
C-EE2. The fate of both compounds in the 
MBR was similar. They detected little radioactivity in the effluent during the first few 
hours of dosing, whilst there was a rapid increase of radioactivity associated to the 
activated sludge. After 3 d of dosing the radioactivity in the effluent tended to stabilise, 
and the increase of radioactivity in the sludge fraction slowed down. These results show 
that EE2 residues have a high tendency to sorb onto sludge, even though the reactor had 
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been fed with unlabelled EE2 for 29 d beforehand. Less than 1% of the radioactivity was 
mineralised. Overall between 79% and 80% of the total applied radioactivity was removed 
from the MBR. A metabolite was detected by radio-HPLC (high-performance liquid 
chromatography), and this increased over the period of dosing, and consisted of 5% of the 
total radioactivity contained in the effluent extract. 
 
A continuous flow through activated sludge configuration was used by Junker et al. (2006) 
to investigate radiolabelled antibiotics. The simulation is a modified setup of the OECD 
303A continuous laboratory scale sewage simulation. The system was modified so it could 
be dosed with radiolabelled compounds. Samples of the influent, effluent, activated sludge 
and the gas phase (trapped volatiles and 
14
CO2) were collected. The total mineralisation of 
the three antibiotics varied from 25% for benzylpenicillin to < 1% for ceftriaxone and 
trimethoprim, accordingly, the amount of radioactivity detected in the effluent was lower 
for benzylpenicillin than the other two compounds. Less than 10% of the radioactivity 
remained in the reactor at the end of the study. This indicates the compounds did not 
significantly sorb to the sludge.  
 
These radiolabelled studies provide an insight into the fate of chemicals, which unlabelled 
studies fail to do. Mineralisation data is a significant benefit of using radiolabelled 
isotopes. Furthermore, HPLC and mass spectrometry systems, connected to radiodetectors 
can be used to obtain parent compound and degradation product profiles. The activated 
sludge processes, so far utilised for radiolabelled studies with APIs, include MBRs and 
CAS systems, SBRs have not been used in conjunction with 
14
C labelled APIs. Moreover, 
the fate of 
14
C labelled APIs has not been investigated in a BNR activated sludge system, 
as Figure 1.6 shows.  
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Figure 1.6  A summary of the published scientific papers investigating the fate of APIs during 
activated sludge treatment. The paper citations can be found in appendix B. 
 
1.9 Summary of literature 
Pharmaceuticals are a heterogeneous group of chemicals that vary in molecular weight and 
structure. This variability, in physical and chemical properties, makes it particularly 
challenging to predict their fate in the environment. Pharmaceuticals are manufactured in 
high quantities worldwide, to supply the growing population. Consumption figures for 
individual APIs of > 1 t are common in the UK, and in many countries around the world. It 
is therefore not surprising that pharmaceuticals are ubiquitous in the environment, at 
concentrations in the ng l
-1
 to μg l-1 range. The main route of entry into the environment, 
for human pharmaceuticals is via STPs, subsequent to the excretion of the parent 
compound and its metabolites in urine and faeces by patients. Once discharged from STPs, 
APIs have been detected in surface water, groundwater and even drinking water. The 
development of superior analytical techniques has made it possible to identify APIs, in a 
variety of environmental compartments. LC-MS/MS is the technique of choice, 
particularly for developing multi-residue methods for APIs in complex matrices due to its 
selectivity and sensitivity.  
 
The terrestrial environment is similarly contaminated with APIs, since many will partition 
into the sludge during the sewage treatment process. The waste sludge is removed from 
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STPs as a by-product of the process, and is most commonly disposed of by application to 
agricultural land. This will directly expose the soil and its biota to APIs. Furthermore, 
agricultural crops grown on land, fertilised with sludge, may become contaminated by 
APIs, which could then pose a human health risk.  
 
In the EU, the environmental risk posed by APIs is regulated through the EMA. REACH 
and the WFD also contribute to the regulation of these chemicals in the environment. A 
number of studies have investigated the toxicity of APIs on aquatic organisms. Diclofenac 
and propranolol are two APIs that have been shown to elicit a toxicological effect on fish 
at environmentally relevant concentrations. 
 
Sewage treatment in the UK and the rest of Europe is influenced by the UWWTD. STPs 
are required to implement stricter discharge consents for nitrogen and phosphorus, where 
their discharges enter sensitive areas. With these areas growing in number, the need for 
BNR plants is also increasing. BNR is a type of secondary treatment that utilises the 
activated sludge process. The wastewater is subjected to a higher level of treatment 
compared to the conventional aeration only activated sludge treatment. The wastewater 
passes through aerobic, anoxic and anaerobic zones, where the processes of nitrification, 
denitrification and bio-P removal are encouraged. 
 
There are two main removal mechanisms for APIs during sewage treatment; 
biodegradation and sorption. The majority of biodegradation occurs during the secondary 
treatment stage due to the high density of microorganisms. The degree of biodegradation is 
dependent on the chemical structure of the API, and the operating conditions at the STP. 
Sorption of APIs to suspended solids is dependent on the physical and chemical properties 
of an API, and the composition of the solid material.   
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It has been suggested in the literature that BNR has a potential to improve the removal of 
APIs. Since BNR treatment is becoming widespread in the UK, it is important to determine 
what outcome this type of treatment is having on the removal of APIs, from an ERA point 
of view. Furthermore, MBRs and SBRs are two types of activated sludge treatment that are 
increasing in popularity, over CAS treatment. A considerable number of studies have 
investigated the application of MBRs in treating APIs, but few have investigated the 
potential of SBRs to remove APIs, and fewer still have investigated a combination of BNR 
in an SBR configuration. It is essential that a range of treatments are investigated to further 
our understanding of API removal. 
 
The fate of APIs during full-scale treatment is difficult to quantify due to low API 
concentrations, the complex matrices typical in STPs, and the variable nature of 
wastewater. Quantifying these removal mechanisms in the laboratory, reduces this 
variability, and makes fate assessments more straightforward. However, problems can still 
arise due to analytical method inconsistencies, because of low concentrations and complex 
matrices. Therefore, the use of radiolabelled chemicals could be an advantageous 
alternative, due to the ease and accuracy of quantifying the 
14
C label. There have been no 
published studies to date, on the fate of radiolabelled APIs in BNR laboratory simulations. 
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Chapter 2 Research strategy and compound selection 
 
2.1 Research strategy 
2.1.1 Rationale 
Whilst there has been a considerable volume of research on the fate of APIs in full-scale 
STPs, less effort has focused on API removal from BNR STPs, and less still on API fate in 
laboratory simulations. The literature review identified SBRs as a treatment process that 
has received comparatively little attention, despite its growing popularity as a full-scale 
treatment option. Radioactively labelled compounds have been used sparsely in the 
literature, to investigate the fate of APIs. This is despite the fact that tracer techniques can 
provide detailed data on the fate pathways of a compound. The literature review therefore 
highlighted the need for more research into API fate, in laboratory BNR simulations. In 
addition 
14
C studies were identified as a technique, to generate more accurate and detailed 
data on the behaviour of APIs during sewage treatment. 
 
2.1.2 Aims and objectives 
The aim of this work was to investigate the behaviour, fate and removal of APIs during 
BNR sewage treatment. Prior to commencement of the work, a set of research objectives 
were established: 
 
 Devise a laboratory treatment system capable of achieving BNR. 
 Compare and contrast API behavior in the laboratory and field. 
 Extract the key removal mechanisms affecting each selected API during BNR 
treatment. 
 Evaluate the merits of BNR treatment for removing APIs. 
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 Make recommendations on the relevance of BNR for inclusion in the fate 
assessments of the ERA process. 
 
2.1.3 Strategy 
A prioritisation strategy was developed to concentrate the research effort on a subsample 
of candidate compounds, which were most suitable to the aims of the work. This is a 
common process undertaken in the literature in ecotoxicity/environmental fate studies on 
APIs (Boxall et al., 2011; Roos et al., 2012). A number of criteria were chosen in order to 
select the most suitable APIs for the work. An important criterion in this work was the 
selection of APIs possessing a variety of physical and chemical properties. This provided 
an opportunity to understand the environmental fate of chemically different compounds 
during sewage treatment. Furthermore, by selecting a broad range of compounds, the 
behaviour of APIs with similar characteristics can be predicted. APIs were selected based 
on consumption figures, the availability of a radiolabelled isotope, physical and chemical 
properties, biodegradability and availability of analytical methods. The compound 
selection process follows on from the research strategy. 
 
Robust and precise analytical methods were developed to quantify the APIs in wastewater. 
A radio-HPLC method was developed to analyse radiolabelled compounds in the 
laboratory BNR rig. By developing a radio-HPLC method for each compound, specific 
analysis of the APIs could be achieved. An analytical method suitable for quantifying the 
unlabelled APIs was required for the full-scale monitoring work. LC-MS/MS is the most 
widely used method in the literature for quantifying multiple compounds in complex 
matrices. Therefore a method was developed and validated to enable monitoring of the 
APIs in full-scale STPs. An SPE method was developed in order to concentrate the APIs 
and clean-up the sample matrices. This is one of the most popular preconcentration 
methods for pharmaceuticals in the literature. The SPE method was applied to wastewater 
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samples prior to analysis by radio-HPLC and LC-MS/MS. Chapter 3 discusses the 
analytical method development and validation processes. Section 3.1 looks at the method 
development of the SPE and LC-MS/MS methods. The final SPE and LC-MS/MS methods 
are outlined in Sections 3.1.6 and 3.1.7, respectively. The SPE-LC-MS/MS method 
validation is presented in Section 3.1.4 and the radiochemistry methods are detailed in 
Section 3.2. 
 
In order to investigate the mechanisms of API removal during BNR sewage treatment a 
laboratory rig was constructed. The chosen configuration was an SBR because there are 
numerous reports in the literature that BNR can be achieved in these systems. Furthermore, 
they are growing in popularity as full-scale plants, due to their flexibility and improved 
operator automation and control. Chapter 4 explains how the SBR rig was developed and 
Section 5.1 discusses the conditions within the SBR rig, and its efficiency in removing a 
set of wastewater variables. The laboratory rig created a controlled environment to 
investigate the selected APIs, and enabled the fate of each API to be elucidated, which 
demonstrated how efficient the system was, for removing APIs with a range of physical 
and chemical properties. 
 
Radiolabelled isotopes were selected for use with the laboratory rig, because of the 
accurate quantification of the 
14
C label in complex matrices such as wastewater. 
Furthermore, to improve the understanding of a chemicals fate, radioisotopes allow mass 
balances to be constructed, if sampling of each potential outlet is undertaken in a closed 
system. When a laboratory simulation mimics a full-scale STP, parallels can be drawn 
between the two, whilst the former also has the benefit of allowing data collection that is 
not possible in full-scale plants. Furthermore, the amount of ultimate biodegradation of the 
labelled isotope can be determined by trapping 
14
CO2 to provide mineralisation data. Die-
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away experiments were performed under batch conditions to generate data on API half-
lives (Section 5.2), which are often reported in the literature. 
 
Data was generated from dosing the APIs semi-continuously into the SBR rig, and 
sampling the off-gas, effluent and solid/water fraction of the WAS (Section 5.3). Specific 
analysis of the aqueous phase was conducted to determine how much parent compound 
remained after treatment. Apparent rate constants such as Kd and Kbiol were calculated, to 
gain more detail into API fate in full-scale STPs, and to compare these widely used 
constants to reported literature values.  
  
Chapter 6 contains the results from monitoring three operational BNR STPs, to understand 
how the removal in the laboratory SBR, compares to what occurs in the ‘real world’. 
Activated sludge and primary effluent collected from an STP, employing nitrification, 
were used to inoculate and feed the laboratory SBR, respectively. Background 
concentrations of the target APIs were analysed in the wastewater, to establish if 
concentrations could be linked to the removal of the investigated APIs in the SBR. An STP 
operating as a Bardenpho system, under nitrifying and denitrifying conditions, was 
sampled, since these Eh conditions were similar to those in the laboratory SBR. Finally an 
STP employing SBR treatment technology was sampled, to act as a direct comparison to 
the laboratory SBR design.    
 
Grab samples were collected from all three STPs, before and after the treatment processes. 
API removal efficiencies were calculated from the influent and effluent concentrations in 
the STPs. Of particular interest to this work, was the impact of the secondary treatment 
process for the removal of each API. Wastewater parameters measured in the laboratory 
rig, were also measured on samples collected for API analysis in the full-scale STPs. This 
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was to compare plant operating efficiencies with one another, and with the laboratory SBR, 
whilst also investigating connections between wastewater parameters and API behaviour.  
 
Based on a combination of laboratory and full-scale data, the behaviour, fate and removal 
of each API was elucidated during BNR treatment. This data provides an insight into the 
capabilities of BNR treatment for eliminating pharmaceuticals, particularly those 
displaying recalcitrant behaviour, as three APIs identified in the compound selection 
process (Section 2.2) have variable removal efficiencies from STPs. This allowed 
proposals to be made on the significance of BNR for removing APIs, and hence whether it 
should be included in the ERA fate assessments. Furthermore, this work will demonstrate 
whether the current biological treatment systems, can successfully remove recalcitrant 
APIs, before they enter the aquatic environment. 
 
2.2 Compound selection 
In order for the laboratory work to commence, the research compounds had to be selected. 
This was an important process, to ensure compounds were chosen that fulfilled the 
objectives of the work. This section discusses the necessity of working with a sub-section 
of the APIs on the market, the reasons behind their selection, and how the selection criteria 
were applied.   
 
With over 3,000 APIs licensed for use in the UK, it is impractical to study them all to a 
level resulting in a detailed investigation of their fate. Hence the initial part of this work 
involved developing and applying a prioritisation methodology, with the aim of selecting a 
suite of pharmaceuticals to investigate in this project. The chosen set of criteria was 
applied to an extensive list of pharmaceuticals prescribed in the UK, and this resulted in 
the selection of five compounds. 
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A number of scientific papers have published methods for ranking pharmaceuticals in 
order of priority, for environmental monitoring and ecotoxicity research. The most 
common selection criteria include human consumption data, environmental concentrations, 
ecotoxicity data, available analytical techniques, physical and chemical properties and 
persistency/fate (Roos et al., 2012; Sadezky et al., 2010). These criteria were assessed for 
their use in this study. The final criteria chosen were: a high consumption by the UK 
population, the availability of a 
14
C labelled isotope, a broad range of physical and 
chemical properties such as pKa and Kow, persistency/fate and the availability of analytical 
methods.   
 
2.2.1 Prioritisation by consumption data 
A high consumption was an important criterion for the selection of target analytes in this 
work. It was important to prioritise those pharmaceuticals consumed in the highest 
quantities in the UK. This is because highly consumed APIs are likely to be present at 
measurable quantities in STPs. There would be little to gain from developing analytical 
methods for APIs not detectable in STPs. Additionally APIs consumed in high quantities, 
are likely to be detected in environmental surface waters at high concentrations, however, 
this will depend on STP removal. These drugs are then a priority for fate and ecotoxicity 
studies, because of the environmental impact they could have on aquatic organisms. 
Removal from STPs is an important determinant of pharmaceutical concentration in the 
environment. Therefore, by focusing research efforts on the main polluters, we can 
investigate ways of removing them before they enter the environment.  
 
The IMS and NHS PrCA reports are the two most comprehensive sources of 
pharmaceutical consumption data in the literature (Jones et al., 2002; Sebastine and 
Wakeman, 2003; Watts et al., 2007). Therefore, these sources were used to prioritise 
pharmaceuticals in terms of their consumption. Two datasets were identified and the data 
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pooled, in order to capture all possible candidates. The PrCA data was taken from the NHS 
(2008) report and the IMS data was published by the DWI (Watts et al., 2007).  
 
The IMS hold information on the quantity of pharmaceuticals issued by hospitals and 
purchased by community pharmacies, and dispensing doctors, but does not capture 
pharmaceuticals issued in private hospitals, supermarkets that do not have a pharmacy 
licence, and direct manufacturer sales to the community (Watts et al., 2007). PrCA reports 
are published annually by the NHS, and include information on all prescription items 
dispensed in the community in England. It is free to the public. The PrCA reports include 
the number of prescription items dispensed for each pharmaceutical, but unlike the IMS 
data, no figures are presented on the weight of items dispensed. This data can be generated 
for each pharmaceutical, but it is laborious. To prioritise the pharmaceuticals in this work, 
the number of prescription items was used, as it was the simplest to extract from the 
dataset. However, this data is not necessarily representative of the weight of active 
ingredient (Jones et al., 2002). Nevertheless, it offers a good indication of those 
pharmaceuticals most likely to be consumed in the highest quantities by the population. 
The DWI data contains the top 50 drugs consumed in the UK in 2004, by weight (Watts et 
al., 2007).  
 
To reduce the size of the NHS dataset, a lower level cut-off was established to remove 
APIs from the selection process with fewer items prescribed. It was decided those drugs 
with < 100,000 prescription items, would be removed from the selection process. This still 
left a substantial number of APIs in the process. Many of those APIs with > 100,000 
prescription items were also on the DWI list. The lowest consumed weight on the DWI list 
was approximately 11 t y
-1
. By combining both sources of data there is a good chance the 
methodology has captured pharmaceuticals consumed in the highest quantities. The 
combination of NHS and IMS data provided a list of 327 compounds. 
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2.2.2 Prioritisation by availability of 14C labelled isotopes  
Radiolabelled isotopes were selected for use in the laboratory experiments. This is because 
they reduce the analytical difficulties, experienced with complex matrices; and mass 
balances of the 
14
C label can be determined. A further benefit of using radioisotopes is the 
ability to ascertain how much ultimate biodegradation of the test chemical is taking place, 
by trapping 
14
CO2. It is extremely expensive to have 
14
C isotopes custom synthesised, and 
because of budget constraints, it was essential that isotopes were available from a specialist 
company. The 327 compounds generated from the previous prioritisation step were 
individually assessed for the availability of a 
14
C isotope. This was conducted by 
researching the companies known to produce 
14
C isotopes (e.g, Perkin Elmer, American 
Radiolabelled Chemicals), and then searching their websites for each API on the list. This 
process significantly reduced the number of potential candidates to 24. These compounds 
can be found in Appendix E, along with their consumption data and physical and chemical 
properties.  
 
Caffeine was the only API on this list not to have any NHS prescription data. This is 
because caffeine is mostly used in combination with analgesics and antihistamines to 
improve their effectiveness. It is not widely used as a pharmaceutical in its own right; 
however, it is used to treat apnoea in newborns. By far the biggest use of caffeine is in the 
food and beverage industry (BASF, 2010).  
 
From this list of potential candidates, a range of compounds were selected for further 
study. The main factors considered in the final compound selection process, were the 
availability of LC methods in the literature, and the possession of a range of physical and 
chemical properties and biodegradabilities, so that different environmental fates could be 
investigated. 
 
Chapter 2 Research strategy and compound selection 
69 
 
Carbamazepine and diclofenac were taken forward as test compounds due to their notoriety 
in the literature for being recalcitrant chemicals (Ternes, 1998; Vieno et al., 2007; Zorita et 
al., 2009). The compounds caffeine, carbamazepine and diclofenac were already present 
on an LC-MS/MS method in use at the University of Portsmouth. The compounds selected 
had a range of molecular weights (138.1 to 296.2 g mol
-1
), water solubilities (4.5 to 
3808.0 mg l
-1
), literature pKa values (3.0 to 14.0) and Kow values (0.16 to 4.0). Furthermore 
biodegradation rates in the literature ranged from the readily biodegradable (salicylic acid 
and caffeine) to the highly persistent (carbamazepine). In summary, a suite of five 
compounds were identified, these included: salicylic acid, caffeine, propranolol, diclofenac 
and carbamazepine. 
 
2.2.3 Description of selected APIs 
2.2.3.1 Salicylic acid 
 
 
 
 
 
Salicylic acid is an analgesic with keratinolytic properties, it is applied topically in the 
treatment of hyperkeratotic and scaling conditions; such as dandruff, ichthyosis and 
psoriasis (Inchem, 1996). Salicylic acid is also a metabolite of acetylsalicylic acid 
(aspirin), which is one of the most extensively, used drugs in the world. Consequently, 
salicylic acid is frequently detected at high concentrations in STPs, with concentrations in 
the influent between 1.5 µg l
-1
 (Kasprzyk-Hordern et al., 2009) and 606 µg l
-1
 (Miege et 
al., 2009) and in effluents up to 68 µg l
-1
 (Matamoros et al., 2009). Salicylic acid has a 
high removal from STPs, with reported removal efficiencies as high as 99% (Gros et al., 
2010). 
Salicylic acid 
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Salicylic acid is a common contaminant of the environment, and has been detected at 
concentrations of 4.1 µg l
-1
 in rivers (Ternes, 1998), despite its high removals from STPs. 
This is most likely due to its ubiquitous presence in STPs, and considerable concentrations 
in the influent. As a result, effluent concentrations are still significant. Salicylic acid has 
also been detected in biosolids at concentrations up to 253 µg kg
-1
 dry mass (Spongberg 
and Witter, 2008). Table 2.1 summaries some of the key properties of salicylic acid.  
 
Table 2.1  The physical and chemical properties of salicylic acid. 
Property Value Units Reference 
Molecular weight 138 g mol
-1
 NCBI (n.d.) 
Solubility in water 
at 25°C 
2,240 mg l
-1
  NCBI (n.d.) 
pKa 3.0 - Marchese et al. (2003) 
Log Kow 1.13 - Comeau et al. (2008) 
Kd 105 
13 – 40  
(Primary sludge) 
30 – 776 
(Secondary sludge) 
l kg
-1 
l kg
-1 
 
Martín et al. (2011) 
Martín et al. (2012) 
Kbiol - - - 
 
2.2.3.2 Caffeine 
 
 
 
 
 
 
The main use of caffeine is in the food and drink industry. However, it is also used in many 
pharmaceutical preparations. Caffeine is often used as a human contamination tracer, 
because it is so widely consumed, and is well removed during sewage treatment. 
Caffeine 
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Therefore, its presence in surface water would indicate the discharge of raw wastewater or 
storm water (Lubliner et al., 2010).  
 
Caffeine is detected at high concentrations in STPs. During a one-year monitoring study of 
an STP in Spain, influent concentrations between 52 and 192 µg l
-1
 and effluent 
concentration between 1.4 and 44 µg l
-1
 were detected (Gómez et al., 2007). Removal rates 
> 85% have been reported for caffeine from STPs (Lin et al., 2009; Sui et al., 2010; Ying 
et al., 2009). As a result of its widespread use, the environment is also heavily 
contaminated with caffeine, and concentrations up to 1.4 µg l
-1
 have been detected in 
receiving water bodies (Comeau et al., 2008). Table 2.2 highlights the main physical and 
chemical properties of caffeine. 
 
Table 2.2  The physical and chemical properties of caffeine. 
Property Value Units Reference 
Molecular weight 194 g mol
-1
 NCBI (n.d.) 
Solubility in water 
at 25°C 
2.17 g l
-1
  IPCS (2012) 
pKa 14.0 - Lacey et al. (2008)   
Log Kow -0.07 - Behera et al. (2011)  
Kd 250 (sediment) 
56 – 1202 (primary 
sludge) 
< 300  
l kg
-1 
l kg
-1 
 
l kg
-1
 
Lin et al. (2010) 
Martín et al. (2012) 
 
Ying et al. (2009) 
Kbiol - - - 
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2.2.3.3 Propranolol 
 
 
 
 
 
 
Propranolol is part of the therapeutic class known as the beta-blockers. They are used to 
treat hypertension, angina, heart failure, atrial fibrillation and heart attacks. Propranolol is 
detected in STPs at lower levels than salicylic acid and caffeine, but this is probably due to 
its lower consumption level, which is reflected in the usage figures (Appendix E). 
However, propranolol is still detectable in STPs, with many published works reporting 
this. Influent concentrations up to 1.1 µg l
-1
 have been reported by Radjenović et al. 
(2009), whilst Gómez et al. (2006) detected concentrations as high as 6.5 µg l
-1
 in hospital 
effluents. Propranolol has a very varied removal rate from STPs, with values from 0 to 
96% (Scheurer et al., 2010; Ternes, 1998). The physical and chemical properties of 
propranolol are outlined in Table 2.3. 
 
Table 2.3  The physical and chemical properties of propranolol. 
Property Value Units Reference 
Molecular weight 259 g mol
-1
 NCBI (n.d.) 
Solubility in water 
at 25°C 
70 mg l
-1
 PhRMA (2009) 
pKa 9.5 - Lacey et al. (2008)  
Log Kow 3.0 – 3.1 - Sipma et al. (2010) 
Kd 366 ± 138 
(secondary 
activated sludge) 
270 (sediment) 
25 – 155 
(secondary sludge) 
480 
l kg
-1 
 
 
l kg
-1 
l kg
-1 
 
l kg
-1
 
Radjenović et al. (2009) 
 
 
Lin et al. (2010) 
Martín et al. (2012) 
 
Astrazeneca (2012) 
Kbiol - - - 
 
Propranolol 
Chapter 2 Research strategy and compound selection 
73 
 
2.2.3.4 Diclofenac 
 
 
 
 
 
 
Diclofenac is a persistent pharmaceutical with a low removal efficiency from STPs. 
Concentrations of diclofenac have been reported to increase after sewage treatment 
(Kasprzyk-Hordern et al., 2009). Diclofenac is one of the most widely studied 
pharmaceuticals in the environment, due to its persistence nature and known toxicity to 
vultures, as well as aquatic species (Oaks et al., 2004).  
 
A maximum diclofenac concentration of 1.2 µg l
-1
 was detected in rivers samples (Ternes, 
1998) and cytological effects have been observed in carp and trout exposed to diclofenac at 
environmentally relevant concentrations of 1.0 µg l
-1
 (Triebskorn et al., 2007). A study 
conducted by Stülten et al. (2008) identified metabolites of diclofenac in six different STP 
effluents. The metabolites are structurally similar to the parent compound, and due to the 
ecotoxicological effects of diclofenac, they could contribute to the overall pharmacological 
profile. A range of removal efficiencies have been reported for diclofenac during sewage 
treatment, from no removal (Rosal et al., 2010) up to 100% (Gros et al., 2010). However, 
removal is mostly below 50%. Maximum influent concentrations have been detected at 
6.3  µg l
-1
 and effluent concentrations at 6.5 µg l
-1
 in an STP treating hospital wastewater 
(Kosma et al., 2010). A summary of the physical and chemical properties of diclofenac can 
be found in Table 2.4. 
 
 
Diclofenac 
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Table 2.4  The physical and chemical properties of diclofenac. 
Property Value Units Reference 
Molecular weight 296 g mol
-1
 NCBI (n.d.) 
Solubility in water 
at 25°C 
2.37 mg l
-1
 NCBI (n.d.) 
pKa 4.1 - Wu et al. (2008) 
Log Kow 4.5 - Wu et al. (2008) 
Kd 16.0 ± 3.1 
118 ± 95 
l kgss
-1 
l kg
-1
 
Ternes et al. (2004a) 
Radjenović et al. (2009) 
Kbiol 0.25 ± 0.2 
1.2 (aerobic 
activated sludge) 
< 0.04 (anoxic 
activated sludge) 
l gss
-1
 d
-1
 
l gss
-1
 d
-1 
 
l gss
-1
 d
-1 
 
Ternes et al. (2004a) 
Suarez et al. (2010) 
 
2.2.3.5 Carbamazepine 
 
 
 
 
 
 
Carbamazepine is one of the most frequently detected APIs. It is a highly recalcitrant drug, 
and as a result, it often exhibits no removal during sewage treatment. For these reasons it is 
a target analyte in many environmental monitoring campaigns. Carbamazepine has been 
suggested as an ideal indicator of sewage derived contamination in the environment. This 
is because of its recalcitrant nature, it is applied orally so has a traceable metabolism 
pathway, and it can be traced back to one source drug (Zhang and Geißen, 2010). 
Carbamazepine is also sold in high quantities in many countries (Zhang and Geißen, 2010). 
Over 30 different metabolites of carbamazepine have been identified, with the main route 
being the formation of carbamazepine-10,11-epoxide, a pharmacologically active 
compound with anticonvulsant properties. These metabolites have been detected in STPs at 
higher concentrations than the parent compound (Leclercq et al., 2009). Influent 
Carbamazepine 
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carbamazepine concentrations have been detected up to 3.1 µg l
-1
 (Kasprzyk-Hordern et 
al., 2009). With effluent concentrations reported at 6.3 µg l
-1
 (Ternes, 1998). Some of the 
key properties of carbamazepine are outlined in Table 2.5. 
 
Table 2.5  The physical and chemical properties of carbamazepine. 
Property Value Units Reference 
Molecular weight 236 g mol
-1
 NCBI (n.d.) 
Solubility in water 
at 25°C 
18 mg l
-1
 NCBI (n.d.) 
pKa 13.9 - Wu et al. (2008)
 
Log Kow 2.45 - Urase and Kikuta, (2005) 
Kd 1.2 ± 0.5 
135 ± 39 
l kgss
-1 
l kg
-1
 
Ternes et al. (2004a) 
Radjenović et al. (2009) 
Kbiol < 0.1  l gss
-1
 d
-1
 Ternes et al. (2004a) 
 
To conclude, the rationale of the work was identified based on a literature search. This 
highlighted a number of gaps in the literature. As a result, the aim of the research was 
established, along with a set of objectives to achieve this. A discussion of how these 
objectives would be achieved was then outlined in Section 2.1.3, along with references to 
where the work was carried out in the thesis. The compound selection was the initial part 
of the research strategy. The outcome of the compound selection process was the 
identification of five pharmaceuticals for further investigation. These compounds are 
commonly investigated in the literature; however, it can be argued that researchers should 
focus their effort on a smaller number of compounds that are highly consumed, persistent, 
and are known to pose an environmental risk, in order to identify successful treatments for 
their removal (Verlicchi et al., 2012). The next part of the strategy was to develop 
analytical methods for the quantification of the compounds in the laboratory and field.  
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Chapter 3 Development of analytical methods 
 
Once the compounds were selected, robust analytical methods were developed. This 
chapter is divided into two sections; the first focuses on the development of the SPE and 
LC-MS/MS methods and their validation. These methods were necessary to analyse APIs 
in full-scale STPs. The second section explores the SPE and radio-HPLC methods used to 
analyse the APIs in the laboratory. 
 
3.1 SPE and LC-MS/MS methods 
Pharmaceuticals are typically found in the ng l
-1
 to μg l-1 range in STPs, thus traditional 
detectors such as ultraviolet-visible (UV-vis), fluorescence or refractive index are unable to 
provide the required sensitivity. Furthermore, sewage presents a complex matrix 
containing a multitude of chemicals, which will interfere with the target analytes. The 
traditional detectors are not selective enough to distinguish one compound from another in 
‘dirty’ samples. However, they do have their applications, and data from other detectors 
can compliment mass spectral data. 
 
LC-MS/MS combined with extensive sample clean up, usually involving SPE, is the 
method of choice for multi-residue analysis of APIs in complex environmental matrices. 
However, there are certain draw-backs with this technique, these are summarised as 
follows by Kasprzyk-Hordern et al. (2010): 
 
1. Analysing APIs with a broad range of physical and chemical properties, makes 
developing sample preparation and HPLC methods very challenging. Acidic, 
neutral and basic compounds have very different requirements.  
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2. APIs are present in the environment at very low concentrations. Therefore, sample 
preconcentration is necessary to obtain API concentrations above the LOQ for the 
instrument/method. 
3. ESI is prone to matrix effects, which can lead to signal suppression or 
enhancement. This can lead to inaccurate results. To prevent this, extensive sample 
clean-up is required.  
 
3.1.1 Purchase and preparation of chemicals 
Before the method development work could begin, analytical standards needed purchasing. 
The IS approach was used in this work, to account for the influence of matrix effects 
during ESI in the mass spectrometer. This is a widely used, and accepted method in the 
literature, for calculating accurate recoveries of target analytes in dirty matrices, where 
matrix effects are particularly common (Conley et al., 2008; Ferrer et al., 2010; Gracia-Lor 
et al., 2012). Salicylic acid, propranolol, diclofenac and carbamazepine were purchased in 
their deuterated form, and caffeine as a 
13
C ring-label. When IS are analogous to the native 
compound, it can be assured that the former will behave in the same way as the target 
analyte (Conley et al., 2008). However, because the IS has a slightly different mass, and is 
not found in the environment it will correct for analyte losses during sample preparation, 
and matrix effects during ESI.  
 
For large multi-residue LC-MS/MS methods, labelled analogues are employed only for a 
selection of the original analytes, this is due to their high costs and lack of commercial 
availability. Therefore a single IS is used to correct for multiple analytes. However, the IS 
needs to display the same matrix effects as the analyte (Gracia-Lor et al., 2011). It is 
preferential to purchase the labelled analogue of the native analyte, where possible. This 
could be accomplished in this method, because there were only five analytes, and the 
isotopically labelled compounds were available.  
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The five target analytes: salicylic acid, caffeine, propranolol, diclofenac and 
carbamazepine were purchased from Sigma-Aldrich Company Ltd, Dorset, England. The 
following isotopically labelled compounds were obtained for the five analytes: salicylic 
acid-d6 and caffeine-
13
C3 (Sigma-Aldrich Company Ltd, Dorset, UK), carbamazepine-d10, 
diclofenac-d4, and propranolol-d7 (qmx Laboratories, Essex, UK). The following solvents 
were purchased from Fisher Scientific UK Ltd, Loughborough: LC-MS grade MeOH, 
HPLC grade water, ACN, formic acid and acetic acid. 
 
Salicylic acid-d6, carbamazepine-d10, diclofenac-d4 and propranolol-d7 were supplied in 
solid form, and caffeine-
13
C3 was supplied as a ready prepared solution. Stock solutions of 
the four deuterated compounds were prepared by weighing out each IS (2.5 mg) and 
adding to separate volumetric flasks (5 ml). LC-MS grade MeOH was added to the 
volumetrics, which were then placed in an ultrasonic bath for 5 min. Once at room 
temperature, the stocks were made up to a concentration of 500 mg l
-1
. A working solution 
(5.0 mg l
-1
) containing the ISs was prepared in LC-MS grade MeOH by transferring the 
stock solutions (100 µl) and the pre-prepared caffeine stock (50 µl) to a volumetric 
(10 ml).  
 
The five target analytes were supplied in powdered form. Individual analyte stock 
solutions (500 mg l
-1
) were prepared in LC-MS grade MeOH. Working stock solutions (10, 
1.0 and 0.01 mg l
-1
) were prepared in LC-MS grade MeOH. An eight-point calibration 
range was prepared, by adding varying volumes of the working stock solutions to HPLC 
vials and the ISs (100 ng), and making up to 1 ml with H2O – LC-MS grade MeOH 
(80:20, v/v). The standard solutions were prepared at analyte concentrations of 1, 5, 10, 50, 
100, 250, 500 and 1000 µg l
-1 
and an IS concentration of 100 µg l
-1
. These concentrations 
were chosen to cover the expected concentration ranges of the pharmaceuticals in STPs, 
after preconcentration, with at least one standard concentration above the expected 
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detection levels. Fresh calibration standards were prepared each time a batch of samples 
was run on the LC-MS/MS. Analyte and IS stocks, and working solutions were stored at 
-18ºC to minimise the degradation of standards (Al-Odaini et al., 2010). 
 
3.1.2 LC-MS/MS method development  
Analysis of samples was performed by a 1200 series Agilent liquid chromatography 
system, connected to a 6410 triple quadrupole mass spectrometer, equipped with an ESI 
source. As described in Chapter 2, an LC-MS/MS method already existed for caffeine, 
carbamazepine and diclofenac and was in use at the University of Portsmouth, where the 
samples in this work were analysed. The method used two separate liquid chromatography 
methods for the analysis of APIs in positive and negative ionisation mode.  
 
Five separate solutions of the analytes (0.5 mg l
-1
), prepared in LC-MS grade MeOH, were 
injected directly into the mass spectrometer, to determine the ionisation parameters for 
each analyte. The software MassHunter Optimizer (Version B.01.04) was used to gather 
data on the two fragments with the highest abundance, i.e. the product (quantifying) and 
precursor (qualifying) ions, the fragmentor voltage and collision energy. This process was 
repeated for the deuterated ISs. Salicylic acid fragments in negative ionisation mode, 
whilst for propranolol this was in positive mode. Diclofenac is acidic like salicylic acid so 
it fragments in negative mode, whilst carbamazepine and caffeine fragment in positive 
ionisation mode.  
 
The original liquid chromatography method was trialled, to determine if it was suitable for 
the inclusion of salicylic acid and propranolol. The mobile phase in negative mode was A 
= HPLC water + 0.05% acetic acid (pH 3.4) and B = MeOH + 0.05% acetic acid and in 
positive mode it was A = HPLC water + 0.1% formic acid and B = ACN + 0.1% formic 
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acid. The mobile phase gradient was adjusted to improve the peak shape for salicylic acid, 
which was particularly problematic because it displayed a broad peak.   
 
The original method needed further adaption in order to achieve good peak shape and 
separation for the two additional analytes (salicylic acid and propranolol). Furthermore, to 
reduce the run time, it was decided to develop a method that allowed positive and negative 
ions to be analysed in one method. Table 3.1 summarises the combinations of liquid 
chromatography conditions trialled in the initial stages of method development. 
 
Table 3.1  The liquid chromatography conditions trialled in the initial phase of LC-MS/MS method 
development.  
Ionisation mode Column 
C8 C18 
+ 
Formic acid Formic acid 
Acetic acid Acetic acid 
- 
Formic acid Formic acid 
Acetic acid Acetic acid 
There were a total of eight liquid chromatography conditions tested.  
 
One of the advantages of mass spectrometry is that complete, chromatographic separation 
of the target analytes, is not necessary for their detection. However, it is advisable to have 
good separation in order to reduce matrix effects (Gros et al., 2006). The different liquid 
chromatography conditions trialled in Table 3.1 were reduced to two options. Both options 
would require compromise between the run time and peak separation. The first option was 
to select a method that produced good peak shapes, but suffered from the overlap of 
salicylic acid and carbamazepine peaks. This method used the C8 column and acetic acid 
mobile phase. The second option was a method that achieved higher ion abundances, but 
produced a broad salicylic acid peak, and still observed peak overlap, but between 
propranolol and carbamazepine. This method used the C18 column with the acetic acid 
mobile phase. 
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It was decided that peak overlap would not be accepted, in order to achieve one method for 
positive and negative compounds. Therefore, as a result of this, and because salicylic acid 
had a broad peak shape with the combined method, two separate methods were run for 
positive and negative ions. Therefore this extended the instrument run time, since each 
sample needed to be run in negative and then positive mode.  
 
3.1.3 SPE method development 
3.1.3.1 SPE with high performance liquid chromatography-ultraviolet (HPLC-UV) 
The SPE method originated from a protocol identified in Batt et al. (2008). The method 
was selected because it was developed for 48 human pharmaceuticals and 6 metabolites 
with varying physical and chemical properties. In this work, although the number of 
analytes was much smaller, the compounds still possessed a wide range of polarities, 
solubilities, pKa and Kow values. Another advantage of the method, was that it utilised 
Oasis MCX SPE cartridges, which are known to produce a cleaner extract, resulting in a 
lower signal to noise ratio (S:N) than Oasis HLB cartridges (Batt et al., 2008).  
 
The protocol in Batt et al. (2008) used 150 mg MCX Oasis cartridges (Waters, 
Hertfordshire, UK) conditioned with ACN (6 ml), followed by water (6 ml). Samples were 
then passed through the cartridges at a rate of 3 – 5 ml min-1. The cartridges were slowly 
washed with water – formic acid (98:2, v/v), and allowed to vacuum dry. The acidic and 
neutral analytes were eluted with ACN (2 x 4 ml) and the basic analytes were eluted with 
ACN – ammonium hydroxide (NH4OH) (95:5, v/v).  
 
A number of modifications were made to the Batt et al. (2008) SPE method to improve the 
recoveries of the analytes in this study. Table 3.2 outlines the stages of method 
development (MD) undertaken. MD 1 is the original method obtained from Batt et al. 
(2008), the only difference was an elution volume of 3 ml for the second elution step, since 
Chapter 3 Development of analytical methods 
82 
 
this allowed eluates to be combined in 1 x 16 ml disposable culture tube (Fisher Scientific 
UK Ltd, Loughborough). These culture tubes were used because they were compatible 
with the SPE manifold. The MD steps were chosen, to optimise the method, for the 
following reasons: (1) increasing the percentage composition of NH4OH, to increase the 
elution of basic compounds (Waters, 2010), (2) changing the elution solvent to MeOH, a 
more polar solvent, to improve the elution of polar compounds (Gracia-Lor et al., 2010), 
and (3) changing the percentage of organic solvent in the wash phase, to improve sample 
clean-up (Agilent Technologies, n.d.). 
 
The methods suitability was trialled with three replicate aliquots (100 ml) of spiked reverse 
osmosis water (ROW). The ROW was spiked with 1 µg from a working solution 
containing all five analytes. The SPE extracts in MD 1 – 4 were analysed by HPLC-UV 
instead of LC-MS/MS, since the former was the instrument available at the time.  
 
Table 3.2  The solid phase extraction method development steps undertaken. The analysis of 
extracts was by HPLC-UV. 
Variable MD 1 MD 2 MD 3 MD 4 
Cartridges MCX 150 mg 
6 cc 
MCX 150 mg 
6 cc 
MCX 150 mg 6 cc MCX 150 mg 6 cc 
pH amendment 
of samples 
None None None None 
Solvent ACN CAN MeOH MeOH 
Wash phase 
composition 
2% formic acid 2% formic acid 2% formic acid 2% formic acid 
and varying % 
MeOH (0, 5, 10, 
25, and 50%). 
Elution one 
composition 
ACN (4 ml) ACN (4 ml) MeOH (4 ml) MeOH (4 ml) 
Elution two 
composition 
ACN and 5% 
NH4OH (3 ml) 
ACN and 6% 
NH4OH (3 ml) 
MeOH and 6% 
NH4OH (3 ml) 
MeOH and 6% 
NH4OH (3 ml) 
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Table 3.3  Average analyte recovery (%) achieved after solid phase extraction of spiked reverse 
osmosis water samples. There were four phases of method development (MD). Extracts were 
analysed by HPLC-UV. 
API 
MD1 MD2 MD3 MD4 
Batt et 
al. 
(2008) 
6% 
NH4OH 
CAN MeOH 
0% 
MeOH 
5% 
MeOH 
10% 
MeOH 
25% 
MeOH 
50% 
MeOH 
Salicylic acid 
 
76.5 
(10.6) 
85.7 
(1.3) 
72.4 
(11.8) 
82.6 
(16.0) 
75.6 
(1.6) 
77.2 
(3.9) 
71.4 
(10.0) 
62.3 
(7.7) 
29.6 
(13.6) 
Caffeine 
 
81.4 
(5.3) 
91.8 
(4.1) 
89.6 
(8.4) 
88.3 
(12.6) 
77.5 
(2.5) 
79.3 
(7.7) 
73.9 
(9.8) 
23.0 
(18.6) 
3.5 
(20.1) 
Propranolol 
 
57.1 
(14.3) 
76.8 
(3.1) 
60.1 
(9.6) 
64.1 
(10.9) 
46.9 
(13.5) 
55.1 
(8.3) 
47.8 
(10.7) 
42.5 
(10.4) 
39.7 
(9.8) 
Diclofenac 
 
86.5 
(1.1) 
89.3 
(2.6) 
85.8 
(2.8) 
85.4 
(9.32) 
78.1 
(2.2) 
76.6 
(4.4) 
75.2 
(4.8) 
69.7 
(7.1) 
62.6 
(8.2) 
Carbamazepine 
 
73.6 
(7.9) 
88.9 
(3.3) 
86.5 
(8.4) 
95.4 
(14.0) 
82.5 
(6.9) 
84.6 
(10.5) 
78.0 
(8.2) 
70.9 
(3.7) 
33.3 
(6.0) 
n = 3 
RSD (%) represents the precision of recovery and are reported in parentheses. 
A higher recovery was obtained in MD 2 compared to the chosen method (MD4), however the 
recoveries of the former could not be replicated, i.e. MD3 (ACN). 
 
Table 3.3 shows the recoveries obtained from MD 1 are reasonable; however, a higher 
recovery, and lower RSD of propranolol is necessary. In MD 2 the percentage of NH4OH 
was increased from 5% to 6%. This was to increase the elution of propranolol from the 
SPE cartridges. The recovery of propranolol was now 77% and the recovery for the other 
compounds was > 85%. To determine if the recoveries could be improved further, the third 
stage of method development involved changing the solvent to MeOH, instead of ACN, 
and a comparison of the two solvents was conducted.  
 
The recoveries obtained with MeOH were slightly higher than those with ACN, even 
though both sets of recoveries were lower than those obtained in MD 2. Therefore, there 
were some repeatability issues between extractions on different days, and between 
replicates on the same day, which is not acceptable. The RSD of replicates should be 
< 10%. The final method development stage, conducted using HPLC-UV, was to vary the 
concentration of MeOH in the wash phase. The wash phase containing 5% MeOH, 
produced the highest recoveries. Decreasing recoveries were obtained with each 
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percentage increment of MeOH after 5%. The recovery was slightly lower for compounds 
when no MeOH was added to the wash phase. It was decided that MD 4, containing 5% 
MeOH in the wash phase, would be the method taken forward for further development.  
 
3.1.3.2 SPE with LC-MS/MS 
The selected SPE method (MD4 with 5% MeOH) was repeated, and the extracts were 
analysed by LC-MS/MS instead of HPLC-UV. The number of replicates was increased to 
five, to improve the accuracy of the compound recovery. The same volumes of ROW 
(100 ml) were spiked with a working solution of analytes, but 200 ng was spiked instead of 
1 µg, which was at a concentration more suitable for mass spectrometry detection. Blank 
ROW aliquots (2 x 100 ml) were also extracted, these acted as matrix matched samples to 
calculate the effect of the ESI source on analyte signal suppression or enhancement. A 
procedural blank sample (100 ml), subjected to the entire extraction procedure, was also 
extracted to determine if there was any contamination during the sample preparation 
procedure.  
 
During the SPE method development stages, the ISs were added to the SPE extract prior to 
analysis by LC-MS/MS. The ISs were also added to ROW blank sample extracts, prior to 
analysis, in order to account for any enhancement or suppression of the analyte during 
ionisation. Any ionisation effect could then be separated from the losses caused by the 
sample preparation procedure. The procedural blank samples did not receive any analyte or 
IS additions.  
 
The initial SPE procedure trialled, in combination with LC-MS/MS analysis of extracts, 
was to condition cartridges with MeOH (6 ml) followed by ROW (6 ml). The samples 
were then passed through the cartridges at a rate of 3 – 5 ml min-1. The cartridges were 
slowly washed with ROW – MeOH – formic acid (93:5:2, v/v) (5 ml) and allowed to 
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vacuum dry. The analytes were extracted from the cartridges by two sequential elution 
steps. Elution one involved extractions with MeOH (2 x 4 ml), and elution two consisted of 
extractions with MeOH – NH4OH (94:6, v/v) (2 x 3 ml). The average analyte recovery 
using the SPE method brought forward from the initial phase of SPE method development 
(Section 3.1.3.1) is shown in Table 3.4.  
 
Table 3.4  Average analyte recovery (%) achieved from the solid phase extraction of spiked 
reverse osmosis water samples. This SPE method is the one selected after method development in 
Section 3.1.3.1. Extracts were analysed by LC-MS/MS. 
 Salicylic acid Caffeine Propranolol Diclofenac Carbamazepine 
Average 
recovery (%) 
23 86 63 92 84 
RSD (%) 6 3 18 6 4 
n = 5. 
The recovery of salicylic acid dropped significantly (Table 3.4) compared with the 
recovery achieved previously with the same SPE method and HPLC-UV analysis (Table 
3.3). The liquid chromatography methods were different and this might have affected 
recovery. The method, however, demonstrates that the cartridges can retain all five 
analytes, with good recoveries > 80% obtained for caffeine, carbamazepine and diclofenac. 
Nevertheless the recovery of salicylic acid needed to be higher, and the variability of 
propranolol replicates should be less. There were three modifications made to the SPE 
method, and each was trialled separately, they are as follows: 
 
Test 1: The SPE method remained the same, but the samples were amended to pH 2 with 
hydrochloric acid. The ROW conditioning step was also acidified with formic acid to pH 2. 
At low pH, basic analytes will be protonated providing maximum ionic interaction with 
sulfonic acid moieties of the Oasis MCX sorbent. Additionally, at pH 2 acidic analytes will 
be mainly unionised, thereby increasing retention by reversed phase interactions, while 
neutral pharmaceuticals will be retained by the same mechanism (Lavén et al., 2009).     
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Test 2: The method was the same as test 1, but no MeOH was added to the wash phase. 
The MeOH in the wash phase might be causing some elution of analytes; therefore only 
formic acid was used. 
Test 3: The method was the same as test 2, but 2% NH4OH instead of 6% NH4OH was 
added to the second elution step. It is beneficial that this elution step elutes all basic 
analytes in the smallest percent NH4OH, so that (1) the elution of interferences is reduced 
and (2) the eluent is more compatible with the LC instruments.  
 
Table 3.5  Average analyte recovery (%) after trialling three SPE method development tests. 
Extract analysis was by LC-MS/MS. 
n = 5. 
 
Table 3.5 shows the recovery was significantly improved for salicylic acid, and was > 90% 
in all tests. Furthermore, the RSD for propranolol is lower in all three tests, with the lowest 
value in test 1. Test 1 also had the highest recovery of propranolol. Recoveries have also 
improved for caffeine and carbamazepine in all three tests, but are slightly lower for 
diclofenac. Test 1 achieved the highest recovery for two analytes; propranolol and 
diclofenac, and for the remaining three compounds all recoveries are similar between tests. 
API Test Average recovery (%) RSD (%) 
Salicylic acid 1 94 2.2 
2 98 1.7 
3 94 1.4 
Caffeine 1 90 3.1 
2 91 1.9 
3 89 7.2 
Propranolol 1 80 2.2 
2 78 9.1 
3 70 12.7 
Diclofenac 1 88 2.8 
2 86 8.2 
3 80 7.3 
Carbamazepine 1 88 0.7 
2 90 2.8 
3 87 3.8 
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Additionally test 1 gives a smaller RSD value for propranolol. Therefore test 1 was 
selected as the extraction preparation method for the wastewater samples.  
 
3.1.4 SPE and LC-MS/MS method validation 
An SPE method was developed that successfully recovered all five analytes at an 
acceptable level > 80% with an RSD < 5%. An LC-MS/MS method was also developed 
that achieved chromatographic separation of the analytes and good peak shape. The 
performance of the SPE-LC-MS/MS method was validated prior to its application with 
wastewater samples. A number of method validation steps were performed in order to 
estimate the following method performance parameters: 
 
1. Instrumental detection limits (IDL) and instrumental quantification limits (IQL) 
2. Linearity and range 
3. Extraction recovery and precision of recovery 
4. Method detection limits (MDL) and method quantification limits (MQL) 
5. Matrix effects 
 
3.1.4.1 Instrumental detection limits and instrumental quantification limits 
The IDL and IQL were determined by analysing decreasing analyte concentrations. The 
following standards were prepared 0.05, 0.1, 0.5, 1, 2, 5, 10, 20, 50, 75 and 100 µg l
-1
 in 
H2O – MeOH (80:20, v/v). The IDL is defined as the analyte concentration that gives a 
S:N of 3 and the IQL is defined as an analyte S:N of 10 (Al-Odaini et al., 2010). The S:N 
was calculated automatically by the software Agilent MassHunter Qualitative Analysis. 
The noise on the chromatogram was manually bracketed both sides of the quantifying 
analyte peak, along with the peak itself. The retention time of this noise was then entered 
into the method editor in the software, and an S:N was automatically calculated for the 
analyte peak. An S:N > 3 designated this concentration as the IDL for the method and an 
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S:N > 10 identified the concentration as the IQL. Table 3.6 shows the IDL and IQLs for 
each API. 
 
Table 3.6  Instrumental detection and quantification limits calculated using an S:N approach of 3 
(detection limit) and 10 (quantification limit) in the calibration standards.  
Compound IDL (µg l
-1
) IQL (µg l
-1
) 
Salicylic acid 0.5 10 
Caffeine 5.0 10 
Propranolol 1.0 5.0 
Diclofenac 2.0 5.0 
Carbamazepine 2.0 5.0 
 
3.1.4.2 Linearity  
The linear range was determined by preparing a range of calibration standards from the 
analytes IDL, to the higher end of its expected environmental concentrations. The 
following calibration standards were prepared in duplicate: 1, 5, 10, 25, 50, 100, 200, 250, 
500 and 1000 µg l
-1
 and ISs (100 µg l
-1
) were added to each standard. The coefficient of 
determination (r
2
) value was used to evaluate the linearity of each analyte. The IS approach 
was used to construct calibration curves (see Section 3.1.7). Acceptable linearity was 
obtained with an r
2
 > 0.99 with ≥ 5 data points (Baker and Kasprzyk-Hordern et al., 2011).  
 
Table 3.7  Linearity data for each analyte was generated from a calibration curve of the 
concentration (x-axis) against the response (y-axis). The r
2 
values were calculated from a linear 
regression fit to the data. 
Compound 
Linearity range 
(µg l
-1
) 
r
2
 
Salicylic acid 0.5 – 1000 0.999 
Caffeine 5.0 – 1000 0.999 
Propranolol 1.0 – 1000 1.000 
Diclofenac  2.0 – 1000
*
 0.998 
Carbamazepine 2.0 – 1000 0.999 
*
The calibration curve for diclofenac was curvilinear and a quadratic equation was fitted to the data 
n = 2. 
 
When a multi-point calibration curve is used, a decision must be made whether to leave the 
intercept or force the calibration curve through the origin. The decision is based on a 
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statistical analysis of how close the calculated y-intercept is to zero. This was tested with 
regression statistics calculated in Minitab 16. The standard error (SE) of the y-intercept is 
based upon estimates of variability at the y-intercept, not the entire curve, and is smaller 
than the standard error of the curve (Dolan, 2009). The SEy of the y-intercept is the 
appropriate value to determine if the curve passes through the origin using Equation 3.1 
and 3.2: 
 
If y-intercept > SEy, set b = value of y-intercept                                                                  
(Equation 3.1) 
If y-intercept ≤ S y, set b = 0                                                                                 
(Equation 3.2) 
This procedure was followed for each set of calibration standards and the intercept altered 
if Equation 3.2 was realised.  
 
The r
2
 values in Table 3.7 are all high, however, most of the calibration points are crowded 
together at the lower end of the curve, and this is where the fit cannot be clearly seen. In 
order to determine how well the regression models fit the data, residual plots were 
constructed (Figures 3.1(a-e)). The observed data (response) is plotted on the (x-axis) and 
the residuals i.e. the difference between observed responses and those predicted by the 
model, are plotted on the y-axis. Figure 3.1(a-e) shows the residual plots obtained from the 
calibration standards with the five APIs. The linear regression model was used for salicylic 
acid, propranolol, caffeine and carbamazepine, whereas a quadratic model was used for 
diclofenac. 
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Figure 3.1(a-e)  The standard residual plots for (a) salicylic acid, (b) diclofenac, (c) propranolol, 
(d) caffeine and (e) carbamazepine. The response is the observed data and the residuals represent 
the difference between the observed responses and those predicted by the model.  
 
Figure 3.1(a-e) provide information on how accurately the regression models fit the data. If 
the data is behaving normally, it is expected that the residuals should scatter randomly 
around zero, throughout the range of fitted values. Figure 3.1(a) and (c-e) exhibit random 
scatter either side of the baseline, however, the residuals at the lower concentrations appear 
to be closer to zero, indicating the model might not be correct at these values. A slight 
pattern can be observed for diclofenac, which suggests the predictor variable of the model 
might not be capturing all the explanatory information in the data.  
 
(a) (b) 
(c) (d) 
(e) 
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3.1.4.3 Extraction recovery  
The extraction recoveries of each analyte were determined in ROW, raw influent, primary 
effluent, activated sludge and secondary effluent using the method in Odaini et al. (2010). 
The recovery was evaluated by spiking four replicates of each matrix with 250 ng 
(2.5 µg l
-1
) of the analytes from a working solution. In the literature, concentrations similar 
to this have been spiked into sewage matrix samples to determine recoveries (Al-Odaini et 
al., 2010; Batt et al., 2008; Vieno et al., 2006). Additionally this concentration was 
selected because the pharmaceuticals have been detected in wastewater at similar 
concentrations (Gómez et al., 2007; Kasprzyk-Hordern et al., 2009; Kosma et al., 2010; 
Radjenović et al., 2009). An additional two samples of each matrix were processed as 
reference samples, by adding the same concentration of analytes to the extract after SPE. 
For each matrix, the percentage recovery was calculated by comparing the analyte 
concentration found in the spiked matrix (Cs), to its concentration found in the reference 
sample of the same matrix (Cr), using Equation 3.3: 
 
Recovery  %    
Cs ( g l
 1
)
Cr ( g l
 1
)
 
(Equation 3.3) 
Where: 
Cs = concentration of analyte found in spiked matrix (µg l
-1
) 
Cr = concentration of analyte found in reference sample (µg l
-1
) 
 
The recoveries calculated in Table 3.8 represent the loss resulting from SPE extraction, 
excluding any losses by matrix interferences during ESI or other instrumental fluctuations. 
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Table 3.8  Average solid phase extraction recoveries (%) for each analyte, calculated in four 
wastewater matrices and reverse osmosis water.  
Compound ROW 
Secondary 
effluent 
Primary 
effluent 
Raw 
influent 
Nitrifying 
MLSS 
Salicylic acid 82 (4) 81 (2) 96 (1) 91 (4) 70 (14) 
Caffeine 79 (4) 85 (4) 100 (4) 98 (2) 80 (10) 
Propranolol 73 (5) 78 (5) 78 (5) 79 (4) 77 (10) 
Diclofenac 81 (8) 68 (4) 48 (4) 47 (7) 12 (9) 
Carbamazepine 79 (3) 84 (3) 84 (3) 82 (2) 75 (9) 
n = 4 
RSD (%) are reported in parentheses. 
 
The extraction recoveries are > 70% in the ROW with RSDs < 10%. The extraction 
recoveries are reasonable for all compounds, in all matrices, with the exception of 
diclofenac. An extraction recovery of 81% was obtained for diclofenac in ROW, however, 
in the more complex matrices of raw influent and primary effluent the extraction recovery 
dropped to 47 and 48%, respectively. In the nitrifying MLSS the extraction recovery was 
lower at 12%, whereas in the cleaner secondary effluent the recovery increased to 68%. 
However, Section 3.1.4.5 on the influence of matrix effects, shows that matrix effects 
(ME) could be reduced when they were corrected relative to the IS (relative ME) (Table 
3.11). Therefore the low extraction recovery of diclofenac in Table 3.8, can be corrected 
for by its IS, as they suffer from the same ionisation effects. 
 
3.1.4.4 Method detection and quantification limits 
The MDLcalc and MQLcalc were calculated (Equations 3.4 and 3.5), for each analyte 
according to the following method (Baker and Kasprzyk-Hordern, 2011; Vieno et al., 
2006): 
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M  calc   
      100
 R   CF
 
(Equation 3.4) 
M  calc   
      100
 R   CF
 
(Equation 3.5) 
Where: 
ER = extraction recovery  
CF = concentration factor. 
 
The concentration factor in this instance was 100. The MDLcalc and MQLcalc are detailed in 
Tables 3.9 and 3.10, respectively.  
 
Table 3.9  Method detection limits of the analytes in four wastewater matrices. 
Compound 
Secondary 
effluent 
(ng l
-1
) 
Primary 
effluent 
(ng l
-1
) 
Raw influent   
(ng l
-1
) 
Nitrifying MLSS 
(ng l
-1
) 
Salicylic acid 6 5 5 7 
Caffeine 59 50 51 63 
Propranolol 13 13 13 13 
Diclofenac 29 42 42 169 
Carbamazepine 24 24 24 27 
 
Table 3.10  Method quantification limits of the analytes in four wastewater matrices. 
Compound 
Secondary 
effluent 
(ng l
-1
) 
Primary 
effluent 
(ng l
-1
) 
Raw influent   
(ng l
-1
) 
Nitrifying MLSS 
(ng l
-1
) 
Salicylic acid 123 104 109 144 
Caffeine 117 100 102 125 
Propranolol 64 64 63 65 
Diclofenac 74 105 106 423 
Carbamazepine 59 60 61 67 
 
The MQLs were used to decide whether an analyte concentration could be reported. Values 
< MQLs had too much error associated with them to offer accurate and reliable 
concentrations.  
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The MDL and MQLs in this study were compared to those reported in the literature. This 
showed that overall the values reported in Tables 3.9 and 3.10 were within a similar range, 
to those determined in other LC-MS/MS methods, using wastewater as the matrix. Lacey 
et al. (2008) reported a LOD and LOQ for salicylic acid, caffeine and diclofenac that were 
considerably higher in influent and effluent samples, than the MDLs and MQLs reported in 
this work. Similarly, in the validation method used by Al-Odaini et al. (2010), the MDLs 
reported in effluent samples were 33 ng l
-1
 and 6 ng l
-1
 for diclofenac and salicylic acid, 
respectively. This compares to a MDL of 6 ng l
-1
 for salicylic acid and 29 ng l
-1
 for 
diclofenac in this study (Table 3.9). 
 
Equations 3.5 and 3.6 are just one method, reported in the literature, for determining MDL 
and MQLs. In other studies a statistical approach has been taken to determine the MDL for 
each analyte as used in Al-Odaini et al. (2010). The procedure involves spiking replicates 
of each matrix with each analyte at a concentration resulting in an instrumental S:N 
between 2.5 and 5. The MDL is then calculated with 99% confidence that the result is 
greater than zero by multiplying the S  of replicate measurements by 3.14, the Student’s t-
value for 6 degrees of freedom (Al-Odaini et al., 2010). Frequently in the literature, studies 
use the S:N approach, discussed in Al-Odaini et al. (2010) for determining MDL and 
MQLs (Gracia-Lor et al., 2010; Lacey et al., 2008; Lavén et al., 2009; Wu et al., 2008). 
 
3.1.4.5 Influence of matrix effects 
The influence of matrix effects (ME) was calculated from Equation 3.6, the equation was 
taken from Vieno et al. (2006): 
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M   %    
 s ( sp  usp)
 s
 x 100 
(Equation 3.6) 
Where: 
Asp = peak area of matrix extracts spiked with analyte working solution (250 ng or 
250 µg l
-1
) 
Ausp = background concentration of the analyte in the same extract matrix 
As = peak area of 250 µg l
-1 
standard. 
 
This procedure evaluated the losses of analytes caused during ionisation, but excluded any 
losses caused by SPE and other sample preparation. Table 3.11 summarises the calculated 
absolute and relative MEs for each analyte. Absolute MEs are based on the peak area of 
analyte without correction for the IS area, and relative MEs were calculated relative to the 
IS area. The concentration spiked to the extracts was  50 μg l-1, however, this 
concentration is expected after the preconcentration of a 100 ml sample during SPE, 
therefore the concentration of analytes in the ‘real’ environmental sample would be 
2.5 μg l-1, and as discussed previously in Section 3.1.4.3 this concentration has been 
reported to be environmentally relevant for the APIs investigated in this study.  
 
Table 3.11  Summary of the matrix effects (%) for each analyte in four wastewater matrices. 
Compound 
Secondary 
effluent 
Primary 
effluent 
Raw influent 
Nitrifying 
MLSS 
Ab Rel Ab Rel Ab Rel Ab Rel 
Salicylic acid 45.7 12.3 93.8 2.6 48.5 5.1 74.0 17.5 
Caffeine -219.0 -4.6 -300.2 -25.2 7.4 -3.3 -144.8 -3.3 
Propranolol -111.1 1.59 -107.8 -4.8 5.8 5.9 -115 1.8 
Diclofenac 36.6 7.2 45.6 -1.8 39.1 2.2 38.3 5.8 
Carbamazepine -154.5 -14.0 -154.7 -19.5 -5.1 -2.6 -149.6 -10.7 
An ME > 0% suggests ionisation suppression (no shading) and ME < 0% suggests ionisation 
enhancement (shaded). Ab = absolute and Rel = relative. 
 
MEs occur in LC-MS/MS during ESI when molecules co-eluting with the target analyte 
alter its ionisation efficiency, leading to ionisation suppression or enhancement. Caffeine 
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for example, suffered a 300% increase in signal strength in the primary effluent. Likewise, 
propranolol and carbamazepine also experienced signal enhancements in the primary 
effluent of 108% and 155%, respectively. Ion suppression was not as dominant as the 
matrix effects caused by ion enhancement. Signal suppression occurred for salicylic acid in 
all wastewater matrices at 49% (raw influent), 94% (primary effluent), 74% (activated 
sludge) and 46% (secondary effluent). Similarly, diclofenac was mostly affected by signal 
suppression.  
 
Correcting the MEs with the IS improved the quality of the data in all instances. This 
shows that the analyte and IS suffered from the same ionisation effects. The relative ME of 
caffeine in the primary effluent went from a signal enhancement of 300% to 25%, using 
the relative calculations. This was the greatest relative ME recorded in any matrix. The raw 
influent produced the lowest MEs, whilst the primary effluent, activated sludge and 
secondary effluent produced similar MEs.  
 
3.1.5 LC-MS/MS autosampler sample queue  
Each time a ‘batch’ of samples was run on the LC-MS/MS, a set of freshly prepared 
calibration standards were run in duplicate, at the beginning and end of the sample queue. 
Additionally a number of MeOH blanks were also prepared to check for any cross-
contamination between sample injections. 
 
3.1.6 Final SPE method 
Wastewater samples were analysed within 24 h of collection. Wastewater aliquots (100 ml) 
were spiked with the IS (100 ng) and filtered through 0.7 µm GF/F Whatman filter papers, 
in order to remove particles that may interfere with the extraction procedure. Samples were 
acidified to pH 2 with formic acid and extracted using Oasis MCX (6cc 150 mg) 
cartridges, purchased from Waters, UK. The cartridges were conditioned with MeOH 
Chapter 3 Development of analytical methods 
97 
 
(6 ml) followed by ROW (6 ml). Samples were then passed through SPE cartridges at a 
flow rate of 3 – 5 ml min-1. The cartridges were washed with ROW – formic acid 
(98:2, v/v) (5 ml). The cartridges were then allowed to vacuum dry. Analytes were eluted 
into 16 ml disposable culture tubes purchased from Fisher Scientific by sequentially 
passing MeOH (2 x 4 ml) and MeOH – NH4OH (94:6, v/v) (2 x 3 ml) through the 
cartridges under a slight vacuum. The combined extracts were evaporated to dryness at 
40ºC under a gentle stream of N2. The dried extracts were reconstituted (1 ml) with H2O – 
MeOH (80:20, v/v). Lastly the extracts were filtered through Chromacol 17 mm RC 
syringe filters (0.45 µm) directly into Fisher Scientific amber HPLC vials. 
 
3.1.7 Final LC-MS/MS method  
As a consequence of the problems discussed above, two separate LC-MS/MS methods 
were utilised, one for negative mode and one for positive mode. These methods are 
summarised in Table 3.12. 
 
Table 3.12  The final liquid chromatography conditions employed for analysis of APIs in positive 
and negative ionisation mode. 
Method parameter Negative Positive 
Column Agilent Zorbax SB-C18 
column (3.0 mm x 50 mm, 
particle size 1.8 µm) 
Agilent Zorbax SB-C18 
column (3.0 mm x 50 mm, 
particle size 1.8 µm) 
Mobile phase composition A: HPLC water and 0.05% 
acetic acid. 
B: MeOH and 0.05% acetic 
acid 
A: HPLC water and 0.1% 
formic acid  
B: ACN and 0.1% formic 
acid. 
Mobile phase gradient 0 min 90% A 10% B 
10 min 0% A 100% B 
16.5 min 0% A 100% B 
16.7 min 90% A 10% B 
0 min 95% A 5% B 
15 min 0% A 100% B 
16 min 0% A 100% B 
16.5 min 95% A 5% B 
Flow rate (ml min
-1
) 0.2 0.3 
Injection volume (µl) 3 3 
Column temperature (ºC) 15 15 
 
Figure 3.2(a-b) displays the chromatography for the five analytes. There is sufficient 
separation of the positive and negative ions. The mass spectrometry analyses were carried 
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out in negative ionisation mode for salicylic acid and diclofenac and in positive ionisation 
mode for caffeine, propranolol and carbamazepine.  
 
MassHunter optimizer (Version B.01.04) was used to determine the mass spectral 
parameters for each compound, these included the ESI mode (+) or (-), optimum fragment 
voltage, collision energy and the choice of precursor and products ions for each analyte. 
Multiple reaction monitoring (MRM) was used to collect data of the two most intense 
transitions; a precursor and product ion. Only one transition was available for propranolol. 
The transitions are shown in Table 3.13.  
 
Each analyte was quantified using the most intense MRM transition by means of internal 
standardisation (Al-Odaini et al., 2010). This was conducted by calculating the ratio of the 
quantifying ion and relative IS peak areas. An eight-point calibration curve was then 
constructed for each analyte by plotting the ratio of the quantifying ion and IS peak area 
(y-axis) against the concentration ratio of the analyte and IS (x-axis) in the analysed 
calibration standards. 
 
For qualitative analyses, such as visualising peaks, extracting ions and comparing 
chromatograms, the software Agilent MassHunter Workstation Qualitative Analysis 
(Version B.01.03 Build 1.3.157.0) was used.  
 
The mass spectral parameters for API analysis during positive and negative ionisation 
mode were as follows: drying gas temperature (350ºC) and flow (10 l min
-1
); nebulizer 
pressure (275.8 kPa); capillary voltage (4000 V); collision gas (N2).  
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Table 3.13  Mass spectrometry conditions optimised for the analytes and ISs. 
Compound name MRM 1 CE (V) MRM 2 CE (V) 
Fragmentor 
voltage (V) 
ESI (+) 
Caffeine 195.2 > 138 16 195.2 > 110.1 20 125 
Carbamazepine 237.3 > 194.1 16 237.3 > 179 36 130 
Propranolol 260.2 > 116.1 12 - - 120 
Caffeine-
13
C3 198.2 > 140 16 - - 130 
Carbamazepine- d10 247.3 > 204.1 20 - - 140 
Propranolol-d7 267 > 116.5 12 - - 125 
ESI (-) 
Salicylic acid 137.1 > 93.2 16 137.1 > 65.2 36 100 
Diclofenac 294 > 250 8 294 > 214 20 86 
Salicylic acid- d6 141 > 97.1 16 - - 70 
Diclofenac-d4 298 > 254 8 - - 81 
CE = collision energy 
MRM = multiple reaction monitoring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2(a-b)  Total ion chromatograms of MRM scan for (a) the positive ions caffeine, 
carbamazepine and propranolol and (b) the negative ions salicylic acid and diclofenac. 
(a) 
(b) 
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3.1.7.1 Quantification and peak confirmation 
A sample peak can be confirmed as the analyte of interest by determining the peak 
retention time, and the ratio of the quantifying (precursor) and qualifying (product) ions. 
The retention time and ion ratio are then compared to the calibration standards run at the 
same time as the samples. The peak can be confirmed as the compound of interest, if the 
retention time is within 2% and the ion ratio is within 20% of the calibration standards 
(López-Serna et al., 2011).  
 
3.2 Radiochemistry methods 
3.2.1 Solid phase extraction method 
Wastewater aliquots (100 ml) were filtered through 0.7 µm GF/F Whatman filter papers. 
Samples were extracted by SPE using Oasis MCX (6cc 150 mg) SPE cartridges. Cartridges 
were conditioned with MeOH (6 ml) followed by ROW (6 ml).The samples were then 
passed through cartridges at a flow rate of 5 ml min
-1
. The cartridges were washed with 
ROW – formic acid (98:2, v/v) (5 ml) and were then allowed to vacuum dry. Radioactivity 
was eluted with MeOH (2 x 3 ml) followed by MeOH – ACN (94:6, v/v) (2 x 3 ml). The 
extracts were evaporated to dryness at 40ºC under a gentle stream of N2. The dry extracts 
were then reconstituted (1 ml) in the mobile phase starting gradient solvents (95:5, v/v) 
(See Table 3.14 for details of the mobile phase starting gradient). 
 
3.2.2 Radio-HPLC method 
A radio-HPLC method was developed to analyse the radiolabelled pharmaceuticals used in 
the laboratory experiments (Figure 3.4(a-d)). The method was used to analyse the 
14
C 
labelled APIs in stocks and wastewater samples. The powdered form of the native analytes 
used in Section 3.1.1, was used to prepare stocks for radio-HPLC analysis. The solvents 
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H2O, ACN, MeOH, acetic acid and ammonium acetate (CH3COONH4) were purchased 
from Sigma-Aldrich. 
 
Sample analysis was performed on an Agilent HPLC 1200 series connected to a Mirastar 
radio-detector. The liquid chromatography conditions are summarised in Table 3.14. 
 
Table 3.14  The mobile phase gradient for the HPLC-UV method. 
Method parameter Negative 
Column C18 Gemini-NX column (50 x 3.0 mm; particle 
size 3 µm) 
Mobile phase composition Mobile phase A consisted of H2O containing 
0.1% acetic acid and 100 mM CH3COONH4. 
Mobile phase B consisted of MeOH – ACN 
(60:40, v/v) 
Mobile phase gradient 0.00 min 95% A 5% B 
2.00 min 95% A 5% B 
11.00 min 0% A 100% B 
13.00 min 0% A 100% B 
13.10 min 95% A 5% B 
17.00 min 95% A 5% B 
Flow rate (ml min
-1
) 0.25 
Injection volume (µl) 100 
Column temperature (ºC) 40 
UV wavelength (nm) 280 
 
The LOD for the Mirastar is 10 Bq per peak or approximately 10 counts per second (CPS). 
Radiolabelled stocks were analysed by radio-HPLC prior to dosing to determine purity.  
 
When running the radiolabelled stocks and samples, MeOH blanks were also injected to 
check for cross-contamination and to clean the injection needle prior to the next injection. 
Furthermore, unlabelled analyte standard solutions (10 mg l
-1
) were prepared in the mobile 
phase starting gradient, in order to confirm the parent compound peak on the radiolabelled 
chromatogram.  
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Figure 3.3(a-d) illustrates the molecular structures of the APIs dosed, and the position of 
the labelled carbon atoms. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3(a-d)  The chemical structures of the dosed 
14
C labelled APIs (a) salicylic acid (b) 
caffeine, (c) propranolol and (d) diclofenac. The position of the radiolabelled carbon atom(s) is 
indicated by an asterisk. 
 
Table 3.15  The specific activity of the compounds and purity of the dosing solutions, measured in 
this work, and by the manufacturer.  
Compound Specific activity 
(Bq μg
-1
) 
Purity by radio-
HPLC in this work 
(%) 
Purity supplied by 
manufacturer  
(%) 
14
C-salicylic acid 4,019 97.0  99 (TLC) 
14
C-caffeine 9,732 97.3  > 97 (HPLC) 
14
C-propranolol 1,637 91.5  99 (TLC) 
14
C-diclofenac 7,297 94.5  > 97 (HPLC) 
 
* 
* 
* 
* 
(a) 
(c) (d) 
(b) 
Chapter 3 Development of analytical methods 
103 
 
0.00 5.00 10.00 15.00 min
Cnt Sum 1-4
3 Sigma
BKG
0
20
40
60
80
100
CPS 
B
K
G
1
B
K
G
2
R
e
g
 
#
1 [
1
4
C
]
s
a
l
i
c
y
l
i
c
 
a
c
i
d
R
e
g
 
#
3
0.00 5.00 10.00 15.00 min
UV_A (280 nm)
0
1
2
3
4
5
6
7
8
9
10 mAU 
S
ig
n
al
 (
C
P
S
)
14C-salicylic acid
0.00 5.00 10.00 15.00 min
Cnt Sum 1-4
3 SigmaBKG
0
50
100
150
200
250
CPS 
B
K
G
1
B
K
G
2
R
e
g
 
#
1
1
4
C
 
c
a
f
f
e
i
n
e
R
e
g
 
#
3
0.00 5.00 10.00 15.00 min
UV_A (280 nm)
0
2
4
6
8
10
12
14
16
mAU 
14C-caffeine
S
ig
n
al
 (
C
P
S
)
0.00 5.00 10.00 15.00 min
Cnt Sum 1-4
3 SigmaBKG
0
50
100
150
200
CPS 
B
K
G
1
B
K
G
2
R
e
g
 
#
1
1
4
C
 
d
i
c
l
o
f
e
n
a
c
R
e
g
 
#
3
0.00 5.00 10.00 15.00 min
UV_A (280 nm)
0
5
10
15
20
25 mAU 
D
i
c
l
o
f
e
n
a
c
S
ig
n
al
 (
C
P
S
)
Retention time (min)
14C-diclofenac
0.00 5.00 10.00 15.00 min
Cnt Sum 1-4
3 SigmaBKG
0
50
100
150
CPS 
B
K
G
1
B
K
G
2
R
e
g
 
#
1
1
4
C
 
p
r
o
p
r
a
n
o
l
o
l
R
e
g
 
#
3
15.00 min
UV_A (280 nm)
5
10
15
20
25
mAU 
P
r
o
p
r
a
n
o
l
o
l
S
ig
n
al
 (
C
P
S
)
14C-propranolol
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4(a-d)  Chromatograms of the dosing stock solutions (a) 
14
C-salicylic (b) 
14
C-caffeine (c) 
14
C-diclofenac and (d) 
14
C-propranolol. The purity of the dosing solutions was > 90% for all 
compounds, this is illustrated by the single radiolabelled peak in the above chromatograms.  
(a) 
(d) 
(c) 
(b) 
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To conclude, analytical methods were developed for API quantification in field and 
laboratory samples. An SPE method was developed for the five analytes. The extracts were 
initially analysed by HPLC-UV (ROW spikes), and then by LC-MS/MS, once a method 
had been developed to quantify the five analytes and their respective ISs. After the SPE 
method development section, the LC-MS/MS method development was described. Next 
the SPE-LC-MS/MS method was validated with four wastewater matrices. The final SPE 
and LC-MS/MS methods were outlined, followed by the radio-HPLC method used to 
analyse the APIs in the laboratory rig. The next phase of the work, focused on the 
development of a laboratory rig, to investigate the fate of the APIs in detail. 
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Chapter 4 Development of the rig 
 
A requirement of this research was to develop a bespoke laboratory simulation for dosing 
radiolabelled APIs, in order to gain detailed information on their fate in a typical BNR STP 
in the UK. An SBR was selected as a suitable system to satisfy this aim, due to the wealth 
of literature published on their compatibility with BNR in the laboratory (Casellas et al., 
2006; Kargi and Uygur, 2003; Lee et al., 2001; Puig et al., 2007b). Furthermore, SBR 
technology has been gaining popularity in recent years, mainly because of their single-tank 
design and ease of automation (Mace and Mata-Alvarez, 2002), which also makes them 
ideal laboratory research systems. The rig design presented in this chapter was original; 
however, the operating conditions were taken from the literature as a result of their success 
in achieving BNR in the laboratory. 
 
4.1 Selection of SBR operating conditions 
The SBR operating conditions were chosen based on a literature search of the operating 
conditions used in successful laboratory BNR SBRs. Table 4.1 details the operating 
conditions identified in the literature. A common SBR cycle length in the literature was 
8 h, this was suitable to achieve nitrification, denitrification and bio-P removal and 
therefore it was chosen in this work (Obaja et al., 2003; Soejima et al., 2008; Tomei and 
Annesini, 2005). An exchange ratio of 0.5 was selected, because it was typical of 
laboratory SBRs in the literature. The outcome of these two conditions was a HRT of 16 h. 
The SRT most common in the literature was 20 d, as illustrated in Table 4.1. To achieve a 
similar SRT, 0.225 l of MLSS was pumped from the reactor once a day. Based on the 
range of MLSS concentrations measured in the rig (2,000 – 2,700 mg l-1) the SRT was 
approximately 17 – 17.5 d. According to Metcalf and Eddy (2003) a SBR requires a SRT 
of between 10 and 30 d to achieve biological nitrogen and  phosphorus removal. The SRT 
in this work satisfies this criterion.   
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The react phase was divided into a combined anaerobic/anoxic period, followed by an 
aerobic period. These conditions were considered the simplest sequence to achieve 
removal of influent NH4
+
-N, NO3
-
-N and PO4
3-
-P. This sequence was employed by Kargi 
et al. (2005), they allocated 3 h to anaerobic/anoxic conditions followed by 4.5 h for 
aerobic conditions. In this work 4 h was given to aerobic conditions because the cycle 
length was only 8 h in total. A settle phase of 35 min was sufficient for the sludge to settle 
out from the treated supernatant, so that more than 2.25 l of clear supernatant was available 
to pump out as effluent.  
 
4.2 Construction of the SBR rig 
It was essential that the SBR was airtight in order to dose and trap 
14
C. Initially, a rig was 
constructed, that was thought to be suitable for holding and cycling wastewater and gases 
through an airtight system. A SBR cycle was observed using water only, and a number of 
modifications were made to the rig as a result of this. Initially the flow of gases into the 
SBR was controlled by the opening and closing of a vacuum. However, there were 
concerns that this would create positive pressure inside the SBR vessel, if the N2 supply cut 
out for any reason. This would be hazardous due to the radioactive nature of the material 
inside the reactor. Instead a system was designed, so that compressed air and N2 were 
pumped directly into the reactor. However, a flow of gas into the vessel was still required 
when sludge or supernatant was pumped out of the reactor, in order to equalise the pressure 
change inside.  
 
To trap any evolved 
14
CO2 released from the reactor, two traps were positioned after the 
reactor. NaOH (2M) was chosen to capture the CO2 as it is used for this purpose by 
AstraZenenca, Brixham Environmental Laboratory in their radiolabelled OECD tests. The 
system was deemed to be airtight when N2 or compressed air was flowing into the reactor 
and the NaOH traps were bubbling. 
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entering vessel
Quickfit adaptor
4.3 SBR apparatus 
The SBR vessel consisted of a glass Quickfit reaction vessel (5 l). A Quickfit lid 
containing five openings was clipped to the neck of the reaction vessel. Parafilm® was 
used to seal the join. The openings in the lid were for the inlet pump to transfer primary 
settled sewage at the start of the cycle, the outlet pump to remove waste sludge and treated 
effluent, redox probe, N2 and compressed air gas flow and for the withdrawal of samples. 
 
Butyl rubber tubing was connected to the outlet gas flow from the N2 and compressed air 
Quickfit adaptors, this can be seen in Figure 4.1. The flow of gas was directed to a split 
valve, which combined the gas flow through more butyl tubing until it entered two NaOH 
traps in series. After the second NaOH trap the gas flow was directed to an extractor 
system.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1  Reactor set-up showing the butyl rubber tubing and connectors enabling gas flow in 
and out of the reactor. 
Chapter 4 Development of the rig 
108 
 
Table 4.1  Reported operating conditions of laboratory sequencing batch reactors designed for biological nutrient removal. 
Reference 
Influent 
composition 
Inoculum 
Working 
volume 
(l) 
Min 
reactor 
volume 
(l) 
Influent 
volume l 
d
-1
 
Exchange 
ratio
*
 
Cycles 
per 
day 
SRT 
(d) 
HRT 
(h) 
Fill 
period 
(min) 
React (h) 
Wastage 
(min) 
Settle 
(min) 
Draw 
(min) 
Idle 
(min) 
Wastewater 
parameters 
measured 
Leung and 
Tam (1994) 
Synthetic wastewater 
(COD = 300 mg l-1, 
total-N = 42 mg l-1, 
total-P = 6 mg l-1) 
Synthetic wastewater 
mixed with settled 
activated sludge 25 5 40 0.8 2 10  45 
AER (4) – 
ANX/ANA 
(3) – AER 
(1) 
 90 60 45 
COD, BOD5,  
NH4
+-N, NO3
--N, 
NO2
- -N, TKN,  
PO4
3--P, total-P,  
TSS 
Tomei et al. 
(2005) 
Synthetic wastewater 
(C:N:P = 100:5:1) 
Not specified 
4.2 2.1 6.3 0.5 3 20 16.1 60 
AER (1.6-
3.1) – ANX 
(3-4.5)  
5 35 15  
VSS, TSS, COD, 
NO3
--N, NO2
- -N, 
total-N 
Kargi and 
Uygur 
(2003)  
Synthetic wastewater 
100/5/1.5 (COD = 
1200 mg l-1, total-N = 
60 mg l-1, total-P = 
18 mg l-1)  
Cultivated 
microorganisms were 
used to inoculate 
synthetic wastewater 
5     10   
ANA (2) – 
ANX (1) – 
AER (4.5) – 
ANX (1.5) 
– AER (1.5)  
    
COD, NH4
+-N,  
PO4
3--P,TSS, TS 
Kargi et al. 
(2005) 
Synthetic wastewater 
100/5/1.5 (COD = 
1200 mg l-1, total-N = 
60 mg l-1, total-P = 
18 mg l-1)  
Cultivated 
microorganisms were 
used to inoculate 
synthetic wastewater 
5 1  0.8  10   
ANA (2) – 
ANX (1) – 
AER (4.5)    45   
COD, NH4
+-N,  
PO4
3--P, NO3
--N 
Obaja et al. 
(2003)  
Diluted piggery 
wastewater 
Activated sludge 
diluted 1:10 with 
piggery-digester 
effluent 
3 2 3 0.33 3 11 24  
ANA (2) – 
AER (4) – 
ANX (1) 
    
COD, BOD5,  
NH4
+-N, PO4
3--P, 
total-N, TS, VSS, VS 
Soejima et 
al. (2008) 
Synthetic wastewater 
COD = 300 mg l-1, 
PO4
3--P = 30 mg l-1, 
NH4
+-N = 40 mg l-1 
Activated sludge 
from a continuous 
EBPR process 
2 1 3 0.5 3 20 16 15 
ANA (1.5) 
– AER (1.5) 
– ANX 
(3.25)  
 65 25  
TSS, NO3
--N,  
NO2
- -N, COD 
Vives 
(2004) 
Urban wastewater 
with an addition of 
200 mg l-1 synthetic 
carbon 
Nitrifying activated 
sludge 
30 20 30 0.33 3 20 24  
ANA – 
AER – 
ANX (6.55) 
 60 27  
COD, NH4
+-N,  
NO3
--N, NO2
- -N, 
TKN, PO4
3--P, TSS, 
MLVSS  
This 
laboratory 
SBR 
Primary effluent with 
an addition of  
200 mg l-1 sodium 
acetate 
Nitrifying activated 
sludge 
4.5 2.3 6.75 0.5 3 17 16 16 
ANA/ANX 
(3) – AER 
(4) 
1 35 10  
COD, DOC, BOD5, 
NH4
+-N, NO3
--N, 
PO4
3--P, total-P,  
total-N, TSS 
Nomenculture: 5 d biochemical oxygen demand = BOD5, total Kjeldahl nitrogen = TKN, total suspended solids = TSS, total solids = TS, volatile 
suspended solids = VS, mixed liquor volatile suspended solids = MLVSS, dissolved organic carbon = DOC, C = carbon, N = nitrogen and P = phosphorus. 
*
calculated by dividing the influent volume per cycle by the working volume  
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Humidifiers containing ROW were situated before the reaction vessel, one humidifier 
received N2 gas and another received compressed air. Butyl tubing exiting the humidifiers, 
directed the gas flow into the reaction vessel. The humidifiers were required to prevent the 
reactor losing moisture. 
 
4.4 Operating conditions 
The SBR cycles were repetitious and were controlled by a central relay system operated by 
the Siemens LOGO plc software. The ‘controller system’ as it will be called from now on, 
was programmed with 3 x 8 h cycles. The controller repeated these cycles indefinitely until 
it was manually stopped. The controller operated four pumps, one stirrer and the N2 and 
compressed air. The timer details programmed into the controller for each outlet socket are 
shown in Figure 4.3.  
 
The reaction vessel was inoculated with 3.0 g l
-1
 dw of activated sludge, from Totnes 
Wastewater Treatment Facility, Totnes, Devon, a NAS plant treating mainly domestic 
waste. The activated sludge was diluted to the desired TSS concentration with primary 
settled effluent, also collected from the same site. The activated sludge biomass was 
continuously mixed during the react phase of operation, by switching on and off a 
magnetic stirrer. The same source of primary settled sewage was used to feed the SBR, and 
40 l was collected twice weekly. This primary settled sewage was added to a 70 l feed 
tank. The tank was thoroughly cleaned between sewage additions. The feed tank was 
maintained at 4ºC throughout the study to reduce the breakdown of inorganic and organic 
matter. A stirrer was set up in the feed tank to continuously mix the primary effluent. 
Sodium acetate was added to the feed tank at a concentration of 200 mg l
-1
 on the same day 
the primary settled sewage was collected, in order to increase the COD level of the sewage, 
and to simulate the VFAs present in wastewater. A further 100 mg l
-1
 of sodium acetate 
Chapter 4 Development of the rig 
110 
 
0 60 120 180 240 300 360 420 480
Time (min)
was added to the feed tank daily, until fresh primary effluent was collected. The SBR rig 
was located in a temperature controlled room at 20ºC. 
 
Figure 4.2 shows the phases of an 8 h SBR cycle. The phases consist of a 10 min fill phase, 
170 min anaerobic/anoxic conditions, 240 min aerobic conditions, 1 min sludge wasting, 
45 min settle and 10 min draw.  
 
 
 
 
 
 
Figure 4.2  8 h sequencing batch reactor cycle: fill (10 min), anaerobic/anoxic (170 min), aerobic 
(240 min), sludge wasting (1 min), settle (45 min) and draw (10 min) (Puig et al., 2007a). 
 
The primary effluent could not be pumped directly into the SBR from the feed tank 
because the temperature was too low, and this would disrupt the bacterial population. 
Therefore, prior to the start of the cycle, the required volume of sewage was transferred by 
a Watson Marlow 520U pump, into a holding vessel where it remained for 100 min until at 
room temperature. From the holding vessel, a second Watson Marlow 520U peristaltic 
pump, set at a flow rate of 0.225 l min
-1
, pumped the wastewater from the holding vessel 
into the SBR. The SBR received 2.25 l of untreated wastewater at the start of each cycle, 
and 6.75 l in every 24 h period. 
 
 
Fill  Sludge 
wasting 
 Ana/anx 
phase 
 Aerobic 
phase 
 Settle  Draw  
Chapter 4 Development of the rig 
111 
 
Fill React 
Draw Fill holding tank 
Sludge wastage Settle 
10 min (pump on) 
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10 min (stirrer o ff) 
6 h 55 min (stirrer on) 
14 min (pump on) 
7 h 1 min (pump off) 43 min (pump off) 
10 min (pump on) 
Syringe dosing pump 
7 h 50 min (pump off) 
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3 h (compressed air off) 1 h (compressed air off) 
1 min (pump off) 
1 min (pump on) 
40 min (N2 off) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3  Timer details programmed into the controller system to create the sequencing batch reactor cycles. 
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At the end of each cycle, a third Watson Marlow 520U pump, set at a flow rate of 
0.225 l min
-1
, transferred the treated effluent (2.25 l) from the SBR into a waste container. 
Therefore, 6.75 l of wastewater was treated and removed daily. The same pump removing 
the treated effluent from the SBR was also employed to waste 0.225 l of mixed liquor at 
the end of the aerobic phase, in one cycle every 24 h. The flow of wastewater through the 
rig is outlined in Figure 4.4(a) and the position of the pumps can be seen in Figure 4.4(b).  
 
4.5 Wastewater analysis 
The SBR influent and effluent was analysed for a number of wastewater variables, 
including: BOD5, DOC, COD, TSS, NH4
+
-N, NO3
-
-N, PO4
3-
-P, total-N and total-P. 
Additionally, samples were taken from the beginning of the anaerobic/anoxic phase, the 
end of the anaerobic/anoxic phase and the end of the aerobic phase. Prior to analysis of 
DOC, NH4
+
-N, NO3
-
-N and PO4
3-
-P, samples were filtered through syringe filters 
(0.45 µm). Hach Lange (Salford, UK) tube kits were employed for much of the analysis. 
The following tube kits were used: NH4
+
-N (LCK 303, 304), NO3
-
-N (LCK 339), PO4
3-
-P 
and total-P (LCK 350, 349, 348), DOC (LCK 386, 385), COD (LCI 400, LCK 314) and 
total-N (LCK 138, 338). Addistas’ were also purchased from Hach Lange to act as quality 
control standards for the tube kits: LCA 700 (NH4
+
-N, PO4
3-
-P), 703 (COD, DOC, NH4
+
-
N, NO3
-
-N, PO4
3-
-P, total-P), 704 (DOC, COD, NH4
+
-N), 707 (PO4
3-
-P), 708 (total-N), 709 
(total-N, PO4
3-
-P, total-P). 
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Figure 4.4(a-b)  Laboratory sequencing batch reactor (a) schematic of the sequencing batch reactor 
and (b) rig set-up in the laboratory. (1) controller; (2) feed tank peristaltic pump; (3) influent 
peristaltic pump; (4) effluent peristaltic pump; (5) feed tank; (6) waste tank; (7) influent holding 
vessel; (8) SBR; (9) NaOH (2M) traps; (10) empty trap and (11) extraction system. 
 
The TSS were determined according to the standard method 2540D (APHA, 1992). 
Whatman 90 mm GF/C filter papers were heated in an oven at 105ºC until dry, then placed 
in a desiccator until cool. The filter papers were then weighed. Triplicate aliquots of 
homogenised sample were passed through the filter papers under vacuum. The filter papers 
(a) 
(b) 
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were placed in the oven overnight, removed and placed in the desiccator until cool, they 
were reweighed, and the suspended solids concentration calculated from Equation 4.1: 
 
TSS  mg l 1    
F    F1
 
   1000 
(Equation 4.1) 
Where: 
F1 = weight of dried filter paper before (mg) 
F2 = weight of dried filter paper after filtration (mg) 
V = volume of homogenised sample filtered (ml) 
1000 = to convert to mg l
-1
 
The BOD5 was determined according to the standard method 5210 B (APHA, 1992). 
Disposable BOD bottles were purchased from Hach Lange. Mineral media was prepared 
by making up the following four mineral salt solutions: A – phosphate buffer, B – calcium 
chloride, C – magnesium sulphate and D – iron (III) chloride (the solution compositions 
can be found in Appendix A). Mineral solutions B-D (1 ml) were added to a volumetric 
(1 l) containing ROW, followed by solution A (10 ml). Solution A was added last to avoid 
precipitation. Allylthiourea, a nitrification inhibitor, was added to the mineral media 
solution at a concentration of 0.053 g l
-1
. The solution was then made up to 1 l with ROW. 
 
A 1 l measuring cylinder was part filled with the mineral media solution, to which the 
wastewater sample was added, the dilution of the sample was between 5 – 7% for the 
influent and 10 – 14% for the effluent. The volume was made up to 1 l with mineral media. 
Parafilm was stretched across the top of the measuring cylinder and the cylinder gently 
inverted. The sample/mineral media mix was transferred to the BOD bottles in triplicate; 
the DO was measured immediately in each bottle using a calibrated DO probe (YSI 5700 
series) and meter (model 50B YSI incorporated). After the readings were taken the bottles 
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were topped up with more of the sample dilution media. It was important that there were 
no air bubbles in the headspace after the stopper was replaced. Dilution media blanks were 
prepared to determine the levels of background oxygen loss. The blanks were prepared by 
adding mineral media solution only, to BOD bottles, and the DO was measure immediately 
after media addition. The samples and dilution blanks were kept at 20 ºC for 5 d. On day 5, 
at the same time the BOD bottles were prepared on day 0, the DO was re-measured in the 
bottles. The BOD5 was then calculated from Equation 4.2: 
 
          
                              
 (Equation 4.2) 
Where: 
S1 = DO of diluted sample immediately after preparation (mg l
-1
) 
S2 = DO of diluted sample after 5 d incubation at 20ºC (mg l
-1
) 
B1 = DO of dilution water blank immediately after preparation, (mg l
-1
) 
B2 = DO of dilution water blank after 5 d incubation at 20ºC (mg l
-1
) 
1/F = Dilution volume/sample volume 
  
The DO, pH, temperature and Eh were measured regularly throughout SBR operation. The 
probes used to take these measurements are detailed in Table 4.2. 
 
Table 4.2  Probes used to measure DO, pH, Eh and temperature in the SBR. 
Parameter Probe 
DO (mg l
-1
) YSI Model 55 
pH Hanna Instrument 
Eh (mV) Russell CMPtRL/S7/400 probe (Ag/AgCl) 
Temperature (ºC) YSI Model 55 
The mV readings displayed on the Russell CMPtRL/S7/400 probe were normalised to a hydrogen 
electrode (Eh), by adding an offset voltage, which is temperature and electrode dependent. The 
value in this case was +213 mV, because the rig was operated at 20ºC. The details of probe 
normalisation were supplied by the manufacturer: Thermo Electron Corporation now ThermoFisher 
Scientific.  
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4.6 Dosing the SBR 
A fresh batch of inocula was collected from Totnes STP each time a different radioisotope 
was dosed to the SBR. Only one API at a time was dosed into the reactor. After the SBR 
was inoculated with the activated sludge, it was operated under SBR conditions for two 
weeks prior to dosing any radioactivity. This allowed the microorganisms in the biomass, 
time to acclimatise to the change in conditions, and to begin removing DOC and nutrients. 
Wastewater parameters were measured at least twice before the reactor was dosed. If the 
reactor was shown to be efficient at removing NH4
+
-N, DOC and TSS, then it was deemed 
acceptable to dose. 
 
The SBR was firstly dosed under batch conditions, this involved dosing a single pulse of 
the radiolabelled isotope, and sampling NaOH traps for any 
14
CO2 evolution. This 
experiment was to monitor the biodegradation of the APIs in a die-away manner, without 
any dilution or withdrawal of the compound. Therefore under these conditions the system 
was not operated as a SBR i.e. adding fresh influent wastewater and removing treated 
effluent. The experiment was run for 5 d, and was not repeated. 
 
Secondly, the SBR was dosed under semi-continuous conditions. This required the 
operation of a dosing pump, so the reactor could be dosed automatically at the start of each 
SBR cycle. Dosing under these conditions is more realistic of the flow to a full-scale STP, 
and therefore provides environmentally relevant data on the fate of the APIs. The SBR was 
operated under these conditions for 5 d. 
 
At the end of the 5 d batch experiment, prior to the start of the semi-continuous dosing, 
SBR operation recommenced, and influent was fed into the reactor and effluent pumped 
out. The SBR was operated like this for one week, which was sufficient time for the SBR 
to begin removing NH4
+
-N, DOC and TSS again. Monitoring was conducted twice during 
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this period, to confirm the efficiency of the SBR. Once this had been established, the SBR 
was dosed under semi-continuous conditions. At the end of semi-continuous dosing, the 
activated sludge biomass was centrifuged to separate the aqueous and solid phases, and 
then both were sub-sampled. 
 
A single inoculum was collected, and dosed, under batch and semi-continuous conditions 
for runs with 
14
C-salicylic acid, 
14
C-caffeine and 
14
C-diclofenac. However, during the 
14
C-
propranolol run, the reactor had to be inoculated twice due to an unforeseen problem with 
the rig. Fresh activated sludge was added to the reactor after operation under batch 
conditions, and prior to dosing under semi-continuous conditions. The second inoculation 
was allowed a two week period to acclimatise, and it was treated the same as the first batch 
of sludge. The sludge was discarded between the batch and semi-continuous dosing 
regimes, and not during dosing with the labelled compound.  
 
4.6.1 Single pulse dosing 
4.6.1.1 Preparation of dosing solutions  
14
C-salicylic acid, 
14
C-caffeine and 
14
C-diclofenac were purchased from American 
Radiolabelled Chemicals, Inc. St. Louis, U.S.A and 
14
C-propranolol was obtained from 
AstraZeneca, UK Ltd. Alderley Park, Macclesfield.  
 
The 
14
C APIs were dosed to the reactor at 22.5 µg, during the fill phase of the cycle. The 
volume of influent added at the start of each cycle was 2.25 l; therefore the dosed API 
concentration in the influent was 10 µg l
-1
. This concentration was selected because it was 
environmentally relevant, whilst allowing sufficient detection by the radiochemistry 
methods. The actual concentration in the reactor, at the start of batch and semi-continuous 
dosing was 5 µg l
-1
, since there was already 2.25 l present in the reactor and this diluted the 
influent concentration. To determine the amount of radioactivity needed to supply this 
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concentration, the specific activity of each labelled isotope is required. The specific 
activity is defined as the amount of radioactivity per unit mass of that radioisotope. The 
specific activity is reported as mCi mmol
-1
 in the documents supplied with the isotope. 
These units were converted to the SI units, Bq µg
-1
. The weight of chemical (22.5 µg) is 
multiplied by the specific activity, to calculate the amount of radioactivity required in one 
dose.  
 
Stock solutions of 
14
C-salicylic acid, 
14
C-diclofenac and 
14
C-propranolol were composed of 
100% radiolabelled chemical, whilst 
14
C-caffeine was prepared by blending unlabelled and 
labelled chemical, in order to reduce the amount of radioactivity dosed to the SBR. A 
summary of the dosing stocks are outlined in Table 4.3. The master stock solutions were 
stored at -20 ºC.  
 
The radioactivity in the dosing stocks was determined by liquid scintillation counting 
(LSC). This was achieved by sub-sampling 3 x 100 µl of the stock, and pipetting into LSC 
vials (7 ml). These vials were counted in a Tri-carb 2900TR liquid scintillation counter. 
The samples were counted for 2 min using the IS (IPA standards) in the counter, to 
determine the level of background radioactivity. Based on the average value of 
radioactivity in the triplicate samples, the level of radioactivity in the stock was 
determined. Each sample was corrected for quenching by comparison to known standards 
using the tSIE external quench correction technique.  
 
Dosing to the reactor was carried out by glass pipette, and was administered above the air-
surface interface. 
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Table 4.3  Summary of the dosing solutions for single pulse dosing. 
 
14
C-salicylic 
acid 
14
C-caffeine 
14
C-propranolol 
14
C-diclofenac 
Radioactivity 
dispensed (MBq) 
0.10 0.17 0.06 0.18 
Solvent  EtOH – H2O 
(20:80, v/v) 
EtOH EtOH (90%) – 
sterilised ROW 
(40:60, v/v) 
MeOH 
Volume of solvent (ml) 0.03 0.04 0.01 2.45 (evaporated 
to near dryness) 
Original specific 
activity (Bq µg
-1
) 
4019 9732 1637 7297 
Mass of unlabelled 
chemical added to 
radiolabel (µg) 
- 12 - - 
Dosing solvent ROW ROW ROW ROW 
Total volume of stock 
(ml) 
10 10 10 10 
Radioactivity dosed 
(MBq) 
0.09 0.10 0.04 0.16 
Mass of compound 
dosed (µg) 
22.57 22.50 22.50 22.47 
Specific activity of the 
dosing solution 
(Bq µg
-1
) 
4019 4545* 1637 7297 
*The specific activity was adjusted in the dosing solution due to the mixing of unlabelled and 
labelled test material. 
 
 
4.6.1.2 Sampling 
Mineralisation to 
14
CO2 was determined by capturing the evolved gas in two NaOH traps in 
series. NaOH traps were emptied into pre-weighed nalgene bottles, they were then 
reweighed and triplicate subsamples (5 ml) were pipetted into glass scintillation vials 
(20 ml). Gold star multi-purpose scintillation cocktail (Meridian) was added to NaOH 
samples and the vials were mixed vigorously. A blank NaOH sample was prepared, to act 
as a matrix matched background sample. The vials were left overnight, prior to analysis by 
LSC to allow the NaOH to photo-fluorescence with the cocktail before they were counted. 
Each group of samples was preceded by one background determination (matrix matched 
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sample) prior to counting. The disintegration rates per second (DSP) or Bq, of the 
appropriate matrix matched blank sample, were subtracted to give a net Bq for each 
sample. Each sample was counted for 20 min, or until a 2 sigma value of less than two was 
obtained, whichever occurred sooner. 
 
The following time points were sampled: day 0 at 12:00, 14:00, 16:00 and 17:00; day 1 at 
09:00 and 17:00; day 2 at 09:00 and 17:00; day 3 at 09:00 and 17:00 and day 4 at 09:00, 
12:00, 14:00, 16:00 and 17:00. On day 1, 2, 3 and 4 at 09:00 both NaOH traps were 
emptied into two separate nalgene bottles, at the remaining time points only the first NaOH 
trap in series, was emptied.  
 
4.6.2 Semi-continuous dosing 
4.6.2.1 Preparation of dosing solutions 
During semi-continuous dosing 22.5 µg of test chemical was dosed to the reactor at the 
start of each SBR cycle. This resulted in a nominal concentration of 10 µg l
-1
 in the 
influent (2.25 l) to the reactor. This was the same concentration dosed during batch 
operation, although under batch conditions it was dosed only once. The reactor was dosed 
by a Watson Marlow 205S pump. The stock was pumped from an amber Schott bottle, 
through portex tubing into the lid of the reaction vessel, and was dispensed just above the 
air-water interface. The Schott bottle was sealed from the environment by a lid with a 
small hole drilled in the centre for the portex tubing. The controller was programmed to 
switch the dosing pump on for 10 min at the same time as the influent peristaltic pump 
(Figure 4.3), this was so the influent and stock were administered to the reactor at the same 
time.  
 
There was sufficient radioactivity in the master stock solutions of 
14
C-salicylic acid and 
14
C-propranolol to dose 100% of the test chemical as radioactivity. However, for 
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14
C-diclofenac and 
14
C-caffeine the amount of radioactivity needed to dose, exceeded the 
amount of radioactivity in the master stocks. Therefore, the dosing stocks were prepared as 
a blend of unlabelled and labelled caffeine and diclofenac. All radiolabelled stocks were 
prepared in autoclaved amber Schott bottles. The empty Schott bottle and lid were weighed 
together, whilst the empty dosing tubing was weighed separately. The radiolabelled stock 
was dispensed to the Schott bottle.  
 
The amount of radioactivity requested was based on the LOD of the liquid scintillation 
counter and the radio-HPLC instruments. Worst case scenarios were calculated based on 
5% and 95% degradation of the test chemical. For example, if 95% of the radioactivity is 
mineralised then most of the radioactivity will occupy the NaOH traps and little 
radioactivity will reside in the reactor. Therefore, the radioactivity in the aqueous phase 
needs to be at a concentration detectable in either a 5 ml subsample for LSC analysis or, 
following SPE, in a 100 µl injection volume for analysis by HPLC. Alternatively, if only 
5% of the compound is mineralised and 95% remains in the reactor, the amount of 
radioactivity in the NaOH traps needs to be above the LOD of the LSC.  
 
To determine the total radioactivity required for dosing, the amount needed to dose one 
SBR cycle was calculated, and this was multiplied by the thirteen SBR cycles in the dosing 
period. Slightly more radioactivity was requested than was needed for dosing, this was to 
allow for any error in the pump operation, and to carry out radio-HPLC analysis of the 
stock.  
 
The stock solutions were prepared to ensure one dose of the test compound was in 10 ml. 
This volume was selected because it was large enough for the dosing pump to administer 
accurately. A known volume of the unlabelled stock, in the cases of 
14
C-caffeine and 
14
C-
diclofenac, or autoclaved ROW, in the cases of 
14
C-salicylic acid and 
14
C-propranolol, was 
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added to the dispensed radioactivity. The solution was subsampled and counted by LSC to 
determine the amount of radioactivity in the stock. The stock was then made up to the 
correct volume. The prepared stock was counted by LSC (see Section 4.6.1.1). The Schott 
bottle now containing the stock and lid were reweighed. The stock bottle, lid and dosing 
line were all weighed at the end of the study to determine how much of the stock had been 
dosed. Based on these calculations the average amount of radioactivity dosed per cycle 
could be calculated. A summary of the dosing solutions is outlined in Table 4.4. 
 
Table 4.4  Summary of the dosing solutions for semi-continuous dosing. 
 14
C-salicylic 
acid 
14
C-caffeine 
14
C-propranolol 
14
C-diclofenac 
Radioactivity 
dispensed (MBq) 
2.14 1.15 0.94 1.00 
Solvent  EtOH – H2O 
(20:80, v/v) 
EtOH EtOH (90%) – 
sterilised ROW 
(40:60, v/v) 
MeOH 
Volume of solvent 
dispensed (ml) 
0.54 0.33 0.22 13.50 
(evaporated to 
near dryness) 
Original specific 
activity (Bq µg
-1
) 
4019 9732 1637 7297 
Mass of 
unlabelled 
chemical added to 
radiolabel (µg) 
- 320 - 300 
Dosing solvent  ROW ROW ROW ROW 
Radioactivity 
dosed (MBq) 
1.35  0.60 0.42 0.54 
Mass of 
compound dosed 
(µg) 
335.90 227.26 255.96 234.68 
Specific activity 
of the dosing 
solution (Bq µg
-1
) 
4019 2627* 1637 2284* 
*The specific activity was adjusted in the dosing solution due to the mixing of unlabelled and 
labelled test material. 
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4.6.2.2 Sampling 
The NaOH traps were emptied at the same time points as those during batch operation (see 
Section 4.6.1.2 for details of NaOH sample preparation). Sludge was wasted once a day at 
the end of the react phase and this was collected in a nalgene bottle. To determine the level 
of radioactivity in solid samples, an aliquot (30 ml) of waste sludge was centrifuged, then 
sub-sampled; weighing 3 x 0.1 g into combustion cones. These cones were kept in the 
freezer until they were combusted by the Packard 307 sample oxidiser. This instrument 
oxidises any 
14
C in the sample to 
14
CO2, and traps it in ‘carbon trap’ scintillation cocktail 
(purchased from Meridian). The sample is then mixed with ‘carbon count’ scintillation 
cocktail (purchased from Meridian), so that there is a 50:50 mix of both types of scintillant. 
The efficiency of the sample oxidiser was checked prior to use by combusting two cones 
spiked with radioactivity. The same concentration of radioactivity was spiked directly into 
LSC vials, and a recovery was calculated by dividing the spiked cones, by the spiked vials 
and multiplying by 100. The recovery should be 100 ± 10%. The remainder of the wasted 
sludge sample was used for TSS determination.  
 
A subsample of the effluent (500 ml) pumped from the SBR during the draw phase, was 
collected in a nalgene bottle. To determine the total radioactivity in the effluent, triplicate 
aliquots (5 ml) were pipetted into LSC vials (20 ml) and Gold-star multi-purpose 
scintillation cocktail was added. For SPE of the effluent, triplicate subsamples (100 ml) 
were transferred to nalgene bottles. SPE of the samples took place no later than 24 h after 
sample collection. The sample preparation method can be found in Section 3.2.1 or 
Appendix D.  
 
NaOH, aqueous, and solid samples were then counted in a Perkin Elmer Tri-carb 2900TR 
liquid scintillation counter. The LSC procedure is detailed in Section 4.6.1.2. 
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To conclude a laboratory SBR rig was developed in order to investigate the mechanisms of 
API removal in a BNR sewage treatment rig. The operating conditions were selected based 
on a literature search of laboratory SBRs that successfully achieved BNR. The controller 
system was operated initially using ROW, so the operation of the rig could be observed 
and refined prior to sewage addition. The SBR was designed so it would be a closed 
system in order to capture any mineralised 
14
CO2. Suitable methods were identified for 
analysing wastewater constituents. The dosing regime of the SBR was discussed, i.e. batch 
followed by semi-continuous and the preparation of the dosing stocks and sampling 
methods. Following on from the construction of the rig, and the procedure for dosing with 
14
C labelled APIs, Chapter 5 presents the results from the rig validation as a BNR system, 
and the results from the batch and semi-continuous dosing.  
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Chapter 5 Rig monitoring 
 
5.1 Rig validation  
In order to investigate the fate of pharmaceuticals during BNR sewage treatment, a 
laboratory rig was constructed, to simulate the conditions present in a typical full-scale 
BNR plant.  
 
5.1.1 Wastewater influent and effluent concentrations 
A number of wastewater variables was measured throughout the SBR operation, and 
during dosing with different 
14
C labelled APIs. This was to determine the efficiency of the 
rig, for removing a set of traditional consent parameters. The SD in Table 5.1 shows there 
is a higher level of variability in the influent, compared with the effluent, for all the 
analysed parameters, except for NO3
-
-N. There is an inherent variability with wastewater, 
which is caused by weather conditions, the time of day and season (Seviour and Nielsen, 
2010).  
 
A one-way ANOVA was carried out to compare the effluent wastewater variables, during 
dosing with different 
14
C labelled compounds. This test was used, to determine if the rig 
removed the wastewater constituents, to similar concentrations in the effluent, between 
runs with different activated sludge biomass. The data was tested for normality using the 
Anderson-Darling method. The data showed a normal distribution for the following 
wastewater constituents: PO4
3-
-P (p = 0.31), total-P (p = 0.94) and total-N (p = 0.24). 
However, for TSS, COD and NO3
-
-N the data needed transforming before it was normally 
distributed. The natural log of TSS was taken, and the data became normalised to p = 0.97. 
The COD data was transformed by taking 1/square root to give a p = 0.08, which is close 
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to being significant (p < 0.05). The NO3
-
-N data was transformed by taking the square root 
and this gave p = 0.46.  
 
However, a transformation could not be found for effluent NH4
+
-N and DOC 
concentrations. This reason for this is because the majority of NH4
+
-N concentrations were 
similar, with six anomalous values that were a lot higher. This is similar to the DOC data 
because the dataset contained one anomalous result (value of 43.8 mg l
-1
). Once this data 
point was removed the data became normally distributed (p = 0.07). 
 
A significant difference (p < 0.05) in the effluent concentrations, between runs with 
different inocula, was identified for the following wastewater constituents: DOC (with the 
anomalous data point removed) (F(6,31) = 3.92, MSE = 5.34, p = 0.005), NO3
-
-N 
(F(6,34) = 3.28, MSE = 1.42, p = 0.012), total-P (F(5,18) = 2.96, MSE = 1.97, p = 0.040) 
and total-N (F(5,18) = 4.32, MSE = 77.9, p = 0.009). Whilst the variability for each 
wastewater constituent (except for NO3
-
-N) was lower after treatment in the SBR, the one-
way ANOVA shows there were differences in effluent concentrations of these parameters 
between runs with different inocula, indicating that the rig did not consistently removal all 
wastewater constituents to a similar level. This is one of the limitations of using real 
wastewater in laboratory simulations.  
 
Table 5.2 summarises the required effluent discharge consents in the UWWTD, for STPs 
treating wastewater from varying agglomeration sizes. The average effluent concentrations 
from the SBR for COD, TSS and BOD5 were 39, 13 and 3 mg l
-1
, respectively. These 
concentrations meet the required effluent levels for full-scale STPs, which demonstrates 
the SBR was operating within the margins of a full-scale plant for these criteria.  
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Table 5.1  Summary statistics for the influent and effluent concentrations of the wastewater 
parameters measured in the SBR rig. 
 Concentration Removal efficiency 
Wastewater 
parameter 
Sampling 
location 
Average  
(mg l
-1
) 
SD  
(mg l
-1
) 
n 
Average 
(%) 
SD (%) N 
TSS 
IN 138.6 92.2 35 
86.7 14.1 33 
OUT 13.1 7.9 33 
BOD5 
IN 101.7 29.9 5 
96.1 3.8 5 
OUT 3.2 2.3 5 
COD 
IN 280.8 176.1 41 
80.1 25.7 41 
OUT 39.1 30.0 41 
DOC 
IN 40.1 22.2 40 
65.8 33.7 39 
OUT 10.1 6.2 39 
Total-P 
IN 6.1 2.6 24 
22.7 20.9 24 
OUT 4.4 1.7 24 
Total-N 
IN 46.9 17.9 23 
52.5 15.4 23 
OUT 21.6 11.6 24 
NH4
+
-N 
IN 23.4 11.7 41 
93.0 12.4 41 
OUT 2.0 3.8 42 
NO3
-
-N 
IN 3.4 4.0 41 No 
removal 
- 41 
OUT 15.4 11.0 41 
PO4
3-
-P 
IN 3.9 2.0 43 No 
removal 
- 43 
OUT 3.8 1.8 43 
 
Table 5.2  The effluent discharge consents outlined in the Urban Waste Water Treatment Directive. 
Population 
equivalent 
TSS  
(mg l
-1
) 
COD  
(mg l
-1
) 
BOD5  
(mg l
-1
) 
Total-N  
(mg l
-1
) 
Total-P  
(mg l
-1
) 
2,000 – 
10,000 
< 60  
125  
 
25 
- - 
> 10,000 < 35 - - 
10,000 – 
100,000 
- - - 15 2 
> 100,000 - - - 10 1 
This study 13 39 3 22 4 
 
Figure 5.1(a) shows that, on two occasions only, the effluent COD failed to meet the 
discharge consent, as stipulated in the UWWTD. The TSS was below the most stringent 
discharge limit of < 35 mg l
-1
, apart from at one sampling point, but in this instance it still 
met the < 60 mg l
-1
 level (Figure 5.1(b)).  
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Figure 5.1(a-d)  The sequencing batch reactor influent and effluent concentrations of four Urban 
Waste Water Treatment Directive consent parameters. (a) COD, (b) TSS, (c) total-N and (d) 
total-P. The dashed horizontal lines indicate the consent concentration identified in the directive. 
 
(b) 
(c) 
(d) 
(a) 
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The average total-N and total-P concentrations in the SBR effluent were 22 and 4 mg l
-1
, 
respectively. These concentrations would not meet the required discharge consents for full-
scale STPs, since the most lenient concentrations (for plants with PE between 10,000 and 
100,000) are 15 mg l
-1
 total-N and 2 mg l
-1
 total-P. Figure 5.1(c) shows that on eight 
sampling days the effluent concentration of total-N did fall below the discharge limit of 
15 mg l
-1
. The effluent concentration of total-P rarely met the discharge consent, as can be 
seen from Figure 5.1(d).  
 
The BOD5 was measured on fewer occasions, but Table 5.3 shows that the effluent oxygen 
demand was considerably below the discharge consent of 25 mg l
-1
, on each sampling 
occasion. 
 
Table 5.3  SBR influent and effluent biochemical oxygen demand concentrations. 
Date Influent (mg l
-1
) Effluent (mg l
-1
) 
16
th
 Dec 2011 53.4 5.2 
18
th
 Dec 2011 116.9 2.3 
3
rd
 Jan 2012 102.6 5.8 
6
th
 Jan 2012 133.4 2.9 
9
th
 Jan 2012 102.4 0.0 
n = 3 
5.1.2 Wastewater removal efficiencies 
Removal efficiencies were calculated for each wastewater parameter measured. Table 5.1 
shows that TSS, BOD5, COD and NH4
+
-N all exhibited average removal efficiencies 
> 80% from the rig. An average removal efficiency of 93% was obtained for NH4
+
-N. The 
box plot in Figure 5.2(a) details the change in the NH4
+
-N profile during the SBR cycle. 
There is a decrease in concentration between the influent and the start of the 
anaerobic/anoxic phase. This is due to influent dilution with the mixed liquor remaining in 
the reactor from the previous cycle. There is no change in NH4
+
-N concentrations between 
the beginning and end of the anaerobic/anoxic phase, indicating there is no anaerobic 
removal of NH4
+
-N occurring. At the end of the aerobic phase, and in the final effluent, the 
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NH4
+
-N concentration decreases significantly. There are a few outlying NH4
+
-N values, 
which occurred when the SBR vessel was not fully aerated, due to a failure in the aeration 
system. The biomass used to inoculate the SBR, already contained an active population of 
nitrifiers, since it was collected from an operational NAS tank. Figure 5.2(a) shows this 
population was able to continue nitrifying NH4
+
-N in the SBR.  
 
 
 
 
 
 
 
Figure 5.2(a-b)  Box plot of (a) NH4
+
-N and (b) NO3
-
-N during the phases of SBR operation: (1) 
influent, (2) start of anaerobic/anoxic phase, (3) end of anaerobic/anoxic phase, (4) end of aerobic 
phase, and (5) effluent. The cross bar shows the median, the box is the inter-quartile range that 
shows the middle 50% of the data, the upper whisker extends to the maximum data point within 1.5 
box heights from the top of the box and the lower whisker extends to the minimum data point with 
1.5 box heights from the bottom of the box, and asterisks represent the outliers that are beyond the 
upper and lower whiskers.  
 
NO3
-
-N exhibited a consistently low removal from the SBR. This is a consequence of 
having the only aerobic period at the end of the react phase. Under aerobic conditions, 
NH4
+
-N is oxidised to NO3
-
-N, which is subsequently reduced to N2 under anoxic 
conditions. In the SBR cycle, there was not a secondary anoxic phase to remove NO3
-
-N 
before it was discharged in the effluent. However, removal of NO3
-
-N was observed during 
the anaerobic/anoxic phase, because concentrations of NO3
-
-N showed a marked decrease; 
this is shown in the box plot in Figure 5.2(b). Therefore, it is likely denitrification was 
occurring in the reactor. 
 
A consequence of the high effluent NO3
-
-N concentrations, was that the removal of total-N 
was reduced, to an average of 52%. Table 5.1 shows the average effluent concentration of 
(a) (b) 
4
+
 
3
-  
-1
 
-1
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total-N was 21.6 mg l
-1
, and the average NO3
-
-N concentration is 15.4 mg l
-1
, this shows 
that the majority of total-N in the effluent, was composed of NO3
-
-N.  
 
DOC was removed with an average efficiency of 66%. DOC concentrations in the effluent 
remained around 10 mg l
-1
; this is shown in Table 5.1. This residual DOC is likely to be 
non-biodegradable DOC, since typically 10% of the soluble organic matter remains in the 
effluent after biological treatment. This remaining DOC, could be composed of, a number 
of different recalcitrant synthetic organic molecules, including: surfactants, organic priority 
pollutants and volatile organic compounds. Furthermore, molecules such as humic acids, 
carbohydrates, protein, fatty acids, extracellular enzymes and cell fragments will also be 
present in the effluent (Shon et al., 2008).  
 
Total-P was removed only marginally in the SBR, with an average removal efficiency of 
23%. Figure 5.3(a) suggests this removal is mostly linked to the removal of TSS because 
of the positive association between the two. There is an average of 15 mg total-P per g TSS 
in the SBR. Figure 5.3(a) shows there are two clusters of values, the lower cluster contains 
the data collected from the influent and effluent samples, and the higher cluster contains 
the activated sludge sample data. The average removal of PO4
3-
-P across all the SBR 
cycles was calculated, and no removal was observed, demonstrating the SBR was 
inconsistent at removing bio-P. The total-P in the effluent, therefore, was mostly composed 
of PO4
3-
-P. Figure 5.3(b) shows that total-P and PO4
3-
-P have a shared variation. 
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Figure 5.3(a-b)  Scatter plots of (a) total-P against TSS and (b) PO4
3-
-P against total-P. 
 
During some SBR cycles there was a marked increase in PO4
3-
-P concentrations at the end 
of the anaerobic/anoxic phase, with decreases in PO4
3-
-P at the end of the aerobic phase, 
however, on many occasions the effluent concentration was not lower than the influent 
concentration, and therefore, no removal was calculated. This suggests that on some 
occasions, the PO4
3-
-P concentrations followed a typical profile expected, if bio-P removal 
was occurring by PAOs. Figure 5.4 shows how the concentration of PO4
3-
-P remained 
relatively constant during the SBR cycle; however, at the end of the anaerobic/anoxic 
phase there was an increase in concentration.  
 
 
 
 
 
 
 
 
 
Figure 5.4  Box plot of PO4
3-
-P during the phases of SBR operation: (1) influent, (2) start of 
anaerobic/anoxic phase, (3) end of anaerobic/anoxic phase, (4) end of aerobic phase and (5) 
effluent. 
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5.1.3 Physical parameter analysis 
There were discernible phases during the react stage of the SBR cycle. The changes in DO 
and Eh encouraged the conditions necessary for BNR bacteria. Figure 5.5(a-b) shows the 
changes in reactor conditions, during anaerobic/anoxic and aerobic phases.  
 
 
 
 
 
 
Figure 5.5(a-b)  Box plot of (a) DO and (b) ORP, during different phases of the SBR cycle: (1) 
anaerobic/anoxic phase, (2) aerobic phase and (3) settle/effluent. 
 
Figure 5.5(a) shows that the DO levels were controllable between the anaerobic/anoxic and 
aerobic phases. The DO data was tested for normality using the Anderson-Darling method, 
and both groups i.e. anaerobic/anoxic and aerobic phases were not normally distributed 
(p < 0.005). The DO data for the anaerobic/anoxic phase is not normally distributed as 
there are two outlying data points, which can be seen in Figure 5.5(a). Furthermore there is 
little variation in the data points as shown in Figure 5.6(a), with 56 data points in the range 
of 0.03 – 0.3 mg l-1. Figure 5.6(b) shows a histogram of the aerobic DO data, which clearly 
shows the data, was bivariate in nature.  
 
 
 
 
 
 
 
Figure 5.6(a-b)  Histograms showing the frequency and distribution of dissolved oxygen data 
measured during (a) anaerobic/anoxic and (b) aerobic conditions. This data is displayed in the box 
plot in Figure 5.5(a).    
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The reason for this bivariate distribution is that measurements were made throughout the 
aerobic phase; therefore, at the beginning of the phase values were still recovering from the 
previous anaerobic/anoxic conditions, so were lower. 
 
The median concentrations during anaerobic/anoxic and aerobic conditions were 0.12 and 
6.51 mg l
-1
, respectively. Kargi et al. (2005) kept the DO in the aerobic phase of their SBR 
> 2 mg l
-1
, and in the anaerobic and anoxic phase, the DO was practically zero, these DO 
concentrations were sufficient to create the aerobic and anaerobic/anoxic conditions, 
respectively.  
 
The DO variations during aerobic conditions in this study, can be attributed to DO 
measurements collected at the beginning of the aerobic phase, before the sludge became 
oxygenated. The Eh is affected immediately by aeration; however, DO does not respond as 
rapidly, since an Eh threshold needs to be reached in order for the DO to increase above 
0 mg l
-1
 (Myers et al., 2006). The scatter plot in Figure 5.7 illustrates this relationship 
between DO and Eh. It shows that after a certain Eh level is reached the DO concentration 
in the sludge begins to increase, however, there is primarily two groups of scatter, one at 
lower DO concentrations (approximately 0 mg l
-1
) and one at higher DO concentrations 
(approximately 6 to 8 mg l
-l
), with only a few data point inbetween these two groups.  
 
 
 
 
 
 
 
 
Figure 5.7  Scatter plot showing the relationship between Eh and DO in the reactor. 
-1 
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Figure 5.5(b) shows the changes in the Eh profile during the 8 h SBR cycle. The data was 
checked for normality using the Anderson-Darling method, and did not have a normal 
distribution (p < 0.005). The histogram in Figure 5.8 shows how the data is skewed 
towards the right.   
 
 
 
 
 
Figure 5.8  Histogram of the Eh values measured during repeated SBR cycles. 
 
The Eh was lower during the anaerobic/anoxic phase; this is a result of the high organic 
loading at the start of the cycle. As the fresh substrate is consumed, oxygen is used up by 
the microorganisms and a reducing environment prevails (Myers et al., 2006). Once the 
aeration system switches on, the Eh instantly begins to increase and the conditions in the 
reactor gradually become oxidising.  
 
The pH was not controlled within the SBR, and was between 7.1 and 8.8. There were slight 
variations in pH during the react phases. The average pH during the anaerobic/anoxic was 
7.92 ± 0.31 (SD, n = 83) and 7.82 ± 0.31 (SD, n = 72) during the aerobic phase. A student 
t-test was conducted and shows the two groups differed significantly from each other 
(t(149) = 2.04, p = 0.043). This difference is likely due to the removal of alkalinity as 
CaCO3, taking place during nitrification (Metcalf and Eddy, 2003).  
 
5.1.4 Discussion  
The physical conditions within the SBR were typical of BNR conditions found in full-scale 
plants, and of those reported in similar laboratory BNR simulations. Distinctive aerobic 
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and anaerobic conditions were created within the SBR, to provide the conditions necessary 
for nitrifiers, denitrifiers and PAOs. The DO was well controlled in the SBR, which 
fundamentally created the conditions suitable for BNR under anaerobic/anoxic and aerobic 
conditions.  
 
There was notable variability in the composition of the influent wastewater; however, 
using real wastewater offers some considerable advantages over synthetic feeds. These 
advantages include: a reduction in bulking and settling problems and a diverse nutrient 
mixture, and continuous supply of new microorganisms entering the reactor, this will help 
create conditions in the reactor that are more analogous to a full-scale plant (Shimp and 
Larson, 1996). The composition of the effluent was less variable than the influent; this 
shows that the SBR was reasonably consistent at removing wastewater parameters across 
runs with different inocula, however, the effluent concentrations of some wastewater 
constituents (DOC, NO3
-
-N, total-P and total-N) were significantly different (p < 0.05) 
between runs with different inocula.  
 
Overall, the SBR rig demonstrated the characteristics of a typical BNR plant in the UK, 
and provided effective removal of the traditional consent parameters. The SBR received a 
relatively weak sewage, with an average BOD of 102 mg l
-1
, TSS of 139 mg l
-1
 and COD 
of 281 mg l
-1
. Over 80% of BOD, COD and TSS were removed from the influent, 
providing a high quality effluent. NH4
+
-N had an average removal efficiency of > 90%, 
however, NO3
-
-N concentrations were high in the effluent, and hence so were total-N 
concentrations. The average total-N removal was 53%. 
 
High effluent NO3
-
-N concentrations resulted at the end of the aerobic phase. This is 
common in plants that do not have a subsequent step to remove NO3
-
-N. Plants that must 
meet very low total-N limits use a secondary anoxic zone, to which supplemental carbon is 
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added. Supplemental carbon sources can be internal, such as fermented wastewater or 
sludge, or external sources such as purchased chemicals. MeOH is a commonly used 
carbon source because of its low cost, however, other sources include EtOH, acetic acid, 
glucose or glycerol (EPA, 2009).  
 
There was some indication from the analysis of NO3
-
-N, during the SBR cycles, that 
denitrification was occurring. This reduction in NO3
-
-N concentrations can be seen at the 
end of the anaerobic/anoxic phase (Figure 5.2(b)). 
 
The removal of bio-P was low in the SBR, this is mirrored by variable bio-P removal in 
full-scale STPs, in the UK (Howell, 2010). This is due to the endemic lack of organic 
matter available to the microbes, particularly during wet weather periods (Manyumba et 
al., 2009). Combined sewerage systems are common in the UK, which means STPs receive 
rainwater run-off, in addition to wastewater from domestic, industrial and commercial 
premises (Defra, 2012). Therefore, as a result of the climate in the UK, and the combined 
nature of the sewerage system, ‘weak’ sewage is inherent in the UK, and as a result there 
are few operational bio-P STPs.  
 
5.2 API batch dosing 
Prior to dosing the SBR under semi-continuous conditions, the reactor was dosed with a 
single pulse of the radioactive API, and its removal was monitored for 5 d. This was so 
kinetic rate constants could be calculated. These rate constants are more reliably estimated 
from short term die-away experiments (Berg and Nyholm, 1996).  
 
5.2.1 Percentage mineralisation  
The mineralisation of a compound occurs when it is degraded to H2O and CO2. A variety 
of other elements may be produced during this process e.g, N, P, and S, which can be 
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incorporated into microbial cell biomass (Alexander, 1999). In the laboratory, when 
utilising 
14
C labelled compounds, the evolved CO2 gas can be captured in a suitable liquid 
such as NaOH, as used in this work. If the CO2 contains the 
14
CO2 label then this can be 
quantified by LSC, and its percentage of the total dosed radioactive label, can be 
determined. 
 
Figure 5.9 shows the mineralisation that occurred under batch conditions during the runs 
with each API. 
14
C-caffeine and 
14
C-salicylic acid produced a significant level of 
mineralisation with 83% and 63% of the total applied radioactivity, respectively, measured 
in the NaOH traps at the end of 13 SBR cycles. After the first SBR cycle (8 h), 27% of 
both 
14
C-caffeine and 
14
C-salicylic acid, had been mineralised to 
14
CO2. For a compound to 
be classed as readily biodegradable, 60% mineralisation is required within a 10 d window 
(OECD, 1992). Based on these figures both salicylic acid and caffeine would be classified 
as readily biodegradable.  
 
14
C-propranolol, unlike 
14
C-caffeine and 
14
C-salicylic acid, produced very little 
mineralisation by the end of cycle 1, with only 1% of the total applied radioactivity in the 
NaOH traps. However, at the end of the 5 d dosing period, 29% of the total applied 
radioactivity was mineralised to 
14
CO2. 
14
C-diclofenac produced even less 
14
CO2 with a 
negligible amount at the end of the first cycle and only 3% produced overall. 
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Figure 5.9  Cumulative radioactivity mineralised during a 5 d test period showing batches with 
14
C-salicylic acid, 
14
C-caffeine, 
14
C-propranolol and 
14
C-diclofenac. Half-lives have been calculated 
for each API using this data and the graphs are presented as Figure 5.11(a-d) and Figure 5.12(a-b). 
 
Figure 5.10(a-d) represents the amount of radioactivity captured in the NaOH traps at each 
sampling point over the 5 d period. Figure 5.10(a) shows that the traps emptied after the 
first SBR cycle, during the run with 
14
C-salicylic acid, contributed the highest percentage 
of 
14
CO2. After this point, the amount of mineralisation in each trap declined over the 
experimental period. Since the traps were not emptied at the end of every cycle, the NaOH 
values at time points 24, 48, 72 and 96 h have the contribution of 
14
CO2 from two SBR 
cycles. Therefore, this explains the higher values at these time points. This pattern is 
similar for 
14
C-caffeine, as is shown in Figure 5.10(b), like salicylic acid the largest 
amount of radioactivity in any trap was collected after the first 8 h cycle. Additionally, the 
overall trend is one of a decline in 
14
CO2 production. There are spikes in 
14
CO2 production 
at 24, 48, 72 and 96 h, again this is because of the joint contribution from two SBR cycles. 
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Figure 5.10(a-d)  The 
14
CO2 recovered in each NaOH trap during dosing with (a) 
14
C-salicylic 
acid, (b) 
14
C-caffeine, (c) 
14
C-propranolol and (d) 
14
C-diclofenac. The data points at 24, 48, 72 and 
96 h include evolved 
14
CO2 collected from two combined SBR cycles represented by (). The 
remaining data points show evolved 
14
CO2 collected from one trap represented by (). 
 
The trend for propranolol is slightly different to the previous two compounds (Figure 
5.10(c)). There is an increase of radioactivity up to roughly the middle of the experimental 
period, after which there is a decline until the end of the experiment. The highest level of 
radioactivity is measured in the traps between 40 – 56 h of operation (5 – 7 SBR cycles). 
The traps emptied after two combined SBR cycles, i.e. cycles 2 – 3, 5 – 6, 8 – 9 and 11 – 
12 can be seen in Figure 5.10(c) as higher values on the scatter plots. However, these 
‘double traps’ follow the same trend, with an increase in 14CO2 production followed by a 
decrease.  
 
14
C-diclofenac showed a different profile to the other three compounds. The amount of 
mineralisation was < 1% in all the traps. However, the general trend was an increase in 
14
CO2 production until the last cycle, when there is a slight decline (Figure 5.10(d)).  
(a) (b) 
(c) (d) 
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5.2.2 Mineralisation half-lives 
Using the mineralisation data for each API, regression models were fitted and half-lifes 
calculated. Two models were fitted to the data; an exponential curve and an exponential 
curve with a linear component. These models were illconditioned to the 
14
C-propranolol 
and 
14
C-diclofenac data. This is because Figure 5.12(a-b) indicates there is a lag phase for 
both compounds. Furthermore there is no data in the region around the endpoint, so any 
estimate of the rate constant (and associated half-life) is associated with a large 
uncertainty. Using the Excel routine to estimate the half-lives of propranolol and 
diclofenac by fitting an exponential function (Figures 5.12(a-b)), the half-life of 
propranolol is 9.1 d and for diclofenac it is 105 d (Table 5.4).  
 
Fits could be made to the 
14
C-salicylic acid and 
14
C-caffeine mineralisation data. The 
exponential fit to the salicylic acid data accounted for 98.8% of the variation (Figure 
5.11(a)). When a linear component was added to the exponential model, 99.8% of the 
variance was accounted for (Figure 5.11(b)). Figure 5.11(b) shows that the exponential 
plus linear model produced the best fit to the data. The linear component accounted for 
3.6% of the model and the exponential phase 47%. The exponential fit to the caffeine data 
accounted for 99.7% of the variance, and for the exponential and linear model this 
increased slightly to 99.9%. The exponential phase of the model accounted for 67%, and 
the linear component was 3.8%.  
 
For both salicylic acid and caffeine, the exponential plus linear component model provided 
the best fit to the data. Therefore these half-lives will be reported here, although Table 5.4 
shows the half-lives for the exponential model also. For salicylic acid the half-life was 
0.3 d and for caffeine this was 0.5 d. Therefore it can be assumed that the parent compound 
half-life would be reached more quickly.  
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Figure 5.11(a-d)  Nonlinear regression fits to 
14
C-salicylic acid and 
14
C-caffeine mineralisation 
data. The percentage radioactivity remaining after mineralisation has been subtracted from the 
starting percentage (100%) and is plotted against time. (a) 
14
C-salicylic acid exponential fit, (b) 
14
C-
salicylic acid exponential and linear fit, (c) 
14
C-caffeine exponential fit, and (d) 
14
C-caffeine 
exponential and linear fit. 
 
Table 5.4  Half-lives of 
14
C-salicylic acid and 
14
C-caffeine calculated from an exponential model 
and exponential plus linear component model, and half-lives of 
14
C-propranolol and 
14
C-diclofenac 
estimated from an extrapolated exponential fit to the data.
 
API Model type K (d
-1
) t(1/2) (d) 
14
C-salicylic acid Exponential 1.29 0.5 
14
C-salicylic acid Exponential + linear 2.09 0.3 
14
C-caffeine Exponential 0.98 0.7 
14
C-caffeine Exponential + linear 1.32 0.5 
14
C-propranolol
 
Exponential 0.08 9.1 
14
C-diclofenac Exponential 0.01 105 
 
 
 
 
(a) (b) 
(c) (d) 
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Figure 5.12(a-b)  Exponential regression fit of (a) 
14
C-propranolol and (b) 
14
C-diclofenac data. The 
plots show the percentage radioactivity remaining after mineralisation has been subtracted from the 
starting percentage (100%) and this is plotted against time. 
 
5.2.3 Discussion  
An order of recalcitrance can be established based on 
14
CO2 production, from the least to 
the most recalcitrant as follows: diclofenac > propranolol > salicylic acid > caffeine. The 
literature chiefly supports this assertion. Salicylic acid has been found to be easily 
biodegradable in the laboratory, with reports of 94% biodegradation at the end of a 28 d 
study (Henschel et al., 1997). The analytical method used to measure salicylic acid 
removal, was oxygen consumption in a manometric respiration test.  
 
Perez et al. (2005) found caffeine was completely removed in 3 d, in a batch test with 
matrices containing primary sewage, aerobic activated sludge and nitrifying activated 
sludge. Caffeine was even removed to zero in treated effluent that had undergone sand 
filtration and disinfection after a period of 10 d. 
 
In a study conducted by Quintana et al. (2005) the removal of a number of acidic APIs, 
including diclofenac, were investigated in batch systems. In the first set of experiments 
20 mg l
-1
 of the test compound was added along with 10 mg l
-1
 of sludge (dw). Analysis of 
parent compound and DOC was carried out. The DOC differentiated between 
(a) (b) 
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transformation of the parent compound to lower weight degradation products and 
mineralisation. Diclofenac remained unaltered during this study with no change in the 
parent compound or mineralisation. In a second set of batch experiments, cometabolic 
degradation was investigated by adding the APIs at a lower concentration of 5 mg l
-1
, 
whilst also adding 50 mg l
-1
 of powdered milk. Again the parent and DOC analysis showed 
that diclofenac was not degraded over the test period of 28 d (Quintana et al., 2005).  
 
Diclofenac has been shown to degrade under some conditions. Kujawa-Roeleveld et al. 
(2008) found that in their aerobic batch experiments, diclofenac was removed by up to 
90% in duplicate tests, after a period of 30 d. A diclofenac concentration of 0.3 mg l
-1
 was 
spiked into sludge collected from a nutrient removing activated sludge plant. The 
concentration of the sludge in the batch systems was not disclosed, but can be assumed to 
be undiluted sludge from the full-scale plant. Therefore, this study demonstrates that 
diclofenac can be removed by biological treatment, however, mostly, diclofenac removal is 
insignificant. 
 
Yamamoto et al. (2007) obtained a removal efficiency of 60% for propranolol from 
activated sludge batch experiments, at the end of a 6 h test period. This value is higher than 
that observed in this study (28% after 104 h), however, the endpoint measured by 
Yamamoto et al. (2007) was the parent compound. More conservative removal efficiencies 
are obtained by measuring CO2 evolution, since it is an indicator of complete removal and 
not removal of the parent compound only. Mineralisation is the only transformation 
pathway whereby the compound is removed completely from the environment. 
 
Both salicylic acid and caffeine were found to be readily biodegradable in the SBR 
activated sludge. This shows the viability of the microbial biomass in the SBR. However, 
diclofenac and propranolol were not readily biodegradable, and if the exponential fit 
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(Figure 5.9(d)) proves to be correct, then diclofenac is in fact very recalcitrant, suggesting 
the length of time it remains in the reactor, and hence the HRT of a full-scale activated 
sludge tank, would not greatly impact on its degradation.  
 
AstraZeneca has conducted a number of unpublished studies (the main findings can be 
found at www.astrazeneca.com), that have looked at the biodegradation of 
14
C-propranolol 
in batch systems. In one study, activated sludge concentrations of 3000 mg l
-1
, were dosed 
with a range of propranolol concentrations, from 0.001 to 100 mg l
-1
. The half-lives of 
propranolol were between 4.9 and 6.8 d (AstraZeneca, 2012). In a similar study, a batch 
test containing 3000 mg l
-1
 solids was dosed at propranolol concentrations of 100, 0.1 and 
0.01 mg l
-1
, half-lives of 14.6, 14.8 and 16.5 d were obtained, respectively (AstraZeneca, 
2012). The value of 8.6 d in this study is within a similar range to that found by other 
activated sludge batch studies using radiolabelled propranolol (notably labelled in the same 
position). However, there is some variability in the half-lives between the studies, the 
cause of which is unknown.  
 
The position of the radiolabelled carbon atoms provides some understanding of how 
microorganisms degrade these chemical structures. The phenylacetic acid ring was 
universally labelled in the diclofenac molecule; therefore microorganisms would need to 
cleave the ring structure in order to convert the 
14
C atoms into 
14
CO2. Due to the low levels 
of mineralisation, it is possible the microorganisms did not possess the necessary enzymes 
to degrade this ring structure. The benzene ring of 
14
C-salicylic acid was also universally 
labelled, and due to the higher levels of mineralisation it seems that the microorganisms 
present in the SBR possessed enzymes capable of cleaving these rings.  
 
The position of the 
14
C atom on the radiolabelled propranolol molecules is on carbon 
number 1. Therefore the ring structure needs to be cleaved in order for 
14
CO2 to be 
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produced. The position of the labelled carbon atom in the caffeine molecule is on the 1-
methyl position. This is a more exposed part of the molecule and might make it easier for 
microorganisms to convert the carbon atom to 
14
CO2. The APIs were not all universally 
labelled due to costs or lack of available labels. 
 
There is a decline in 
14
CO2 production towards the end of the dosing period for all APIs. 
The reasons for this are unclear; however, there might be a number of factors at work, and 
these might vary for each compound. Batch systems do not operate under steady-state 
conditions, because they are closed systems, therefore the concentration of the test 
compound, organic matter and nutrients will be in constant flux, which will affect the 
composition of the microbial community. The populations responsible for the initial 
degradation may have been inhibited due to the depletion of any number of substances 
required for growth. It is widely suggested in the literature, that cometabolism is 
responsible for the biodegradation of APIs in the environment; due to their sub-enzyme 
activating concentrations (Gauthier et al., 2010; Ottmar et al., 2012; Quintana et al., 2005). 
If the carbon source(s) the microorganisms use for energy have been depleted, then the 
concurrent degradation of the APIs cannot take place either.  
 
In the case of salicylic acid and caffeine the remaining radioactivity could be composed of 
degradation products that are not amenable to further ultimate biodegradation. Moreover, 
this radioactivity could be associated to the activated sludge biomass, and therefore, the 
compound cannot be further transformed by microorganisms.  
 
The microbial population seems capable of degrading 
14
C-salicylic acid and 
14
C-caffeine 
without any pre-adaption period, due to the high levels of mineralisation after the first SBR 
cycle. Whereas Figure 5.12(a-b) shows that for 
14
C-propranolol and 
14
C-diclofenac there is 
a lag-phase, prior to mineralisation of these compounds. This could be because salicylic 
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acid and caffeine are widely detected in full STPs at high concentrations; therefore the 
microbial population may have become acclimatised to these APIs, by developing the 
necessary enzymes capable of degrading the compounds. However, propranolol and 
diclofenac are also found ubiquitously in STPs, albeit at lower concentrations. It is likely 
that the chemical structure of salicylic acid and caffeine is more amenable to 
biodegradation than that of propranolol and diclofenac.  
 
A typical HRT employed in a full-scale biological nitrogen removing plant varies from 5 to 
30 h (Metcalf and Eddy, 2003). This would be sufficient time to mineralise both 
14
C-
salicylic acid and 
14
C-caffeine by 50%. However, it would take 218 h for 50% 
mineralisation of 
14
C-propranolol and 2520 h for 50% mineralisation of 
14
C-diclofenac. 
Longer HRTs associated with BNR, allow microorganisms a longer contact time with the 
API, and thus for compounds that are biodegradable, a greater removal efficiency will be 
achieved. However, for APIs such as diclofenac, the HRT would make very little impact 
on its removal. Furthermore, it depends on the type of BNR process in place as to the 
length of the HRT, for example, the modified Ludzack-Ettinger process requires a HRT 
between 5 and 15 h whereas SBRs designed for nitrogen removal have a typical HRT of 
between 20 and 30 h (Metcalf and Eddy, 2003). It is not always practical for the plant to 
extend the HRT, particular if the plant receives a high flow of wastewater.  
 
5.3 API semi-continuous dosing 
The SBR was dosed semi-continuously with the four chosen APIs. Semi-continuous 
loading refers to the fill-and-draw flow a SBR reactor receives. A batch of influent is 
received at the start of the cycle, and this wastewater is subjected to treatment in the 
reactor for the duration of the SBR cycle. Whilst also being simple to operate in the 
laboratory, a semi-continuous regime allows API removal to be monitored under more 
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environmentally realistic operating conditions. The APIs were dosed separately to the 
system, since radioactivity is a non-specific method of analysis. 
 
As discussed in the literature review (Section 1.6), sorption and biodegradation are the two 
main removal mechanisms for APIs. The degree to which APIs are removed by these 
mechanisms, will affect how much of the compound is discharged in the effluent, and 
consequently into the environment. All the potential routes of removal were monitored in 
the laboratory SBR, and accordingly, the contribution of sorption and biodegradation could 
be determined. 
 
5.3.1 Mineralisation 
5.3.1.1 Total mineralisation 
There are clear differences in the amount of 
14
CO2 produced, during SBR dosing with the 
four APIs (Figure 5.13). Dosing with 
14
C-salicylic acid produced the highest level of 
mineralisation, with 25.2% of the total applied radioactivity converted to 
14
CO2 at the end 
of a 5 d dosing period. This is a significant amount of mineralisation, in comparison to that 
produced during the runs with 
14
C-propranolol and 
14
C-diclofenac. Caffeine also exhibited 
a substantial amount of mineralisation during the 5 d test period, with 14.5% of the applied 
radioactivity degraded to 
14
CO2. Caffeine, like salicylic acid, is well removed in full-scale 
STPs (Sui et al., 2010).  
 
Conversely, propranolol and diclofenac are more persistent during the sewage treatment 
process. In this study, the radiolabelled isotopes show that only 3.7% and 0.2% of the total 
radioactivity dosed during the 5 d test period was degraded to 
14
CO2, for 
14
C-propranolol 
and 
14
C-diclofenac, respectively (Figure 5.13).  
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Figure 5.13  The percentage of applied radioactivity mineralised to 
14
CO2 for the four APIs during 
semi-continuous dosing. 
 
5.3.1.2 Mineralisation per cycle 
Figure 5.14(a-d) shows the percentage mineralisation measured at the end of each SBR 
cycle for all four compounds. The percentage mineralisation of 
14
C-salicylic acid and 
14
C-
propranolol increase over time, up to cycles 9 – 10, then 14CO2 production starts to decline. 
The mineralisation of 
14
C-caffeine fluctuates a lot at the beginning of the dosing period, 
but it then starts to increase steadily. Alternatively, 
14
CO2 production for 
14
C-diclofenac 
remains negligible during the entire dosing period (Figure 5.14(d)). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14(a-d)  The mineralisation to 
14
CO2 recovered in each NaOH trap during dosing with (a) 
14
C-salicylic acid, (b) 
14
C-caffeine, (c) 
14
C-propranolol and (d) 
14
C-diclofenac. The data points at 
24, 48, 72 and 96 h include evolved 
14
CO2 collected from two combined SBR cycles represented by 
(). The remaining data points show evolved 14CO2 collected from one trap represented by (). 
(a) (b) 
(c) (d) 
1
4
 
2
 
14 14 14 14 
Chapter 5 Rig monitoring 
150 
 
5.3.2 Pseudo-first order degradation rate constant (Kbiol) 
Kbiol is the first order rate constant for microbial removal of an API per unit of biomass (as 
MLSS) and therefore, assuming first order kinetics, the rate of change in the concentration 
of an API in a reactor, due to biodegradation, can be described by Equation 5.1 (Ternes 
and Joss, 2006): 
dC
dt
   
Ct dt Ct
dt
     biol    SS   S 
(Equation 5.1) 
Where: 
C = total compound concentration (µg l
-1
) 
t = time (d) 
Kbiol = reaction rate constant (l kgMLSS d
-1
) 
XSS = suspended solid concentration in the reactor (kgMLSS l
-1
) 
S = soluble compound concentration (µg l
-1
) 
 
In radiolabelled studies, where the radioactivity as CO2 is trapped in the off-gas, the rate of 
mineralisation (Kbiol(M)) can be directly estimated. Rearranging Equation 5.1, and 
substituting the sum of the daily trapped radioactivity gives Equation 5.2: 
 
 biol (M)   
   
 SS   S
 
(Equation 5.2) 
Where: 
DD = sum of mineralisation as 
14
CO2 (converted to μg l
-1
) 
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Table 5.5  The ultimate biodegradation rates (Kbiol(M)) of the four APIs in the SBR. 
API 
Kbiol(M) (l kgMLSS d
-1
) 
SBR cycles 
1 – 3 4 – 6  7 – 9 10 – 12 
14
C-salicylic acid 563.4 569.2 951.5 672.7 
14
C-caffeine 295.6 49.8 61.0 76.9 
14
C-propranolol 39.6 20.4 26.0 23.2 
14
C-diclofenac 0.5 0.5 0.4 0.6 
 
Table 5.5 shows the Kbiol(M) values of the APIs during different phases of the dosing 
period. The Kbiol(M) summarises the mineralisation data presented in Figures 5.14(a-d). 
14
C-
salicylic acid had the highest Kbiol(M) values, followed by 
14
C-caffeine. The Kbiol(M) values 
of 
14
C-salicylic acid increase until cycles 7 – 9, after which the rate of mineralisation 
decreases. Unlike 
14
C-salicylic, the Kbiol(M) values of 
14
C-caffeine are highest at the start of 
the dosing period (cycles 1 – 3). The 14C-caffeine mineralisation rates from cycle 4 
onwards are an order of magnitude lower than those of 
14
C-salicylic acid. The Kbiol(M) 
values of 
14
C-propranolol are an order of magnitude lower than those of 
14
C-salicylic. 
14
C-
diclofenac has the lowest Kbiol(M) values, these are two orders of magnitude lower than 
14
C-
propranolol, and three orders lower than 
14
C-salicylic acid. 
 
5.3.3 HPLC analysis of SBR effluent 
5.3.3.1 SPE spikes and sample recoveries 
The SBR effluent was extracted during dosing with each 
14
C labelled API, to determine 
how much parent compound was present. Table 5.6 shows the amount of radioactivity 
injected on to the HPLC column.   
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Table 5.6  Radioactivity in extract after solid phase extraction counted by liquid scintillation 
counting. Sub-samples (100 µl) of the extract were injected on to the HPLC column for specific 
analysis. 
Compound Time (d) 
Replicate SPE 
extract 
Radioactivity injected 
in 100 µl (Bq) 
14
C-salicylic acid  
2 
 
1 0.3 
2 0.3 
3 0.3 
14
C-caffeine 
0 
1 1.2 
2 1.2 
3 1.2 
1 
1 2.5 
2 2.5 
3 2.4 
14
C-propranolol 
1 
1 32.5 
2 31.1 
3 31.1 
2 
1 35.8 
2 34.9 
3 34.5 
3 
1 37.6 
2 37.4 
3 34.1 
4 
1 39.6 
2 40.1 
3 40.2 
14
C-diclofenac 
2 
1 104.1 
2 109.8 
3 110.1 
3 
1 112.0 
2 111.2 
3 111.8 
 
The effluent from the 
14
C-salicylic acid run was extracted on day 2. Final effluent collected 
before any radioactivity had been dosed to the SBR was spiked with 
14
C-salicylic acid. A 
recovery of 93.3 ± 3.3% (SD, n = 3) was obtained after filtration and SPE. Figure 5.15 is 
an example of the chromatogram obtained for the spiked samples, and shows a single peak 
for salicylic acid, which corresponds to the UV trace for unlabelled salicylic acid. The 
recovery of three replicate SPE effluent samples, only yielded a 2.1 ± 0.2% (SD, n = 3) 
recovery of radioactivity. Table 5.6 shows only a small amount of radioactivity was 
obtained in the extract, the radioactivity was below the LOD of the radio-detector, 
therefore no radioactive peaks could be obtained. This suggests that the radioactivity 
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detected by LSC in the effluent, was mostly composed of degradation products not retained 
on the SPE cartridges, since the method was optimised for salicylic acid. Therefore, it 
seems that the majority of 
14
C-salicylic acid had been removed during the SBR cycle, 
which is consistent with literature removals from full-scale plants. Therefore, primary as 
well as ultimate degradation to CO2 and H2O are responsible for the removal of salicylic 
acid.  
 
Similar results were obtained after extracting effluent samples during dosing with 
14
C-
caffeine. A recovery of 90.4 ± 0.6% (SD, n = 3) was achieved for spiked effluent samples, 
a chromatograph typical of the spiked samples can be seen in Figure 5.16. However, 
samples collected from the effluent during dosing on days 0 and 1 only achieved a 
recovery of 5.3 ± 0.1% and 2.3 ± 0.0% (SD, n = 3), respectively. Table 5.6 shows the low 
level of radioactivity extracted after SPE. Again, this low SPE efficiency for effluent 
samples, suggests that the radioactivity was mostly composed of degradation products.  
 
 
 
 
 
 
 
 
Figure 5.15  Chromatogram of a final effluent sample, spiked with 
14
C-salicylic acid and extracted 
by solid phase extraction. CPS = counts per second. 
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Figure 5.16  Chromatogram of a final effluent sample, spiked with 
14
C-caffeine and extracted by 
solid phase extraction. CPS = counts per second. 
 
The 
14
C-diclofenac effluent chromatograms, contrast to those of salicylic acid and caffeine. 
Figure 5.17(b) shows that the majority of the radioactivity in the effluent was composed of 
14
C-diclofenac. The efficiency of the extraction technique, calculated from the recovery of 
radioactivity after spiking effluent with 
14
C-diclofenac, was 82.5 ± 2.1% (SD, n = 3) 
(Figure 5.17(a)). The average recovery of the radioactivity in effluent samples from day 2 
and 3 was 81.8 ± 2.6% and 83.1 ± 0.3% (SD, n = 3), respectively. The absence of 
detectable degradation products in the effluent, suggests there was little primary, as well as 
ultimate biodegradation occurring for 
14
C-diclofenac. However, the production of 
degradation products should not be discounted, since they may have been present in the 
radioactivity not recovered by SPE. 
 
The effluent from the SBR was collected on days 1, 2, 3 and 4 for HPLC analysis during 
14
C-propranolol dosing. The extraction recovery for 
14
C-propranolol spiked into effluent 
samples was 51.2 ± 1.1% and 49.7 ± 6.4% (SD, n = 3), the recoveries were carried out on 
different days (Figure 5.18(a)). The extraction recoveries obtained for the effluent 
radioactivity, were 56.0 ± 1.5% on day 1, 52.2 ± 1.0 on day 2, 49.1 ± 2.6 on day 3 and 
49.0 ± 0.4% on day 4 (SD, n = 3). Chromatograms similar to the one in Figure 5.18(b) 
were also obtained on days 1, 2 and 3.  
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A degradation product of 
14
C-propranolol was observed on all the effluent HPLC 
chromatograms, during dosing with this API (reg #2). Nonetheless, the chromatogram 
clearly shows that the majority of radioactivity recovered was 
14
C-propranolol. As a result 
of integrating the area under the peaks (in triplicate for the same chromatograph due to 
variations in background radioactivity) a percentage area of propranolol and the 
degradation product could be obtained. On day 4 an average of the three replicate extracts 
provided a percentage area of 65.3% for the propranolol peak. The degradation product 
had a percentage area of 17.6%. The remaining 17.1% of the radioactivity is spread around 
the baseline, this radioactivity is below the limit of detection for the Mirastar radio-
detector, and so defined peaks cannot be integrated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.17(a-b)  Chromatograms of (a) final effluent sample, spiked with 
14
C-diclofenac and 
extracted by solid phase extraction and (b) SBR effluent (day 2) extracted by solid phase extraction 
during dosing with 14C-diclofenac. CPS = counts per second. 
 
(a) 
(b) 
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It is difficult to extrapolate the composition of the HPLC chromatograms to the actual 
composition of the effluent, since the method recovery was only 50%. Therefore, 50% of 
the radioactivity in the effluent is not accounted for, because it was not retained by the SPE 
cartridges. Therefore, if this remaining 50% was propranolol, then the contribution of the 
degradation product to the effluent composition will be smaller, and likewise if it is a 
degradation product the contribution of propranolol will be less.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18(a-b)  Chromatograms of (a) final effluent sample, spiked with 
14
C-propranolol and 
extracted by solid phase extraction and (b) SBR effluent (day 4) extracted by solid phase extraction 
during dosing with 
14
C-propranolol. CPS = counts per second. 
 
5.3.3.2 14C-propranolol chromatograms 
Due to the aforementioned problems with the low recovery of propranolol, careful 
consideration must be given to the percentage areas of the propranolol and degradation 
effluent peaks in Table 5.7. It is impossible to establish any conclusive trends between the 
two peaks due to these limitations. However, from cycle 4 – 10 there is a decrease in 
(a) 
(b) 
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propranolol area and an increase in the percentage area of the degradation product. These 
changes might be linked, if the degradation of propranolol is directly causing the formation 
of this degradation product (see Figure 5.18(b)). On day 4, the propranolol peak area 
increases, this could be associated to the slight drop in 
14
C-propranolol mineralisation on 
day 4 (See Figure 5.14(c)), which suggests that propranolol degradation might have been 
inhibited. Alternatively, these variations in Table 5.7 might be due to variations in the SPE 
method recoveries.  
 
In Table 5.7 the degradation product peak percentages are in the lower tail, therefore 
approximate normal distribution cannot be assumed like it can for percentages in the 
middle range. The data was checked for normality and it was found to be normally 
distributed according to the Anderson-Darling method (p = 0.82). 
 
Table 5.7  Average area of effluent chromatogram (%) covered by propranolol and degradation 
product peaks.  
SBR cycle 
Propranolol area*  
(%) 
Degradation product area*  
(%) 
4 69.6(± 5.6) 12.4(± 1.9) 
7 63.9(± 7.3) 16.2(± 6.2) 
10 58.2(± 8.0) 18.0(± 1.3) 
13 65.3(± 8.0) 17.6(± 2.2) 
n = 3 
*Peak areas were calculated by fully integrating chromatograms, and subtracting the baseline 
background from the peak areas. The SD (%) is reported in parentheses. 
 
5.3.3.3 Total applied radioactivity in the effluent 
The percentage contribution of 
14
C-propranolol and 
14
C-degradation product peaks, to the 
total applied radioactivity, can be calculated from Equation 5.3: 
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Rt   Pa
 t
 
 (Equation 5.3) 
Where:  
Rt = total radioactivity counted in the effluent by LSC (Bq) 
Pa = peak area on chromatogram (%) 
At = total applied radioactivity (Bq) 
 
It was determined that 6.9% of the total applied radioactivity, was composed of the effluent 
degradation product. In terms of ERA, a degradation product, will itself, only require an 
assessment when it reaches 10% of the total applied radioactivity (Escher and Fenner, 
2011). Propranolol contained in the SBR effluent accounted for 27.6% of the total applied 
radioactivity. This data shows that in the laboratory SBR, the majority of the extracted 
effluent was composed of 
14
C-propranolol.   
 
5.3.3.4 Concentration of effluent 14C-propranolol 
Concentrations of propranolol were calculated in the effluent using Equation 5.4: 
 
 Pa   Rt 
Sact
/  . 5 
 (Equation 5.4) 
Where:  
Sact = specific activity of 
14
C-propranolol (Bq µg
-1
) 
2.25 = volume of effluent discharged after one SBR cycle (l) 
 
Table 5.8 shows the effluent propranolol concentrations for the four daytime cycles on 
days 1 – 4. The effluent concentration of propranolol increases during the dosed cycles. 
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The concentration of propranolol, dosed to the SBR influent at the start of each cycle, was 
calculated from Equation 5.5: 
 
 t / 13
Sact
 /  . 5 
(Equation 5.5) 
Where: 
Dt = total radioactivity dosed (Bq) 
13 = number of dosed SBR cycles  
2.25 = volume of effluent discharged after one SBR cycle (l) 
 
Table 5.8  Influent and effluent concentrations of propranolol in the rig and the calculated removal 
efficiencies based on these concentrations.  
SBR cycle Influent (µg l
-1
) Effluent (µg l
-1
) Removal (%) 
4 8.74 2.40 72.5 
7 8.74 2.62 70.0 
10 8.74 2.63 69.9 
13 8.74 3.25 62.8 
Effluent concentrations of propranolol were calculated from liquid scintillation counts of the 
effluent, corrected for the percentage of propranolol in the effluent using the data from Table 5.7 
 
A nominal concentration of 8.74 µg l
-1
 was dosed at the beginning of each SBR cycle. 
Removal efficiencies were calculated for each daytime cycle. Table 5.8 shows how the 
percentage removal of propranolol decreases from day 1 until the end of the dosing period 
on day 4. However, this decrease over time could be a result of variations in the analytical 
method. The average removal efficiency of propranolol was 68.8 ± 4.2% (SD, n = 4).  
 
5.3.4 Distribution of radioactivity in the solid and aqueous phases 
Figure 5.19(a-d) describes the radioactivity in the reactor solids and aqueous phases during 
the dosing period. At the end of the dosing period, i.e. end of cycle 13, 23.2% of the total 
applied 
14
C-salicylic acid was measured in the solid phase of the reactor, and only 5.8% of 
the radioactivity was measured in the aqueous phase. Figure 5.19(a) shows the relationship 
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between the radioactivity in the reactor solids and the aqueous phase. The percentage of 
applied radioactivity in the aqueous phase remains constant during the dosing period. 
However, the percentage of applied radioactivity in the reactor solids increases almost 
linearly up to SBR cycle 7, after which it appears to level-off. Similarly, the radioactivity 
in the reactor during dosing with 
14
C-propranolol also increases over time (Figure 5.19(b)). 
At the end of the dosing period 33.8% of the total applied 
14
C-propranolol was in the 
solids. The radioactivity is also slowly rising in the aqueous phase and by cycle 13 this is at 
8.5% of the total applied radioactivity. The radioactivity in the solid phase during 
14
C-
propranolol dosing increases at a much faster rate than during dosing with 
14
C-salicylic 
acid.  
 
 
 
 
 
 
 
  
 
 
 
Figure 5.19(a-d)  Partitioning of radioactivity in the reactor during dosing with (a) 
14
C-salicylic 
acid, (b) 
14
C-propranolol, (c) 
14
C-caffeine and (d) 
14
C-diclofenac. 
 
The partitioning behaviour of 
14
C-caffeine and 
14
C-diclofenac in the reactor is different to 
14
C-salicylic acid and 
14
C-propranolol. A smaller fraction of the total applied radioactivity 
was associated to the solids, this was 7.3% and 5.6% for 
14
C-caffeine and 
14
C-diclofenac, 
respectively. This indicates that caffeine and diclofenac have a weaker affinity to the solid 
(a) (b) 
(c) (d) 
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fraction of the sludge, compared to salicylic acid and propranolol. The percentage of total 
applied radioactivity in the aqueous phase, for 
14
C-caffeine and 
14
C-diclofenac is 8.7% and 
19.5%, respectively. Therefore, during 
14
C-diclofenac dosing, there was a higher amount of 
radioactivity in the aqueous phase than the solid phase (Figure 5.19(d)).  
 
5.3.5 API sorption 
5.3.5.1 Kd values 
The Kd can be calculated in a number of different ways. In the literature some authors use 
MLSS (Radjenović et al., 2009; Wick et al., 2009), this was also used by Shimp and 
Larson (1996) to calculated an apparent Kd for their radioactive isotopes. The Kd was an 
apparent value because it was calculated from radioactivity, not parent compound, and 
therefore, the radioactive compounds are not resolved. In some Kd calculations, it is the 
COD that is used instead of MLSS (Maurer et al., 2007). Whilst Ternes et al. (2004a) 
suggested that the wastage rate of solids is the most suitable way of presenting Kd values. 
This is based on the assumption that the sludge remaining in the reactor, should be in 
equilibrium with the compound concentration in solution, therefore, it is only the newly 
generated sludge that is available for sorption. 
 
The apparent Kd, corresponding to the distributions of the APIs between the aqueous phase 
and activated sludge, were calculated by the three different methods identified in the 
literature: MLSS, COD and WAS. 
 
The Kd was calculated from the equation in Shimp and Larson (1996), that used the MLSS 
concentration to calculate the Kd (Equation 5.6): 
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 d        
 s 1000
 M SS
 / l 
(Equation 5.6) 
Where:   
Kd(app) = apparent radiolabelled sorption coefficient (l kg
-1
)  
Ds = mixed liquor adsorbed to solids (Bq ml
-1
)  
Dl = mixed liquor dissolved in aqueous phase (Bq ml
-1
) 
1000 = conversion factor for converting g to kg 
XMLSS = mixed liquor suspended solids (kg l
-1
) 
 
To calculate the Kd based on the sorption to COD, a linear regression was conducted to 
determine the relationship between TSS and COD in the reactor. The data points used in 
this regression were taken from influent and effluent analyses of both COD and TSS. 
There was a strong linear relationship between TSS and COD with a correlation coefficient 
(r) of 0.948 (COD = 23.4 + 1.82(TSS) n = 68 p < 0.001). Equation 5.6 was substituted with 
COD instead of MLSS to give Equation 5.7: 
 
 d        
 s 1000
 C  
 /  l 
(Equation 5.7) 
Where: 
XCOD = chemical oxygen demand (kg l
-1
) 
 
Lastly, the Kd was calculated based on the amount of sludge generated per litre of 
wastewater treated. The Kd in this instance is calculated from Equation 5.8: 
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 d        
 s 1000
   S 
 /  l   
(Equation 5.8) 
Where: 
XWAS = production of WAS per litre of wastewater treated (kgSS·l
-1
) 
 
The Kd values calculated from Equations 5.6 – 5.8 show large disparities depending 
whether MLSS, COD or WAS was used in the calculation. Table 5.9 shows that the 
calculation using the COD produces the lowest Kd values for all the APIs, followed by the 
MLSS, and then the WAS. Therefore, Kd will differ quite considerably depending on the 
Kd method of calculation.  
 
The Kd values for each compound follow the same pattern across the different methods of 
calculation. Therefore, the calculated Kd values in the middle of the range of values, i.e. 
those calculated by Equation 5.6, will be used to describe the trends seen for each of the 
APIs during the SBR cycles. Additionally, MLSS seems to be the most frequently used 
method for Kd calculation in the literature. 
 
Table 5.9 shows that the Kd values for 
14
C-salicylic acid and 
14
C-propranolol are increasing 
over time. The Kd values for propranolol increase steadily, however, for salicylic acid there 
is a sharp rise between cycles 4 and 7. Kd values for 
14
C-caffeine and 
14
C-diclofenac are 
more consistent over the dosing period. The Kd values for 
14
C-caffeine drop between cycle 
1 and 7, but then begin to rise again. This can be seen in Figure 5.19(c) as the radioactivity 
associated to the solids decreases whilst the radioactivity in the aqueous phase increases. 
From cycle 7 onwards the fraction of radioactivity in the aqueous phase remains constant 
and the radioactivity in the solid phase increases. 
14
C-diclofenac has the lowest and most 
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consistent Kd values of all the APIs. This is reflected in Figure 5.19(d) as the radioactivity 
in the solid phase stays constant; however, the overall trend for the radioactivity in the 
aqueous phase is one of gradual increase.  
 
Table 5.9  Apparent Kd constants for the linear sorption isotherm calculated using three different 
equations (Equations 5.6 – 5.8). 
 SBR 
cycle 
14
C-salicylic 
acid 
14
C-caffeine 
14
C-propranolol 
14
C-diclofenac 
Kd(app) 
(l kg
-1
 WAS) 
1 10482 25871 41612 8067 
4 18031 16349 40491 6161 
7 46741 7330 51770 5740 
10 48536 8443 56714 7297 
13 49623 13432 59879 4611 
Kd(app) 
(l kg
-1
 COD) 
1 191 471 758 147 
4 329 298 737 112 
7 852 134 942 104 
10 885 154 1032 133 
13 904 244 1090 84 
Kd(app) 
(l kg
-1
 MLSS) 
1 349 862 1387 269 
4 601 545 1349 205 
7 1558 244 1725 191 
10 1618 281 1890 243 
13 1654 448 1995 154 
 
In order to visualise the relationship between radioactivity in the aqueous and solid phases, 
the aqueous phase radioactivity (Bq l
-1
) was plotted on the x-axis against the radioactivity 
sorbed per unit of adsorbent (Bq kg
-1
) on the y-axis. For all compounds except 
14
C-
propranolol, no relationship between the predictor and response could be observed. Figure 
5.20(a-b) shows this relationship for 
14
C-propranolol; it is an expression of the linear 
sorption isotherm (Kd). A linear and quadratic function was fitted to the data. The linear 
regression produced an r
2
 (adjusted) value of 0.921 and p = 0.006. When the quadratic 
model was fitted, a higher r
2
 (adjusted) value was obtained of 0.988 and p = 0.006 (linear) 
and p = 0.052 (quadratic). The data shows there is a significant quadratic component to 
data i.e. p = 0.052. Although there appears to be a non-linear trend, with only five data 
points it is difficult to establish this conclusively. The lowest data point is an influential 
point for any model fitted to the data.  
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Figure 5.20(a-b)  Linear isotherm of 
14
C-propranolol reactor data, plotted to show the radioactivity 
in the aqueous phase (Bq l
-1
) against the radioactivity in the solid phase (Bq kg
-1
). The data is fitted 
with (a) linear regression model and (b) quadratic regression model. 
 
Kd values are commonly reported in the literature, because they require a simple 
calculation providing a value that can be compared between compounds in the same study, 
and with literature values. However, the Kd may not be the most suitable descriptor for the 
sorption of APIs. Kd values can be applied with confidence only to conditions under which 
the linear adsorption isotherm has been demonstrated to be applicable, since an inherent 
assumption of the Kd is that adsorption is linear (Cantrell et al., 2002). The Kd assumes that 
adsorption is independent of contaminant concentration. Therefore, the Kd should remain 
constant across the concentration interval, however, at high surface loadings adsorption 
typically becomes nonlinear, resulting in error when using the linear adsorption approach 
(Cantrell et al., 2002). Therefore, the Kd may only be suitable at very low contaminant 
concentrations. 
 
Isotherm models are used to describe circumstances where sorption relationships deviate 
from linearity, such as when the contaminant loaded onto the available adsorption sites is 
large enough to impact the linear adsorption model (EPA, 1999a). The two most frequently 
used, are the Freundlich and Langmuir isotherms (Maarof et al., 2004). 
 
 
(a) (b) 
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5.3.5.2 Freundlich and Langmuir isotherms 
The Freundlich and Langmuir isotherms were fitted to the sorption data for each API. Fits 
were made to the data and the associated r
2
 and p values of the models were compared.  
 
The Freundlich isotherm describes the concentration dependent non-linear isothermal 
equilibrium, between a solute on the surface of an adsorbant, and the concentration of the 
solute in the contacting liquid. The constants Kf and 1/n describe the behaviour of the 
particular adsorbate and absorbant at a particular temperature. The 1/n describes the 
adsorption intensity, and the Kf describes the adsorption capacity (Maarof et al., 2004). 
Radiolabelled studies allow apparent constants to be estimated Kf(app) and n(app) in a similar 
manner to Kd(app). By taking the logarithms of the Freundlich equation the following 
linearised equation is obtained (Equation 5.9): 
 
log  
x
m
   log f  
1
n
logCe 
(Equation 5.9) 
Where: 
x/m = adsorption per kg of adsorbent, which is obtained by dividing the amount of 
radioactivity (x) by the weight of the MLSS (m) (Bq kg
-1
) 
Kf = Freundlich capacity factor 
Ce = equilibrium concentration of adsorbate in solution after adsorption (Bq l
-1
) 
1/n = Freundlich intensity parameter 
 
The Freundlich isotherm was applied by plotting the logarithmic values of the radioactivity 
per kg MLSS (m/x) and radioactivity per litre in the aqueous phase (Ce).  
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The Langmuir isotherm is an alternative sorption isotherm, which may have the best fit in 
cases where the sorbent becomes saturated at higher concentrations of API, i.e. sorbents 
with a finite number of sorption sites (Hörsing et al., 2011; Tolls, 2001). The Langmuir 
isotherm was developed by assuming: (1) a fixed number of accessible sites are available 
on the adsorbent surface, all of which have the same energy, and (2) adsorption is 
reversible. Equilibrium is reached when the rate of adsorption onto the surface is the same 
as the rate of desorption from the surface. The Langmuir sorption constants; a and b can be 
determined by linearising the Langmuir equation as follows (Metcalf and Eddy, 2003): 
 
Ce
x m 
   
1
ab
  
1
a
 Ce 
(Equation 5.10) 
Where:  
x/m and Ce are the same parameters as in the Freundlich equation (Equation 5.9) 
a = constant related to the area occupied by a monolayer of sorbate, reflecting the sorption 
capacity (Cs,max) (Bq kg
-1
) 
b = direct measurement for the intensity of the adsorption process (KL) (l Bq
-1
). 
 
The Langmuir isotherm was applied by plotting Ce/(x/m) against Ce. A straight line 
indicates the suitability of the model to describe adsorption. However, since there is a 
dependent variable on both sides of the regression, there will be a relationship between the 
two. 
 
The Freundlich isotherm was applied to each compound, and the relationship between the 
radioactivity in the solid and aqueous phases was plotted. However, no relationship could 
be observed between the predictors (aqueous phase radioactivity) and the response (solid 
phase radioactivity), except for 
14
C-propranolol. Figure 5.21(a-b) shows the plot of the 
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Freundlich adsorption isotherm data, and the linear and quadratic regression fits applied. 
An r
2
 (adjusted) value of 0.97 was obtained from the linear regression equation, and this 
was significant to p = 0.002. A quadratic regression model was fitted to the data and an r
2
 
(adjusted) value of 0.99 and this was significant to p = 0.002 (linear) and p = 0.064 
(quadratic). The quadratic component is borderline significant. Compared to the linear 
isotherm, there is less of a quadratic component to the Freundlich isotherm expression. 
Therefore it can be suggested that the Freundlich adsorption isotherm is most suitable for 
describing the sorption isotherm of propranolol in this system as there was a significant 
linear component. However, although the quadratic regression provided a better fit to the 
Freundlich isotherm, any model fitted to the data is heavily biased by the lowest data point, 
which is very influential.  
 
 
 
 
 
 
 
Figure 5.21 (a-b)  Freundlich isotherm of 
14
C-propranolol data fitted with (a) linear and (b) 
quadratic regression models. 
 
An 1/n value of 1.19 is obtained from the linear regression equation of 
14
C-propranolol, 
this indicates that the data fits an S-type isotherm since a value of 1/n > 1 represents an 
isotherm where the sorption energy increases with increasing surface energy. Hence, as 
propranolol concentrations increase within the system, which has a relatively fixed amount 
of biomass, the total percentage of propranolol removed by sorption increases. Therefore, 
Kd is probably not the most suitable parameter to describe the sorption of 
14
C-propranolol.  
If the linearity parameter (n) = 1, then the Kf is equivalent to the Kd and the partition 
between the two phases is independent of the concentration, and therefore, the relationship 
(a) (b) 
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is linear. A value of 1/n < 1 indicates a L-type (Langmuir) isotherm where the marginal 
sorption energy decreases with increasing surface concentration (Site, 2001). 
 
The sorption data for propranolol was also fitted to the Langmuir isotherm. An r
2
 value of 
0.51 (p = 0.109) was obtained from a linear regression fit to the Langmuir isotherm. A 
quadratic fit was not successful in achieving a suitable fit to the data, with an r
2
 value of 
0.80 and p = 0.109 (linear) and p = 0.147 (quadratic). Therefore a comparison of the 
sorption isotherms indicates the Freundlich isotherm best satisfies the 
14
C-propranolol data. 
Both the Freundlich and Langmuir isotherms showed unsatisfactory fits to the data for 
salicylic acid and caffeine, so no fit could be made. 
 
The Freundlich sorption isotherm gives an r
2
 (adjusted) value of 0.13 (p = 0.297) for 
diclofenac. This shows that the Freundlich isotherm model does not adequately describe 
the adsorption of 
14
C-diclofenac onto activated sludge. The 1/n value is 0.25; suggesting 
the diclofenac dataset is most accurately described with an L-type isotherm. This type of 
isotherm indicates that as diclofenac concentrations increase within a system, with a fixed 
amount of biomass, the total percentage of diclofenac removed by sorption will decrease.  
 
Failure to take this non-linearity into account, as assumed by using the Kd can lead to gross 
overestimates of removal. The Langmuir isotherm offers the best fit to the diclofenac data 
with an r
2
 (adjusted) value of 0.80 (p = 0.026) (Figure 5.22). One of the biggest 
assumptions of the Langmuir isotherm is that the solids have a limited adsorption capacity 
(Limousin et al., 2007), i.e. adsorption is taking place at specific localised sites on a 
homogenous surface (Yanniotis and Blahovec, 2009). Therefore according to this 
assumption, the isotherm reaches a plateau (this is contrary to the Freundlich isotherm). 
The KL and Cs,max are the Langmuir sorption coefficient and the maximum capacity of the 
sorbent, respectively (Tolls, 2001). The positive value for the Langmuir adsorption 
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capacity constant for diclofenac (Cs,max = 1.30 x 10
-3
), indicates the suitability of the 
Langmuir isotherm to explain the adsorption process of diclofenac, since this constant is 
indicative of both the surface binding energy and monolayer coverage (Maarof et al., 
2004). 
 
 
 
 
 
 
 
 
 
Figure 5.22  Langmuir isotherm of 
14
C-diclofenac data. 
 
5.3.6 Mass balance 
SBR cycle 7 was chosen to show the flow of radioactivity during one of the SBR cycles. 
The data used to construct these mass flows can be found in Appendix C. The percentage 
values were normalised to the dose entering the reactor at the start of the cycle. Figures 
5.23 – 5.26 show that the largest percentage of radioactivity in the system, is what remains 
in the reactor and is subject to the next treatment cycle. This percentage is slightly lowered 
for 
14
C-diclofenac because a larger proportion of radioactivity is discharged in the effluent 
(83% of the influent dose). 
14
C-propranolol has the highest percentage of dosed 
radioactivity in the WAS (19.7%) followed by 
14
C-salicylic acid (15.0%). 
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Figure 5.23  Mass flow of 
14
C-salicylic acid during cycle 7 (day 3), expressed as a percentage of 
the dose per cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24  Mass flow of 
14
C-caffeine during cycle 7 (day 3), expressed as a percentage of the 
dose per cycle. 
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Figure 5.25  Mass flow of 
14
C-propranolol during cycle 7 (day 3), expressed as a percentage of the 
dose per cycle. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26  Mass flow of 
14
C-diclofenac during cycle 7 (day 3), expressed as a percentage of the 
dose per cycle. 
 
Table 5.10  Recovery of dosed radioactivity from the sequencing batch reactor for each API. 
APIs Recovery (%) 
14
C-salicylic acid 85.8 
14
C-caffeine 76.0 
14
C-diclofenac 106.8 
14
C-propranolol 85.6 
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The recoveries are reasonable for all compounds (Table 5.10), however, the recovery of 
14
C-caffeine is particularly low compared to the other APIs. It is thought that the lower 
recovery of salicylic acid and caffeine could have resulted from inefficiency in gas 
trapping by NaOH, particularly because the batch operation showed salicylic acid and 
caffeine to be the most biodegradable. This could explain the lower levels of radioactivity 
trapped in the NaOH during 
14
C-caffeine dosing under SBR conditions, compared with 
dosing of 
14
C-salicylic acid, even though during batch conditions more mineralisation 
occurred during dosing with 
14
C-caffeine. Extrapolation of small sub-samples can 
introduce errors giving recoveries > 100%.  
 
5.3.7 Distribution of radioactivity  
The distribution of the radioactivity in each compartment of the SBR is shown in Figure 
5.27. The recovery of radioactivity from each compartment in the rig was calculated as a 
percentage of the total radioactivity applied, the compartments monitored were: gas traps, 
effluent, WAS and reactor contents (aqueous and solids).  
 
 
 
 
 
 
 
 
 
 
Figure 5.27  Distribution of radioactivity in each compartment of the SBR for 14C-propranolol, 
14
C-diclofenac, 
14
C-salicylic acid and 
14
C-caffeine. 
 
14 14 14 14 
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The largest fraction of the recovered radioactivity for all APIs was in the effluent. Specific 
analysis has shown that the composition of this radioactivity varies depending on the API. 
Caffeine and salicylic acid are well removed, and there is little parent compound remaining 
in the effluent, conversely, the effluent discharged from the SBR during dosing with 
14
C-
diclofenac was mostly composed of the parent compound. However, significantly, the 
detection of radioactivity in the effluent, during dosing with salicylic acid and caffeine, 
indicates that degradation products are released, even though the parent compound is 
largely removed.  
 
The total radioactivity in the WAS is composed of a similar percentage of the total applied 
radioactivity for all four APIs, making up 5.1%, 3.2%, 4.7% and 7.0% for 
14
C-salicylic 
acid, 
14
C-caffeine, 
14
C-diclofenac and 
14
C-propranolol, respectively. However, this is 
because only a small fraction of the total volume of MLSS is wasted each day. However, 
when looking at the percentage of total applied radioactivity associated to the solids, in the 
reactor (excluding the WAS), for 
14
C-salicylic acid and 
14
C-propranolol this figure is 
19.4% and 28.3%, respectively. This suggests that association to the solids can be an 
important removal mechanism for some APIs, keeping them retained in the reactor/tank, 
but because only a small fraction of the total volume of reactor solids is wasted this 
removal pathway is small compared to biodegradation.   
 
5.3.8 Discussion  
It is widely known from literature studies that salicylic acid is well removed from STPs, 
with removal efficiencies as high as 99% in full-scale plants (Gros et al., 2010; Martín et 
al., 2012). Likewise, caffeine is reported to exhibit high removals in STPs, which is mainly 
a result of biological transformation (Xue et al., 2010). The high mineralisation, 
particularly for 
14
C-salicylic acid during the dosing period, is in agreement with these 
removals from full-scale STPs. Furthermore SPE of the effluent, discharged from the SBR, 
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shows that the majority of 
14
C-salicylic acid and 
14
C-caffeine are degraded. This is because 
the SPE method recovered < 3% (
14
C-salicylic acid) and < 6% (
14
C-caffeine) of 
radioactivity for each API, whereas the recovery of radioactivity from the spiked samples 
was > 80%. Salicylic acid and caffeine were selected for inclusion in this study due to their 
highly biodegradable behaviour during biological sewage treatment. This was important so 
they could act as positive controls, to verify the viability of the microbial biomass in the 
reactor. This high level of mineralisation, particularly for a continuous system, shows there 
was an active community of degrading microorganisms in the reactor. 
 
The literature suggests that both propranolol and diclofenac have low and varied removal 
efficiencies from STPs. Verlicchi et al. (2012) reviewed the removal efficiencies of a range 
of APIs, from different therapeutic classes, reported in literature CAS systems. Removal 
efficiencies between 3% and 65% were reported for diclofenac, for propranolol this was 
between 0% and 59%. The review also showed that there has been more work conducted 
on the removal of diclofenac, than propranolol during sewage treatment. These ranges 
reported in Verlicchi et al. (2012) are similar for both APIs, and a recent study by Martín 
et al. (2012) adds further support to this assumption. They found that diclofenac, had an 
average removal efficiency of 14% from four STPs, whilst the removal of propranolol was 
only marginally better at < 16%. During dosing under semi-continuous conditions, this 
work has shown that propranolol is slightly more responsive to biodegradation than 
diclofenac, due to the slightly higher mineralisation, and the presence of a degradation 
product on the radio-chromatogram.    
 
Wick et al. (2009) investigated the biological transformation of beta-blockers and psycho-
active drugs during wastewater treatment. Batch experiments were conducted with diluted 
activated sludge collected from the same STP in March and October 2007. Propranolol had 
a transformation rate of 0.36 ± 0.07 and 0.46 ± 0.03 l gSS
-1
 d
-1 
(± SD), respectively. The 
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authors classified all the beta-blockers as having a significant dissipation over the sampling 
period of 48 h. Similarly, Maurer et al. (2007) estimated a pseudo-first order rate constant 
of 0.39 l gCOD
-1
 d
-1
 for propranolol in activated sludge. The authors concluded that 
propranolol was biologically degradable in an STP; however, the rates are low and hence 
degradation is usually incomplete. 
 
Joss et al. (2006) investigated the removal of diclofenac in batch systems. They chose an 
environmentally relevant concentration of 3 µg l
-1
, and each batch system contained 
0.5 gSS l
-1
 of activated sludge from either a CAS plant or MBR. The calculated Kbiol for 
diclofenac in both types of sludge was 0.1 l gSS d
-1
. Therefore, diclofenac was classified as 
exhibiting no substantial removal by degradation. Suarez et al. (2010) investigated the 
potential of nitrifying and denitrifying conditions for the removal of 16 PPCPs. The PPCPs 
were dosed to two continuous stirred-tank reactors; one reactor was operated under anoxic 
denitrifying conditions and the other under aerobic nitrifying conditions. The reactors were 
operated for more than 1.5 y. The results showed diclofenac had a removal of 22 ± 28% 
(SD) in the aerobic reactor and a reduced removal of 2 ± 5% (SD) in the anoxic reactor. 
Therefore, even after a prolonged period of time, when microbial acclimation is expected 
to have taken place, the removal of diclofenac still remains low. In a similar study by 
Suarez et al. (2005) five APIs were dosed into a laboratory activated sludge reactor, 
consisting of an aerobic and anoxic zone, for nitrification and denitrification, respectively. 
Again, diclofenac was only removed to a small extent, with the observed removal rates 
always < 20%. Based on both studies just discussed (Suarez et al., 2005; 2010) it can be 
concluded that the removal of diclofenac is low and occurs mainly under aerobic 
conditions.   
 
The differences in the sorption of APIs in this study are reflected in the Kd values in Table 
5.9. Table 5.9 also shows the disparity in Kd values, resulting from the use of different 
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sorption equations. Although Kd is not always the best descriptor of sorption behaviour, it 
is commonly reported in the literature, therefore, using it here allows comparisons to be 
made. However, caution must be exercised when comparing Kd values, with those from 
other studies, since they are specific to the systems they were measured in.  
 
Table 5.11  Log of Kd values in Table 5.9 (using the MLSS calculation in Equation 5.6). 
API 
Log Kd(app)  
SBR cycle 
1 4 7 10 13 
14
C-salicylic acid 2.54 2.78 3.19 3.21 3.22 
14
C-caffeine 2.94 2.74 2.39 2.45 2.65 
14
C-propranolol 3.14 3.13 3.24 3.28 3.30 
14
C-diclofenac 2.43 2.31 2.28 2.39 2.19 
 
Based on the concentration of the APIs in the solid and aqueous fractions of the 
wastewater, Martín et al. (2012) calculated the log Kd values in secondary sludge for two 
of the APIs in this study (salicylic acid and propranolol), whilst analytical methods were 
developed for diclofenac and caffeine, these compounds were not detected in the 
secondary sludge. The Kd was expressed in l kg
-1
. The calculated log Kd values for 
salicylic acid were between 1.47 and 2.89, whilst in this study they ranged from 2.54 to 
3.22 (Table 5.11), the ranges overlap, but the values from the SBR are higher. Similarly, 
higher log Kd values were obtained for 
14
C-propranolol in the SBR (2.54 and 3.22), 
whereas in the study by Martín et al. (2012), the values were from 1.40 to 2.19. Radjenović 
et al. (2009) calculated the Kd for propranolol in secondary activated sludge, and obtained 
values of 366 ± 138 l kg
-1 
(RSD, n = 7). The average of five Kd values measured in this 
study was 1670 ± 292 l kg
-1 
(SD), a value 4 – 5 times higher than that reported by 
Radjenović et al. (2009). Astrazeneca conducted an ERA on propranolol, and based on 
laboratory findings concluded that propranolol has a Kd value of 480 l kg
-1
 (AstraZeneca, 
2012). This value is similar to the one reported by Radjenović et al. (2009).  
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Diclofenac has very low reported Kd values of 16 ± 3.1 l kg
-1
 (SD, n = 4-6) and 
118 ± 95 l kg
-1
 (RSD, n = 7) (Radjenović et al., 2009; Ternes et al., 2004a). The values in 
this study range from 154 – 269 l kg-1. Again, the values are slightly higher than those 
reported in the literature, however, they are similar in magnitude. Caffeine is reported to 
have Kd values less than 300 l kg
-1
 (Ying et al., 2009). The Kd values in this study, range 
from 244 – 862 l kg-1, with two Kd values below 300 l kg
-1
, however, the first Kd value 
calculated in cycle 1 is 862 l kg
-1
. The limited sorption of caffeine and diclofenac to the 
SBR sludge, can be explained by their physical and chemical properties. Caffeine is a 
hydrophilic compound with a low log Kow value and diclofenac is an acidic pharmaceutical 
with a pKa of 4.1. Acidic compounds occur as ions at neutral pH and have little tendency 
of adsorption to the sludge (Ying et al., 2009).  
 
The reasons for higher values in this study, could be because Kd values are specific to the 
system where they were generated, so the activated sludge in the SBR will have different 
properties to sludge in CAS systems for example. It might be that sludge from SBRs has a 
higher adsorption capacity. Furthermore, apparent Kd values are calculated in this study, 
this is based on radioactivity and not parent compound. This is not likely to be a problem 
for diclofenac, since it seems to be fairly recalcitrant in the SBR. However, for caffeine 
and salicylic acid, the majority of radioactivity in the effluent, appears to be composed of 
degradation products, this could explain the lack of fit to any sorption isotherms. In this 
study, Kd values were calculated based on the entire fraction of radioactivity associated to 
the solids, because samples were combusted. Therefore, distinctions have not been made 
between extractable radioactivity and radioactivity taken up into the biomass constituents. 
Studies that determine Kd values using unlabelled chemicals, extract the target compound 
using solvents. Therefore, Kd values will differ depending on how the solid fraction of the 
chemical was analysed.  
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Ternes et al. (2004a) concluded, that for APIs with a sorption coefficient of ≤ 500 l kg-1, 
sorption onto secondary sludge is negligible, and any removal can be attributed to 
biodegradation. Based on the Kd values calculated in this study, removal of 
14
C-diclofenac 
by sorption would be negligible, and three out of five Kd values for 
14
C-caffeine would also 
result in negligible sorption. However, all of the Kd values for 
14
C-propranolol are 
> 500 l kg
-1
 and so are four out of five Kd values for salicylic acid. So for 
14
C-salicylic acid 
and 
14
C-propranolol, removal of radioactivity from the SBR by sorption seems to present a 
significant removal pathway. The Kd values are in agreement with the fits to the sorption 
isotherms for propranolol and diclofenac. The Freundlich isotherm shows that as the 
concentration of propranolol increases, so does the adsorption, this is reflected in the high 
Kd values for propranolol. Whereas, the Langmuir isotherm shows the opposite, i.e. as the 
concentration of diclofenac increases, the amount of sorption decreases. The low Kd values 
for diclofenac support this.  
 
By reviewing the literature, the fate of each API observed in the laboratory SBR, seems in 
agreement with what has been found in full-scale STPs. Therefore, a hierarchy of 
environmental contamination can be established, by reviewing the mass flows of 
radioactivity shown in Figures 5.23 – 5.26. Figure 5.23 shows salicylic acid has the lowest 
applied dose (29.6%) in the SBR effluent. Based on specific analysis of this effluent, the 
majority of the parent compound was degraded. Figures 5.24 and 5.25 show caffeine and 
propranolol have a similar percentage of the applied dose leaving the reactor in the 
effluent. However, analysis of the effluent during 
14
C-caffeine dosing, showed that this 
compound was not detectable, whereas radio-HPLC analysis of the effluent during 
14
C-
propranolol dosing, showed 64% of the effluent was composed of 
14
C-propranolol. 
Furthermore, 9.7% of the 
14
C-caffeine dose was mineralised, whereas for 
14
C-propranolol 
this was 4.6%. Therefore, caffeine would be less likely than 
14
C-propranolol to remain in 
the effluent after sewage treatment. This data shows that diclofenac was least affected by 
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the sewage treatment process, and therefore, is most likely to enter the aquatic environment 
after sewage treatment. This is because 83% of the applied dose, in cycle 7, was discharged 
in the effluent (Figure 5.26). Radio-HPLC analysis of the effluent revealed the majority of 
this was 
14
C-diclofenac.  
 
This hierarchy considers only the API most likely to enter the aquatic environment. This is 
not necessary the order that would cause the greatest environmental impact, as there are 
other factors to consider, such as the ecotoxicology of the parent and degradation products, 
the reduction of concentration by photo-degradation and the initial concentration of the 
API in the influent.  
 
Although diclofenac is most likely to contaminate the aquatic environment, propranolol 
and salicylic acid would be most likely to enter the terrestrial environment. This is because 
a substantial amount of radioactivity 33.8% and 23.2%, for 
14
C-propranolol and 
14
C-
salicylic acid, respectively, was associated to the solids in the reactor. However, desorption 
may occur, or there may be further transformation of the APIs during sludge treatment, i.e. 
anaerobic digestion. Yamamoto et al. (2007) calculated a mass balance of the parent 
compound in their batch systems, and identified that 37% of propranolol was sorbed to the 
activated sludge solids, and 23% was unknown in its composition, this could be 
degradation products or non-extractable propranolol in the solids. 
 
If radiolabelled compounds are labelled in a sufficient number of locations, then the fate of 
the parent compound and all the degradation products associated to it can be monitored. 
The profile of these radiolabelled compounds in the aqueous and solid phases can be 
elucidated, if methods are applied to resolve this radioactivity. Therefore, this method 
allows the monitoring of all compounds associated to the parent, without focusing solely 
on the fate of the parent, like many full-scale monitoring campaigns and laboratory studies 
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using unlabelled compounds. Radiochemistry techniques, in conjunction with parent 
compound analysis by LC-MS/MS, are powerful tools for elucidating the fate of APIs in 
the laboratory. 
 
To conclude, an SBR rig was developed that successfully removed a number of wastewater 
variables commonly measured in full-scale plants. Once rig efficiency had been 
established, the four APIs were dosed, individually, under batch conditions in order to 
generate half-lives, which are often reported in the literature. A second dosing regime was 
employed to generate realistic fate data on the APIs under semi-continuous conditions. 
Data was collected on the mechanisms of API removal during BNR treatment. The next 
phase of the research was to validate the behaviour of the APIs observed in the rig; by 
monitoring operational STPs. Furthermore, the full-scale monitoring work was an 
opportunity to investigate in more detail, the behaviour of the APIs observed in the rig. 
 
Chapter 6 Site monitoring of operational sewage treatment plants 
182 
 
Chapter 6 Site monitoring of operational sewage treatment plants 
 
Samples were taken from three full-scale STPs; one in Ireland, and two in the UK. 
Samples were collected from various locations along the aqueous flow, to determine plant 
removal efficiencies, and the influence of activated sludge treatment on the removal of four 
APIs investigated in the SBR. In addition to these APIs, an additional compound, 
carbamazepine, was included on the monitoring list. The cost of buying this compound as a 
14
C labelled isotope was high, but it is a key contaminant of STPs and the environment, 
and is widely reported for its recalcitrance during sewage treatment. Therefore, it was 
included in the monitoring study to expand the knowledge of its removal from different 
STP configurations. 
 
This work was necessary to gain some current monitoring data on the behaviour of APIs in 
full-scale systems. This data was used, to demonstrate how similar the laboratory SBR 
was, to operational plants, for the removal of salicylic acid, caffeine, propranolol, 
diclofenac and wastewater variables. This was achieved by quantifying a number of 
wastewater parameters, and the target APIs in each sample. This will also help to identify 
any relationships between the APIs and plant operating conditions. 
 
6.1  Sampling sites  
The five target APIs were analysed in three full-scale STPs, employing different plant 
configurations, in order to meet nutrient discharge consents. A sophisticated nitrogen 
removing STP at Havant (Southern Water Plc, Budds Farm Wastewater Treatment works, 
Southmoor Lane, Havant, Hampshire, PO9 1JW, grid reference: SU 707 055) was selected 
as one of the sampling sites. This site was chosen due to its large PE (400,000) and 
because it is designed to remove NH4
+
-N and NO3
-
-N by the operation of aerobic and 
anoxic zones (Figure 6.1(b)). Budds Farm STP receives two wastewater flows, one from 
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Portsmouth and the other from Havant. These are combined prior to the activated sludge 
tanks.  
 
The second sampling site at Totnes STP (South West Water Ltd, Totnes Wastewater 
Treatment Facility, Newton Road, Totnes, Devon, TQ9 6LS, Grid reference: SX 807 610) 
was chosen because it was used to source the wastewater for the laboratory rig. Therefore, 
determining concentrations of the APIs at this plant, provided an indication of the 
concentrations the microorganisms had already been pre-exposed to, prior to dosing with 
the radiolabelled APIs. This could affect the degradability of the APIs in the laboratory rig, 
if the microorganisms had already been pre-exposed to high concentrations. Figure 6.1(a) 
shows the layout of the plant and the location of the sampling points. 
 
The third sampling location was at Ringsend, Dublin (Celtic Anglian Water Ltd, Ringsend 
Wastewater Treatment Works, Pigeon House Road, Dublin 4, Grid reference: 
SG 207 906). This plant was selected because it employed SBRs to treat the wastewater, 
providing the opportunity to compare the efficiency of a laboratory and field SBR for 
removing APIs. The wastewater entering Ringsend STP is treated by 24 SBRs during 
secondary treatment. The SBRs at Ringsend are one of the largest in the world, so they 
provided an ideal opportunity to discover more about how these systems remove APIs. 
Figure 6.1(c) shows the plan of this STP and the sampling locations. 
 
Sampling from three full-scale STPs will allow comparisons of API removal in different 
full-scale BNR processes. Table 6.1 summaries the operating conditions at each full-scale 
plant. 
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Table 6.1  A description of the operating conditions at each site. 
Plant operating 
condition 
Budds Farm Ringsend  Totnes  
Primary treatment Primary lamellas Primary lamellas Primary 
sedimentation tank 
Secondary 
treatment 
Nitrifying-denitrifying 
four-stage Bardenpho 
process with MeOH 
dosing. 
Nitrifying SBRs Carbonaceous 
removal followed by a 
NAS tank. 
Tertiary treatment None UV UV 
PE 400,000 1,700,000 9,598 
Average flow  
(m
3
 d
-1
) 
Portsmouth: 60,563 
Havant: 37,772 
450,000 5,616 
HRT (h)  
24 
1.5 carbonaceous 
removal; 1 nitrifying 
tank 
SRT (d) 
12 
Summer: 10-15 
Winter: 15-20 
0.63 for carbonaceous 
removal; 4.4 
nitrifying tank 
 
6.1.1 Sample collection and storage 
Triplicate grab samples were collected from Budds Farm and Ringsend STPs, whilst only 
single samples were collected from Totnes STP. Samples were collected sequentially 
throughout the STP, and once one set of samples had been collected, another two sets were 
collected in the same locations. Grab sampling was chosen as it is a quick and easy 
sampling technique to provide quantitative data on API concentrations (Zhang et al., 
2009). Furthermore grab samples can be extracted immediately, reducing any degradation 
of the target analytes (Baker and Kasprzyk-Hordern, 2013). 
 
Samples were collected using a stainless steel bucket, rinsed in succession before use, with 
warm water, MeOH and ROW. Samples were collected from a number of locations at each 
STP. At Totnes STP, samples were taken from the raw influent, settled primary effluent, 
the UNOX carbonaceous tank, the nitrifying tank, the final clarifiers and the final effluent 
(after UV). At Budds Farm STP, the samples were taken from the raw influent, settled 
primary effluent, the primary anoxic zone, the re-aeration zone and the final effluent after 
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secondary treatment. At Ringsend STP samples were taken from the raw influent, primary 
effluent, SBR tanks, and the final effluent (Figure 6.2(a-c)). 
 
In particular, this study wanted to assess how efficient the activated sludge treatment was 
for removing the APIs. The sampling regime was selected, since it allowed each treatment 
step to be assessed for its contribution, to the removal of the target analytes. Many studies 
in the literature have used this approach when sampling STPs (Gabet-Giraud et al., 2010; 
Wick et al., 2009; Xue et al., 2010). 
 
The wastewater samples were collected in amber glass containers, which had been 
thoroughly cleaned with detergent and water, acetone and finally ROW. The glass bottles 
were filled to the top ensuring there was no empty headspace. Samples were stored at 4ºC 
until analysis within 24 h. A number of wastewater parameters were also measured at each 
sampling point, these included BOD5, TSS, COD, NH4
+
-N, NO3
-
-N, PO4
3-
-P, total-N and 
total-P. 
 
Figure 6.1(a-c) show aerial photographs of the STPs sampled in the study. Budds Farm 
STP takes up the largest area, even though Ringsend STP treats the largest population 
equivalent.  
 
 
 
 
 
 
Figure 6.1(a-c)  Aerial photographs of the three sampling sites (a) Totnes STP (b) Budds Farm 
STP and (c) Ringsend STP. 
  
(b) (a) (c) 
Chapter 6 Site monitoring of operational sewage treatment plants 
186 
 
Primary 
lamellas
Primary 
anoxic 
zone
Aeration 
lanes
Secondary 
anoxic zone
Re-
aeration 
zone
Final 
clarification 
tank
Mixed liquor recycle
RAS
Discharged 
to Solent
*
* *
*Preliminary 
treatment
*
Primary 
lamellas
Intermediate 
pumping
Double Decker SBR
UV 
disinfection
Discharged 
to Dublin 
Bay
Preliminary 
treatment
* * * *
* *
*
24 SBRs
Screens & 
grit 
removal
Separator (2 
off)
Rotary 
screen
Aeration 
tank
Secondary 
clarification 
tank (2 off)
Nitrifying 
tank
Final 
clarification 
tank (3 off)
UV 
disinfection
Discharged 
to river
RAS RAS
WAS WAS
*
*
* *
* *
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2(a-c)  Schematics of the sampling sites (a) Totnes STP, (b) Budds Farm STP and (c) Ringsend STP. The asterisks indicate the sampling 
locations. 
(a) 
(c) 
(b) 
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6.1.2 Wastewater parameter analysis 
The BOD5, COD and TSS methods were the same as those described in section 4.5. For 
the analysis of NH4
+
-N, NO3
-
-N, PO4
3-
-P, total-N and total-P, Palintests were employed. 
Table 6.2 outlines the Palintest product codes for each wastewater parameter measured. 
The tubes were read on a photometer 5000. 
 
Table 6.2  The Palintests used for the analysis of wastewater constituents in samples collected from 
operational plants. 
Wastewater constituent Palintest product code 
NH4
+
-N AP152 
NO3
-
-N AP163 
PO4
3-
-P AP177 
total-N PL408 and PL404 
total-P PL416 
  
6.2 Wastewater parameters  
A number of wastewater parameters were measured on each grab sample collected from 
the three STPs (Table 6.3). The data in Table 6.3 includes one data point from Totnes STP, 
and an average of three samples collected at different times, on the same day, from Budds 
Farm and Ringsend STPs. Each plant had a different configuration, and was operated to 
remove certain consent parameters. Both Totnes and Ringsend STPs are NAS plants, 
designed to remove BOD and NH4
+
-N from the wastewater stream. Whereas, Budds Farm 
STP is capable of nitrifying, as well as denitrifying wastewater, due to the presence of 
anoxic zones. 
 
Budds Farm STP received the highest carbon load to the plant, with COD and BOD 
concentrations of 810 and 422 mg l
-1
, respectively, in the influent, whilst Totnes STP had 
the lowest at 243 and 108 mg l
-1
 COD and BOD, respectively. Figure 6.3 shows Totnes 
and Ringsend STPs have similar COD concentrations in the effluent, whilst the 
concentration at Budds Farm STP is lower. All three plants were efficient at removing 
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suspended solids (> 90%). Ringsend and Budds Farm STPs also removed COD by > 90%, 
whilst Totnes STP had a slightly lower removal at 82%. Likewise, BOD removal for 
Ringsend and Budds Farm STPs was high at 96% and 99%, respectively, whilst removal at 
Totnes STP was 69%.   
 
The highest suspended solids concentration was measured in the BOD activated sludge 
tank at Totnes STP (3,763 mg l
-1
), but there was a drop in suspended solids concentration 
in the subsequent NAS tank (2,725 mg l
-1
). Budds Farm STP had the second highest 
activated sludge suspended solid concentrations, at 3,600 and 3,447 mg l
-1
 in the anoxic 
and aerobic tanks, respectively. The activated sludge tanks at Ringsend STP contained the 
lowest suspended solids concentrations of 2,134 and 2,321 mg l
-1
, in the first and second 
aeration tanks, respectively.   
 
Concentrations of NH4
+
-N were highest in the influent of Ringsend STP (50 mg l
-1
), 
followed by Budds Farm STP (40 mg l
-1
) and then Totnes STP (10 mg l
-1
). Concentrations 
of NO3
-
-N were low in the influent at all three STPs. Figures 6.4(a-c) show the NH4
+
-N 
and NO3
-
-N profiles at the three STPs. The data for Totnes STP in Figure 6.4(a), shows a 
reduced NH4
+
-N concentration in the BOD activated sludge tank, however, the subsequent 
NAS tank reduces concentrations further, to almost zero. Although influent NH4
+
-N 
concentrations are the lowest for Totnes STP, the effluent NO3
-
-N concentrations are 
higher than Ringsend and Budds Farm STPs (Figure 6.3). Removal of NH4
+
-N at Totnes 
STP was high (100%), however, because there was not a process to remove NO3
-
-N, the 
total-N removal was low (10%).   
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Table 6.3  Wastewater variables measured on each grab sample in the three operational sewage treatment plants. 
 Concentration (mg l
-1
) 
Location COD BOD TSS NH4
+
-N NO3
-
-N PO4
3-
-P Total-N Total-P pH Temp (ºC) 
Totnes STP    
Raw influent 243 108 134 9.8 0.9 1.4 20 2.8 6.97 16.1 
Primary effluent 185 107 111 8.7 17 1.5 37 2.9 7.37 15.9 
BOD activated sludge 4,491 No data 3,763 1.4 2.9 2.2 244 66 6.48 16.6 
Nitrifying activated sludge 3,197 385 2,725 0.02 16 1.8 206 35 6.66 17.2 
Secondary effluent 23 10 10 < 0.02 16 1.9 19 2.1 6.63 17.1 
Final effluent 43 33 9 < 0.02 16 1.9 18 2.1 6.87 16.8 
Removal efficiency (%) 82 69 93 100 No removal No removal 10 26 - - 
Budds Farm STP    
Raw influent 810 (281) 422 (123) 269 (48) 40 (9.1) 0.05 (0.03) 12 (2.7) 49 (5.3) 10 (1.7) 7.69 (0.18) 21.1 
Primary effluent 646 (13.5) 291 (11.9) 153 (2.3) 49 (2.1) 0.02 (0.01) 22 (1.8) 51 (1.7) 12 (0.8) 7.27 (0.05) 20.5 
Anoxic activated sludge 4,108 (265) 1,176 (79) 3,600 (157) 33 (13) 0.24 (0.05) 42 (2.0) 277 (42) 135 (36) 7.03 (0.02) 22.1 
Aerobic activated sludge 3,638 (68) 996 (143) 3,447 (179) 4.3 (2.1) 8.6 (1.6) 21 (2.3) 220 (26.5) 100 (13.3) 6.90 (0.02) 20.7 
Final effluent 9.0 (7.9) 4.6 (0.82) 19 (6.5) 1.5 (0.21) 5.9 (1.2) 13 (0.23) 5.1 (0.17) 4.8 (0.00) 7.33 (0.05)            - 
Removal efficiency (%) 99 (1.2) 99 (0.62) 93 (3.6) 96 (1.0) No removal No removal 89 (1.3) 53 (8.8) - - 
Ringsend STP    
Raw influent 478 (208) 290 (38) 358 (122) 50 (29) 0.29 (0.19) 2.7 (3.0) 84 (34.6) 5.0 (0.66) 6.95 16.0 
Primary effluent 383 (58) 240 (29) 163 (52) 42 (3.1) 0.5 (0.12) 8.7 (1.5) 65 (8.5) 6.3 (1.2) 7.07 16.0 
Aerate 1 3,273 (289) 1,499 (214) 2,134 (221) 4.4 (2.1) 1.1 (0.44) 20 (2.3) 230 (18.2) 53 (3.9) 6.35 17.0 
Aerate 2 3,335 (196) 1,572 (54) 2,321 (258) 5.1 (3.8) 0.7 (0.26) 20 (3.8) 265 (3.7) 48 (2.9) 6.35 17.0 
Settle 45 (6.5) 14 (1.7) 19 (5.8) 0.3 (0.36) 3.0 (1.3) 9.1 (0.29) 11 (1.3) 3.4 (0.02) 6.26 17.0 
Decant  43 (0.67) 11 (2.1) 16 (1.6) 0.5 (0.38) 3.1 (0.70) 9.7 (2.0) 11 (0.90) 3.2 (0.11) 6.27 17.0 
Final effluent 40 (1.5) 11 (0.70) 19 (7.4) 1.0 (0.56) 2.7 (0.26) 9.2 (0.74) 10 (1.1) 3.3 (0.22) 6.70 18.0 
Removal efficiency (%) 91 (3.3) 96 (0.30) 95 (0.33) 98 (0.13) No removal No removal 87 (3.2) 32 (14) - - 
Totnes STP (n = 1) and Budds Farm STP and Ringsend STP (n = 3). SD (%) values are in parentheses.
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The data from Budds Farm STP in Figure 6.4(b) shows reduced NH4
+
-N concentrations in 
the primary anoxic tank. Concentrations of NH4
+
-N are then removed significantly during 
aerobic conditions, to 1.5 mg l
-1
 in the final effluent. Concentrations of NO3
-
-N remain low 
in the anoxic tank, which is expected as denitrification should be occurring. The NO3
-
-N 
concentrations increase slightly during aerobic conditions due to the nitrification of 
NH4
+
-N. Concentrations of NO3
-
-N are higher in the effluent, than the influent; therefore, 
no removal can be reported. Removal of NH4
+
-N is high at 96%, and so is total-N, with a 
removal efficiency of 89%.  
 
Concentrations of NH4
+
-N at Ringsend STP are significantly reduced in the first SBR 
aeration tank, with little further removal seen in the second aeration tank; however, 
lowered concentrations are then detected in the settling tank. An increase in NO3
-
-N 
concentration is seen only in the settling tank. Again, NH4
+
-N removal is high at 98%, but 
interestingly so is total-N removal (87%).  
 
None of the STPs showed high removals of PO4
3-
-P; however, total-P was removed to 
some extent in all plants. Budds Farm STP saw the highest removal of total-P, but this was 
still only 53%. The majority of this, is likely to have come from the removal of total-P, 
with the suspended solids.  
 
 
 
 
 
 
 
 
Figure 6.3  The effluent concentrations for a range of commonly measured wastewater variables at 
three STPs, including five consent parameters (COD, BOD, TSS, total-N and total-P).  
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Figure 6.4(a-c)  The NH4
+
-N and NO3
-
-N concentrations at each sampling location in three STPs: 
(a) Totnes STP, (b) Budds Farm STP and (c) Ringsend STP. RI = raw influent, PE = primary 
effluent, BAS = BOD activated sludge, NAS = nitrifying activated sludge, ANX = anoxic activated 
sludge, AER = aerobic activated sludge, A1 = first aeration tank, A2 = second aeration tank, S = 
settle, D = decant, SE = secondary effluent and FE = final effluent. 
 
6.3 API concentrations  
Table 6.4 contains the data from the full-scale monitoring campaign. Values for Totnes 
STP represent an individual sample, whilst for Budds Farm and Ringsend STPs the 
reported values are an average of three samples. Concentrations < MQL have been 
identified as such, with the MQL in parentheses, these concentrations could not be reliably 
reported. 
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Figure 6.5(a-c) graphically displays the API concentrations in Table 6.4. In all three STPs, 
salicylic acid and caffeine had the highest influent concentrations, with caffeine detected at 
higher concentrations than salicylic acid. The influent concentrations of caffeine at Budds 
Farm STP, reached a maximum of 166 µg l
-1
. Concentrations of both APIs were 
significantly reduced during the activated sludge treatment in all three plants.  
 
Influent concentrations of propranolol, carbamazepine and diclofenac are 1 – 3 orders of 
magnitude smaller than caffeine in all three STPs. Diclofenac was present at higher 
concentrations than propranolol and carbamazepine at Budds Farm and Ringsend STPs, 
however, at Totnes STP it was < MQL in every sample collected.  
 
Totnes STP has two activated sludge tanks in series; the secondary effluent from the first 
BOD activated sludge tank is fed to the NAS tank to remove NH4
+
-N. Figure 6.5(a) shows 
that the concentrations of salicylic acid and caffeine are greatly reduced in the BOD 
removing tank, to 1.1 and 0.24 µg l
-1
, respectively, however the nitrifying tank further 
reduces their concentrations to 0.39 µg l
-1
 and < MQL for salicylic acid and caffeine, 
respectively. Concentrations of carbamazepine are 1 – 2 orders of magnitude lower than 
those of salicylic acid and caffeine in the influent at Totnes STP, whilst concentrations of 
diclofenac and propranolol were < MQL. Concentrations of propranolol increased in the 
two activated sludge tanks, from < MQL to 0.35 µg l
-1
 and then 0.52 µg l
-1
, in the BOD 
and NAS tanks, respectively. In this monitoring campaign, Totnes STP has the lowest 
concentrations of the target APIs.  
 
Figure 6.5(b) shows the results for Budds Farm STP. APIs are detected at the highest 
influent concentrations in this STP, with the exception of diclofenac. Interestingly, 
salicylic acid and caffeine concentrations are lowered in the anoxic tank, but this is not 
observed for the other APIs. Even with this apparent removal in the anoxic tank, 
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concentrations of salicylic acid and caffeine are still high at 13 and 20 µg l
-1
, respectively. 
The concentrations of these APIs are reduced further in one or more of the subsequent 
tanks: aeration lanes, secondary anoxic and the final re-aeration tanks, so that 
concentrations in the re-aeration tank are 0.80 µg l
-1 
and < MQL for salicylic acid and 
caffeine, respectively. This reduction in API concentration in the activated sludge tanks is 
not seen for propranolol, carbamazepine and diclofenac.  
 
The API concentrations at Ringsend STP are inbetween those of the other two STPs, with 
the exception of diclofenac, which was detected at the highest average influent 
concentration. There seems to be more variability in raw influent and primary effluent 
concentrations for salicylic acid and caffeine at Ringsend STP, than at the other two plants; 
however, this variability is considerably less in the SBR tanks and final effluent. 
Concentrations of both salicylic acid and caffeine are reduced significantly in the first 
aeration tank. However, the concentrations of propranolol, carbamazepine and diclofenac 
do not exhibit this same decline in the aeration tank, and concentrations of carbamazepine 
remain constant throughout the STP. The concentration of all APIs increases from the first 
aeration tank to the second aeration tank, before decreasing again in the settling tank.  
 
Figure 6.6 compares the API effluent concentrations at each STP. With the exception of 
caffeine and diclofenac at Totnes STP, and caffeine at Budds Farm STP, all the APIs were 
detected > MQLs in the effluent samples. Totnes STP had the lowest API concentrations in 
the effluent, but this plant also had the lowest concentrations in the influent. Additionally, 
the majority of the wastewater received at Totnes STP is domestic in origin, so there is 
very little contribution from industry or hospitals, like there is at Budds Farm and 
Ringsend STPs. Budds Farm and Ringsend STPs have similar concentrations in the 
effluent, with diclofenac present at the highest concentrations in both. Carbamazepine is 
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present at the second highest concentration at Budds Farm STP (1.1 µg l
-1
); whilst at 
Ringsend STP caffeine has the second highest concentration in the effluent (1.2 µg l
-1
).  
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5(a-c)  The average concentration of APIs measured in different compartments of three 
STPs: (a) Totnes STP, (b) Budds Farm STP and (c) Ringsend STP. Totnes STP (n = 1), Budds 
Farm and Ringsend STPs (n = 3). Error bars represent the SD. In cases where all replicate 
concentrations were < MQL, the MQL concentration has been represented and ‘< M  ’ is written 
above the bar. Where there was only one or two replicate concentrations < MQL these were not 
included in the average and SD determinations. 
 
(a) 
(b) 
(c) 
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Table 6.4  Concentration and removal efficiencies of APIs in wastewater samples, collected from three sewage treatment plants. 
 APIs concentrations (µg l
-1
) 
Location Salicylic acid Caffeine Propranolol Carbamazepine Diclofenac 
Totnes STP  
Raw influent 6.3 20 < MQL (0.06) 0.37 < MQL (0.11) 
Primary effluent 4.8 14 < MQL (0.06) 0.24 < MQL (0.11) 
BOD activated sludge 1.1 0.24 0.35 0.42 < MQL (0.42) 
Nitrifying activated sludge 0.39 < MQL (0.13) 0.52 0.41 < MQL (0.42) 
Secondary effluent 0.21 < MQL (0.12) 0.10 0.26 < MQL (0.07) 
Final effluent 0.21 < MQL (0.12) 0.08 0.21 < MQL (0.07) 
Removal efficiency (%) 97 > 99 -35 44 - 
Budds Farm STP  
Raw influent 57 (1.6) 162 (4.1) 0.42 (0.13) 1.1 (0.19) 3.9 (1.9) 
Primary effluent 75 (8.0)  158 (18) 0.45 (0.04) 1.4 (0.12) < MQL (0.12) 
Anoxic activated sludge 13 (1.9) 20 (2.8) 1.0 (0.06) 1.4 (0.04) 5.9 
Aerobic activated sludge 0.80 (0.04) < MQL (0.13) 0.91 (0.04) 1.3 (0.04) 4.3 (0.99) 
Final effluent 0.36 (0.03)  < MQL (0.12) 0.31 (0.02) 1.1 (0.05) 4.1 (0.57) 
Removal efficiency (%) 99 (0.0) > 99 (0.0) 21 (25) -6 (24) -39 (109) 
Ringsend STP  
Raw influent 43 (16) 81 (35) 0.19 (0.08) 0.48 (0.16) 5.1 (3.1) 
Primary effluent 36 (4.6)  92 (7.8) 0.22 (0.13) 0.44 (0.10) 6.0 (2.4) 
Aerate 1 0.81 (0.25) 0.97 (1.07) 0.23 (0.02) 0.55 (0.02) 4.1 (0.27) 
Aerate 2 1.0 (0.14) 1.27 (1.41) 0.42 (0.05) 0.66 (0.02) 5.8 (1.4) 
Settle 0.41 (0.04) < MQL (0.12) 0.17 (0.01) 0.54 (0.02) 3.5 (0.69) 
Decant  0.48 (0.10) 0.30 (0.02) 0.19 (0.02) 0.61 (0.11) 3.5 (0.52) 
Final effluent 0.60 (0.08) 1.2 (0.47) 0.18 (0.00) 0.52 (0.02) 3.2 (0.50) 
Removal efficiency (%) 98 (0.7) 98 (0.9) -7 (47) -19 (45) -1 (99) 
Totnes STP (n = 1), Budds Farm and Ringsend STPs (n = 3). The SD is reported in parentheses.  
Diclofenac was detected at Totnes STP, but it was < MQL. The MQL concentrations are reported in parentheses where samples are < MQL. 
Removal efficiencies were calculated using the influent and effluent concentrations reported in the above table. Removal efficiencies were calculated for 
caffeine using the MQL concentration for secondary effluent reported in Table 3.12.  
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Figure 6.6  API concentrations in the final effluent of the three STPs. Totnes STP (n = 1), Budds 
Farm and Ringsend STPs (n = 3). Error bars represent the SD. In cases where all replicate 
concentrations were < MQL, the MQL concentration has been presented and ‘< M  ’ is written 
above the bar. 
 
The General Linear Model was used, to determine if there were any trends in API 
concentration between sampling locations within the STPs, and between the STPs. The 
sampling locations across the three plants were grouped together into five categories: raw 
influent, primary effluent, activated sludge, secondary effluent and final effluent. The data 
was tested for normality using the Anderson-Darling method, this highlighted deviations 
from normality due to a number of zero values. It was not possible to find a transformation 
for the data. However, the residual versus fitted value plots, indicated that the residuals 
were evenly distributed.  
 
Table 6.5 shows the test results from the General Linear Model (shaded in grey) and the 
Tukey’s pairwise comparison test, used to determine which means were significantly 
different. The results show that a significant difference (p < 0.001) was identified for each 
API (response) when it was compared to STP (model factor). The Tukey’s post-hoc test 
revealed a significant difference between Budds Farm STP, and Ringsend and Totnes STPs 
for all APIs. The concentration of salicylic acid, caffeine and propranolol, were not 
significantly different between Ringsend and Totnes STPs, however, for diclofenac and 
carbamazepine there was a significant difference in concentration between these two STPs. 
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Table 6.5  The results from the General Linear Model (shaded grey areas) and Tukey’s post-hoc test. 
*Denotes a significant difference (p < 0.05). PE = primary effluent, AS = activated sludge, SE = secondary effluent and FE = final effluent.
 Salicylic acid Caffeine Propranolol Diclofenac Carbamazepine 
STP p < 0.001* p < 0.001* p < 0.001* p < 0.001* p < 0.001* 
Tukey test results 
Budds Farm Ringsend p = 0.0067* 
Totnes p = 0.0003* 
Ringsend p = 0.0026* 
Totnes p = 0.0002* 
Ringsend p = 0.0001* 
Totnes p = 0.0001* 
Ringsend p = 0.0195* 
Totnes p = 0.0163* 
 
Ringsend p < 0.0001* 
Totnes p < 0.0001* 
Ringsend Totnes p = 0.1042 Totnes p = 0.1570 Totnes p = 0.5345 Totnes p < 0.0001* Totnes p = 0.0003* 
Location p < 0.001* p < 0.001* p < 0.001* p = 0.444 p = 0.002* 
Tukey test results 
RI PE p = 0.9314 
AS p < 0.0001* 
SE p < 0.0001* 
FE p < 0.0001* 
PE p = 0.9998 
AS p < 0.0001* 
SE p < 0.0001* 
FE p < 0.0001* 
PE p = 0.9941 
AS p = 0.0001* 
SE p = 0.8632 
FE p = 0.9740 
PE p = 0.6974 
AS p = 0.9903 
SE p = 0.4750 
FE p = 0.9410 
PE p = 0.4888 
AS p = 0.0041* 
SE p = 0.2620 
FE p = 0.9997 
PE AS p < 0.0001* 
SE p < 0.0001* 
FE p < 0.0001*  
AS p < 0.0001* 
SE p < 0.0001* 
FE p < 0.0001* 
AS p < 0.0001* 
SE p = 0.9757 
FE p = 0.8513 
AS p = 0.8392 
SE p = 0.9937 
FE p = 0.9830 
AS p = 0.3003 
SE p = 0.9879 
FE p = 0.6064 
AS SE p = 0.9868 
FE p = 0.9799 
SE p = 0.9308 
FE p = 0.9970 
SE p = 0.0004* 
FE p = 0.0001* 
SE p = 0.6023 
FE p = 0.9936 
SE p = 0.6852 
FE p = 0.0074* 
SE FE p = 0.8931 FE p = 0.8627 FE p = 0.5349 FE p = 0.8850 FE p = 0.3502 
Chapter 6 Site monitoring of operational sewage treatment plants 
198 
 
The model factor: location, presents a more complex analysis because there were more 
levels involved. A significant difference was identified for salicylic acid (p < 0.001), 
caffeine (p < 0.001), propranolol (p < 0.001) and carbamazepine (p = 0.002) between the 
sampling locations in the STPs. However, diclofenac concentrations were not significantly 
different between sampling locations (p   0.444).   Tukey’s test identified a significant 
different between the raw influent and primary effluent, and the other three sample 
locations (activated sludge, secondary effluent and final effluent), for salicylic acid and 
caffeine. The propranolol data shows the location, significantly different to the others, is 
the activated sludge. For carbamazepine, concentrations in the activated sludge samples, 
were significantly different, to concentrations in raw influent and final effluent samples.  
 
6.4 API removal efficiencies 
Figure 6.7 shows the removal efficiencies of each API at the three STPs. The removal 
efficiencies were calculated from Equation 6.1: 
 
Removal efficiency        
Cin  Cout
Cin
   100 
(Equation 6.1) 
Where: 
Cin = Concentration in the influent (µg l
-1
) 
Cout = Concentration in the effluent (µg l
-1
) 
100 = Conversion to percent 
 
The removal efficiencies of salicylic acid and caffeine, are consistently high across the 
three STPs, with efficiencies near to 100% at each plant (Figure 6.7).  
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The removal of propranolol, carbamazepine and diclofenac, differs to that of salicylic acid 
and caffeine, because the former three APIs have much lower and more variable removal 
efficiencies across the plants, and also within the same plant. Occasionally, moderate 
individual removal efficiencies were obtained for these compounds, such as 65% for 
diclofenac at one sampling point in Ringsend STP, however, at another sampling point on 
the same day, a removal of -114% was calculated. A removal of 44% was established for 
carbamazepine from Totnes STP; however, this is based on the collection of one sample 
only. A removal efficiency of 36% and 47% was obtained for propranolol, from Ringsend 
and Budds Farm STPs, respectively, at one sampling point. 
 
It is difficult to establish which STP is more efficient at removing these three recalcitrant 
APIs, as removals were so variable. Negative removal efficiencies were also frequently 
obtained. Diclofenac in particular, had low removal efficiencies at Budds Farm and 
Ringsend STPs, with more than twice the influent concentration detected in the effluent. 
Propranolol had an average removal of 21% from Budds Farm STP; this was the highest 
average removal of the aforementioned three recalcitrant APIs. It seems that propranolol 
and carbamazepine were slightly better removed from Budds Farm STP, whilst diclofenac 
had a better average removal from Ringsend STP.  
 
A one-way ANOVA was used to determine if there were any significant differences in the 
removal of the recalcitrant APIs (propranolol, diclofenac and carbamazepine) between 
Budds Farm and Ringsend STPs (Totnes STP was excluded because only one sampling 
point was measured). The percentage removal data for each API was tested for normality 
using the Anderson-Darling test, and each API was found to be normally distributed 
(propranolol, p = 0.498; carbamazepine, p = 0.229, diclofenac, p = 0.082). There were no 
significant differences in API removal, between Budds Farm and Ringsend STPs, and 
therefore the null hypothesis is accepted.  
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Figure 6.7  Removal efficiencies (%) of APIs in the three STPs: Totnes, Budds Farm and 
Ringsend. Removal efficiencies could not be calculated for propranolol and diclofenac, since 
concentrations were < MQLs in either the influent or effluent sample, or both. 
 
 
 
 
 
 
 
 
 
Figure 6.8  Fitted line plot of percentage removal data for propranolol and carbamazepine from 
Budds Farm and Ringsend STPs. 
 
Figure 6.8 idicates a positive correlation was identified between the removal efficiencies of 
propranolol and carbamazepine, the linear regression fit resulted in an r
2
 (adjusted) value 
of 0.87 and a p value of 0.004. This indicated there was a significant relationship between 
the two variables.  
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6.5 API concentrations and wastewater parameters 
A Pearson’s correlation matrix was conducted in Minitab 16, to determine if there were 
any correlations between the APIs, and the measured wastewater parameters. Significant 
positive associations were identified between the APIs themselves. These associations 
were between caffeine and salicylic acid (r = 0.98, p = < 0.001) shown in Figure 6.9(a) and 
carbamazepine and propranolol (r = 0.81, p = < 0.001) in Figure 6.9(b). The r values imply 
there is a strong positive relationship between the variables, which is significant at the 
p = 0.001 level.  
 
A number of significant positive associations were identified between the APIs and the 
wastewater parameters. A positive relationship was observed between salicylic acid and 
NH4
+
-N (r = 0.85, p = < 0.001), and also between caffeine and NH4
+
-N 
(r = 0.74, p = < 0.001). Furthermore, positive associations were observed between salicylic 
acid (r = 0.60, p = 0.001) and caffeine (r = 0.66, p = < 0.001), and the pH of the 
wastewater.  
 
The pH is significantly different between sampling locations (F(4, 23) = 8.47, MSE = 0.08, 
p = < 0.001).   Tukey’s post-hoc test reveals that the activated sludge and secondary 
effluent samples had a significantly different pH to the other sampling locations. Similarly 
a significant difference was identified between NH4
+
-N and sampling location.   Tukey’s 
post-hoc test showed that the activated sludge, secondary effluent and final effluent 
samples had significantly different concentrations of NH4
+
-N, compared to the raw influent 
and primary effluent. Salicylic acid and caffeine had significant positive associations with 
NH4
+
-N and pH, indicating their removal is influenced by the activated sludge process.  
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Figure 6.9(a-b)  Scatter plot of (a) salicylic acid and caffeine and (b) propranolol and 
carbamazepine concentrations in all wastewater samples at the three STPs. 
 
Wastewater parameters exhibit a great deal of shared variation, as they can respond to 
treatment processes in a similar way. Propranolol had a significant positive association 
with organic matter (i.e. COD, BOD and TSS). This is shown by plotting propranolol 
against TSS (Figure 6.10); however, this positive relationship is dependent on the highest 
cluster of values. 
 
 
 
 
 
 
 
 
 
Figure 6.10  Scatter plot of propranolol and TSS concentration (r = 0.76, p < 0.001). 
 
Both carbamazepine and propranolol have a positive linear association with temperature, 
with carbamazepine having the strongest association (r = 0.94, p = < 0.001). A one-way 
ANOVA was calculated to test for an effect of sample location on temperature. There were 
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no significant differences in temperature, between sampling location. Temperature does 
have a significant association with PO4
3-
-P (r = 0.74, p = 0.001) and a slightly weaker 
association to total-P (r = 0.61, p = 0.009). These positive associations to PO4
3-
-P and 
total-P are also present for propranolol and carbamazepine. 
 
In order to investigate the relationships between the variables in more detail, principal 
component analysis (PCA) was carried out. It is a type of multivariate analysis and was 
used on this dataset in order to form a small number of linearly uncorrelated variables 
(principal components, PC) from a set of 13 variables (Table 6.6). The aim of PCA is to 
explain the maximum amount of variance with the fewest number of PC.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11(a-b)  Outputs from the principal component analysis, (a) scree plot of eigenvalues 
(measure of the amount of variation explained by each principal component) versus the 
components or variables, and (b) loading plot showing the correlation structure (loadings) of the 
first and second principal components, the cosine of the angle between the lines is the correlation 
between the variables. Thus if two lines are at 90 degrees, this indicates zero correlation, lines that 
are close together are closely correlated and ones in opposite directions are negatively correlated. 
Nate = nitrate, TSS = total suspended solids, COD = chemical oxygen demand, BOD = 
biochemical oxygen demand, orthoP = orthophosphate, Amm = ammonium, PRO = propranolol, 
CBZ = carbamazepine, SA = salicylic acid, CAF = caffeine, DCF = diclofenac. 
 
(a) 
(b) 
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Figure 6.11(a) is a scree plot from the PCA output; it shows that PC1 explains the majority 
of the variance in the data i.e. has the largest eigenvalue. The subsequent PCs explain less 
and less of the variance, and have smaller eigenvalues. The total variance explained by the 
first four PCs is 90.7%. The ‘elbow’, or the point at which the curve bends, is considered 
to indicate the maximum number of PCs to extract, in this case it is indicated at component 
7.  
 
Figure 6.11(b) is a plot of the loadings, or correlations between the PC scores and the 
original variables. The cosine of the angle between the lines is the correlation between the 
variables. Those lines at 90 degrees have zero correlation, lines closer together are more 
closely correlated, and lines in opposite directions are negatively correlated. The variables: 
TSS, COD, total-N, total-P and BOD are all very closely correlated, and this would be 
expected as these variables are all interdependent, since they measure similar wastewater 
properties. Propranolol and PO4
3-
-P are very closely correlated to each other, and to 
carbamazepine. NO3
-
-N is negatively correlated to NH4
+
-N, this would be expected 
because as NH4
+
-N concentrations decrease, NO3
-
-N concentrations increase, this can be 
seen in Figure 6.4(a-c). Caffeine and salicylic acid are very closely correlated to each 
other, and both are correlated to NH4
+
-N. Diclofenac accounts for little of the variation in 
PC1 and PC2 so its loading was not significant. 
 
A correlation matrix containing the variables and scores of the PCs was carried out; the PC 
loadings can be found in Table 6.6. The loadings shown are those which exhibited a 
significant correlation (p < 0.05), and the r values are reported. 
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Table 6.6  The principal component loadings of the principal component scores and the original 
variables. The data shown here are the correlation coefficients (r) from a Pearson’s correlation 
matrix and were reported if they were significant to p < 0.05. 
 
 
PC loadings measure the importance of each variable in accounting for the variability in 
the PC. The high correlation between PC1 and the variables: propranolol, carbamazepine, 
COD, BOD, TSS, PO4
3-
-P, total-N and total-P, indicates that these variables are associated 
with the direction of the maximum amount of variation in the dataset, and vary together. 
This also indicates that the removal mechanisms for propranolol and to a lesser extent 
carbamazepine, are influenced by the solids and organic loading.  
 
There is a strong negative correlation between the variables: salicylic acid, caffeine and 
NH4
+
-N and PC2, which indicates that these variables are responsible for the next largest 
variation in the data, perpendicular to PC1. NO3
-
-N is positively correlated to PC2, 
suggesting when salicylic acid, caffeine and NH4
+
-N are high, NO3
-
-N is low. This 
suggests that the removal of salicylic acid and caffeine is affected by the processes 
governing nitrification.  
 
Diclofenac is negatively correlated to PC3. This PC only accounts for 10.8% of the 
variance; therefore diclofenac has little contribution to the overall variation in the dataset. 
However, the negative correlation is high (-0.82), so there is a possibility that some other 
Variable PC1 PC2 PC3 PC4 
Salicylic acid - -0.943 - - 
Caffeine - -0.924 - - 
Propranolol 0.854 - 0.314 - 
Carbamazepine 0.570 -0.505 0.405 0.454 
Diclofenac - - -0.817 0.399 
COD 0.947 - - - 
BOD 0.856 - -0.326 - 
TSS 0.946 - - - 
NH4
+
-N - -0.886 - - 
NO3
-
-N - 0.620 0.521 - 
PO4
3-
-P 0.819 - - - 
Total-N 0.924 - - - 
Total-P 0.954 - - - 
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mechanism, not measured by the variables in this dataset, is affecting the removal of 
diclofenac. Carbamazepine shows correlation to all four principal components, which 
suggests its removal, could be influenced by a number of different processes. 
 
Figure 6.12(a-b) shows 3D scatter plots of the first three PCs, plotted against each other, 
and categorised by STP (Figure 6.12(a)) and sampling location (Figure 6.12(b)). 
  
 
 
 
 
 
Figure 6.12(a-b)  3D scatter plots of the principal component scores categorised by (a) sewage 
treatment plant and (b) sample location. A full separation was not observed in the 2D scatter plots 
(Figure 6.13(a-c)), but is obtained here in the 3D plots. The associated variance of the plotted 
principal components is PC1: 47.1%, PC2: 25.9% and PC3: 10.8% (total variance: 83.8%). 
 
Figure 6.12(a) shows there is a clear separation of the STPs, in the score plot of the first 
three PCs. The 2D scatter plots (Figure 6.13(a-c)) show the relationship between each pair 
of the first three PCs, grouped on the basis of STP. These plots show that Figure 6.13(c) 
separates out the PC scores the most. Therefore by using the PC loadings identified in 
Table 6.6, it can be determined that the variables causing these differences at each STP, are 
low salicylic acid, caffeine, carbamazepine, NH4
+
-N and high NO3
-
-N, which are explained 
by PC2, and low diclofenac, BOD and high NO3
-
-N, propranolol and carbamazepine 
explained by PC3. PC2 accounts for 25.9% of the variation and PC3 accounts for 10.8% 
therefore only 36.7% of the variation in the dataset is covered by these two PCs.   
 
 
 
(b) (a) 
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Figure 6.13(a-c)  2D scatter plots of the principal component scores categorised by sewage 
treatment plant (a) PC1 versus PC2 (b) PC1 versus PC3 and (c) PC2 versus PC3. 
 
In Figure 6.13(a) there appears to be two separate groups of points, each containing data 
from all the STPs. The reasons for this could be because the largest amount of variation in 
PC1 and PC2 is not caused by STP, but by variation in the sampling locations. PC1 
accounts for the variance in propranolol, carbamazepine, BOD, TSS, COD, PO4
3-
-P, 
total-N and total-P, and they all vary together, whereas PC2 accounts for the negative 
correlation of caffeine, salicylic acid, carbamazepine, NH4
+
-N and the positive correlation 
of NO3
-
-N. Therefore these variables might not be different between the STPs, but between 
the sampling locations. To summarise, PC1 accounts for the variance in terms of the TSS, 
organic fractions and sorption, and PC2 accounts for the biological removal of NH4
+
-N. 
PC1 and PC2 account for the most variance in the dataset (total of 73%).   
 
 
 
 
 
(a) (b) 
(c) 
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Figure 6.14(a-c)  2D scatter plots of the principal component scores categorised by sampling 
location (a) PC1 versus PC2 (b) PC1 versus PC3 and (c) PC2 versus PC3. 
 
The 3D plot in Figure 6.12(b) indicates there is a separation of the variables measured at 
the five different sampling locations, with the activated sludge variables being the most 
distinct from the others. Clustering can be observed for the raw influent and primary 
effluent samples, and secondary effluent and final effluent samples. Figure 6.14(a-c) looks 
at the 2D relationships between the first three PCs. Figure 6.14(a) confirms that the pattern 
of separation observed in Figure 6.13(a) was a result of the differences between sampling 
location. Figure 6.14(b-c) do not separate out the sampling locations as clearly as Figure 
6.14(a). It can be concluded that PC1 and PC2 best separate the sampling locations, and 
this is a result of increases in COD, BOD, TSS, PO4
3-
-P, total-N, total-P, propranolol and 
carbamazepine, when PC1 increases, against increases of salicylic acid, caffeine, 
carbamazepine and NH4
+
-N when PC2 decreases, and increases in NO3
-
-N when PC2 
increases. 
 
 
 
(a) 
(c) 
(b) 
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6.6 Discussion  
6.6.1 Wastewater parameter in full-scale STPs 
In all three STPs: COD, BOD and TSS were well removed. Budds Farm STP received an 
influent containing the highest COD concentration, but produced an effluent with the 
lowest concentration of COD. A high influent COD concentration is necessary at Budds 
Farm STP, in order to provide enough carbon for the denitrifying bacteria, particularly in 
the secondary anoxic tanks. The presence of anoxic tanks is likely to improve the removal 
of COD, due to the utilisation of the carbon source for denitrification.  
 
Removal efficiencies of NH4
+
-N are considerable at all three plants, indicating the presence 
of an active population of nitrifying bacteria. At Budds Farm STP, there is a decrease in 
NH4
+
-N concentrations in the anoxic zone. This concentration change is most likely due to 
a dilution effect by recycles entering the tank from aerobic zones, rather than NH4
+
-N 
removal occurring under anoxic conditions.  
 
Removal of NH4
+
-N at Totnes STP occurs in both the BOD and nitrifying tanks. The 
nitrifying tank is required as a polishing step to remove NH4
+
-N levels to zero. Totnes STP 
is the most efficient plant at eliminating NH4
+
-N, since Budds Farm and Ringsend STPs 
still contained > 1 mg l
-1
 in the effluent.  
 
The majority of NH4
+
-N removal occurs in the first aerobic tank at Ringsend STP; this is 
the fill tank and has the longest HRT, which might be the reason for this significant 
decrease. Interestingly, little NH4
+
-N removal is seen in the second aeration tank, but 
concentrations decrease in the settling tank. Concentrations of NO3
-
-N remain low 
throughout Ringsend STP, with only a slight increase from influent concentrations in the 
settling tank. This suggests that some denitrification must be occurring in the aeration 
tanks, particularly in the first aeration tank where most of the NH4
+
-N removal appears to 
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be occurring. This is likely, since the fresh wastewater added to the first aeration tank 
(aeration 1) will change the DO profile, due to organic matter consumption, which depletes 
the DO presenting favourable conditions for NO3
-
-N removal, i.e. a carbon source and a 
low DO environment. A high total-N removal at Ringsend STP, further suggests that this 
plant can remove NO3
-
-N. Furthermore, Totnes STP, which is designed for nitrification 
only, does not share this high total-N removal with Ringsend STP, suggesting the SBR 
design might be beneficial for removing total-N.  
 
Budds Farm STP achieved the lowest effluent total-N concentrations, which meets the 
UWWTD consent of 10 mg l
-1
 for STPs with PE > 100,000 (Table 5.2 in Section 5.1.1). 
The average effluent total-N concentration at Ringsend STP would meet the UWWTD 
consent; however, Totnes STP would not, with an average concentration of 18 mg l
-1
. 
However, it is unlikely that Totnes STP has a consent level on total-N since it is 
discharging to a river, and so total-P, not total-N is the limiting nutrient causing eutrophic 
waters.  
 
There is a low removal of PO4
3-
-P in all three STPs. This is expected since the plants do 
not have an anaerobic zone, which is essential for the ‘release’ stage of bio-P removal. 
 
6.6.2 API concentrations in full-scale STPs 
Concentrations of the target APIs detected in the STPs monitored in this study, are at 
similar concentrations to those reported in the literature. Concentrations detected at 
Ringsend STP can be directly compared with concentrations reported in a previous 
monitoring campaign conducted at the site, by Lacey et al. (2012), which investigated, 
among other APIs, the five APIs in this study. Lacey et al. (2012) collected 24 h composite 
samples from the influent and effluent, every month for one year, between 2007 and 2008. 
Carbamazepine was the most frequently detected API, with concentrations ranging from 
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0.06 (LOQ) – 0.55 µg l-1 in the influent, and LOQ – 6.50 µg l-1 in the effluent. An increase 
in effluent carbamazepine concentrations was observed in > 90% of samples (in the three 
monitored STPs). In this work carbamazepine was detected at an average concentration of 
0.48 µg l
-1
 in the influent, and 0.52 µg l
-1
 in the effluent. These concentrations are within a 
similar range to those detected by Lacey et al. (2012), but at slightly lower effluent 
concentrations.  
 
Diclofenac conversely was only detected in one of the samples collected from Ringsend 
STP by Lacey et al. (2012), and this was at a concentration of 0.5 µg l
-1 
in the effluent. 
Concentrations of diclofenac in this study are higher in the influent and effluent, which 
could be due to changes in prescribing practices between 2012 (when this data was 
collected), and 2007/8 (when the data in Lacey et al. (2012) was collected). Similarly, 
propranolol was detected only once during the sampling campaign conducted by Lacey et 
al. (2012), and this was at a concentration of 0.31 µg l
-1 
in the effluent. Propranolol is at 
similar concentrations in this study; however, it was detected in every sample collected. 
 
Lacey et al. (2012) detected caffeine and salicylic acid at the highest concentrations, with 
maximum levels in the influent of 13.9 and 12.8 µg l
-1
, respectively. Salicylic acid was not 
detected in the effluent, but caffeine was detected at a maximum of 22.7 µg l
-1
, which was 
greater than the influent concentration. Salicylic acid and caffeine were found at lower 
influent concentrations in the work by Lacey et al. (2012), than in this study. However, 
caffeine has much lower concentrations in the effluent of this study, than the sampling 
campaign conducted between 2007 and 2008.  
  
Totnes STP has the lowest API concentrations in the influent and effluent. This could be 
because the influent to the plant was diluted, as a result of a rain event during sampling. 
This is likely, since Totnes STP receives influent from a combined sewerage system. 
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Diclofenac is present < MQL in all the samples at Totnes STP, which might be a result of 
the rain event, or because the population served by Totnes STP, consume this API in lower 
quantities. However, there is no data to support this assertion. Budds Farm STP has 
exceptionally high influent concentrations of caffeine, with a maximum detected 
concentration of 166 µg l
-1
. However, higher concentrations have been reported in the 
literature by Gómez et al. (2007), when they detected influent concentrations up to 
192 µg l
-1 
in an STP in Spain. 
 
6.6.3 Removal efficiencies in full-scale STPs 
Removal efficiencies of the APIs in this study are similar to those reported in the literature. 
Studies by Martínez Bueno et al. (2012) and Gómez et al. (2007) reported removal 
efficiencies of caffeine > 80%. A recent study by Hedgespeth et al. (2012) reported a 
removal efficiency > 95% for caffeine, in every month that two STPs were sampled. The 
removal of caffeine in this study was > 97% in all instances. The literature, reports high 
removal rates of salicylic acid from STPs, which supports the > 97% removal achieved in 
this study. Martín et al. (2012) obtained an average removal efficiency of 99% for salicylic 
acid, which the authors propose is a result of biodegradation. Salicylic acid has a low pKa, 
therefore it would be expected mainly in the aqueous phase.  
 
Unlike salicylic acid and caffeine, propranolol has a range of removals from the STPs in 
this study; the average efficiencies are -7% (Ringsend STP) and 21% (Budds Farm STP). 
In the literature, propranolol has a varied removal, which is mostly low. Scheurer et al. 
(2010) reported no overall removal of propranolol from four STPs, three of which 
employed secondary treatment and one utilised tertiary treatment. In another study by 
Rosal et al. (2010) removal of propranolol from an A2O nitrifying-denitrifying and bio-P 
plant was only 1%. Removal < 20% was observed by Wick et al. (2009) from a nitrifying 
and denitrifying plant. Slightly higher removal efficiencies of 59% were obtained by 
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Radjenović et al. (2009) from a nitrifying-denitrifying plant, with even higher removals of 
66% and 78% from two MBRs in the same study.  
 
In this study, a number of negative removal efficiencies for propranolol were obtained. 
This could be due to sampling errors, since one of the limitations of grab sampling is that 
samples only yield an instantaneous measurement of API concentration, which suffers 
from the uncertainty of short-term and long-term concentration variations occurring in 
STPs (Zhang et al., 2009). This can also explain the range of removal efficiencies obtained 
at the same plant. However, the grab sampling technique has little effect on the removal of 
salicylic acid and caffeine, because they are readily removed during wastewater treatment.  
 
The negative removal efficiencies observed, could be a result of deconjugation of 
metabolite conjugates in the activated sludge tank, thus releasing the parent compound. 
Additionally, desorption of the parent compound from particulate matter might occur for 
weakly bound APIs. Moreover, Verlicchi et al. (2012) pointed out that the low 
concentrations some APIs are found at, may lead to instrumental errors, causing an 
apparent release of the investigated substance rather than an undetected removal.  
 
Diclofenac, like propranolol, has varied removal efficiencies from the three STPs, with an 
average removal of -1% (Ringsend STP) and -39% (Budds Farm STP). The removal 
efficiencies within each plant are varied; at Budds Farm STP, these are 20%, 27% and 
-165% and at Ringsend STP, they are 47%, 65% and -114%. Diclofenac is often quoted in 
the literature with having negative removal efficiencies (Lacey et al., 2012). Gómez et al. 
(2007) reported an average removal efficiency of 59% for diclofenac from an activated 
sludge plant. This is at the higher end of the reported removal efficiencies in the literature. 
The removal of diclofenac from an anaerobic/anoxic/aerobic activated sludge process 
combined with MBR treatment, was < 20% (Xue et al., 2010). Radjenović et al. (2009) 
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reported a removal efficiency of 22% from a CAS plant with a HRT of 11.5 h and a SRT 
of 10 d. A review by Verlicchi et al. (2012), into the occurrence of pharmaceuticals in 
urban wastewater treatment plants, summarised the reported literature removal efficiencies 
for a large number of APIs. Removal efficiencies for diclofenac ranged from 3 – 65%. 
These results indicate that diclofenac has a potential to be partially removed by sewage 
treatment, although its removal is less than caffeine and salicylic acid, and is not as 
consistent.  
 
The removal of carbamazepine in this study was 44% from Totnes STP, -33%, 3% and 
11% from Budds Farm STP (average -6%) and -69%, -4% and 17% from Ringsend STP 
(average -19%). These removal efficiencies are low, and although slightly more consistent 
than diclofenac, are still variable compared to those calculated for salicylic acid and 
caffeine. According to the review by Verlicchi et al. (2012) carbamazepine is reported to 
have removal efficiencies between -67 and 35%, these are similar to the removal 
efficiencies calculated in this study, and indicate the behaviour of carbamazepine in STPs 
is variable.  
 
6.6.4 Associations between wastewater parameters and API concentrations 
In order to investigate possible correlations between concentrations of APIs and plant 
process parameters, a Pearson’s correlation matrix was generated in Minitab 16. A number 
of correlations were determined. A positive association (r = 0.98, Figure 6.9(a)) was 
identified between caffeine and salicylic acid, because they are both significantly removed 
in the activated sludge tanks. Interestingly, the concentrations of propranolol and 
carbamazepine are also correlated, whilst no correlations are seen between carbamazepine 
and diclofenac, and diclofenac and propranolol. The reason for this correlation could be 
because propranolol and carbamazepine, like salicylic acid and caffeine behave in a similar 
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way during the sewage treatment process; however, they possess different physical and 
chemical properties.  
 
The positive relationships identified between the APIs; salicylic acid and caffeine, and 
NH4
+
-N, might be directly linked to NH4
+
-N removal by ammonium-oxidising bacteria. 
These bacteria might also cometabolically degrade salicylic acid and caffeine by the 
monooxygenase enzymes they produce. However, it is impossible to distinguish what 
mechanisms are causing this removal of salicylic acid and caffeine, except to say that 
oxygenated conditions favour the biodegradation of these APIs.   
 
The significant positive relationship between propranolol and TSS is particularly notable. 
The scatter plot in Figure 6.10 shows that at increasing TSS concentrations, a higher 
concentration of propranolol is detected. However, this positive relationship is strongly 
influenced by the highest cluster of data points. A one-way ANOVA test was carried out, 
to determine if there were any significant differences in API concentration, between the 
five types of sampled wastewater. A significant difference was identified for propranolol, 
and a Tukey’s post-hoc test, revealed concentrations were significantly higher in activated 
sludge samples. This significant difference was not detected for the other recalcitrant APIs: 
carbamazepine and diclofenac. These significantly higher concentrations in the activated 
sludge, might be because propranolol is accumulating within these systems, due to an 
affinity for the solids, which is seen in the SBR rig during 
14
C-propranolol dosing. 
Subsequent desorption or saturation of sorption sites, could then lead to the increase in 
propranolol concentrations in the secondary and final effluents. This might have 
implications for the treatment of waste sludge from STPs, and ultimately for the terrestrial 
environment. 
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The PCA loadings show there is a clear divide in the removal mechanisms, occurring 
between variables associated with the first and second PCs. The first PC suggests that 
removal by sorption to solids, and organic matter, could be an important mechanism for 
propranolol and carbamazepine removal, whereas PC2 shows that perhaps biodegradation 
is more important for the removal of salicylic acid and caffeine, because as they decrease, 
so does NH4
+
-N, whilst NO3
-
-N increases. There is a high correlation of diclofenac with 
PC3, which only explains 10.8% of the variation in the dataset, so this suggests the 
removal mechanism for diclofenac has not been captured by the data. Carbamazepine is 
significantly correlated to PC1-4, suggesting that there might be multiple removal 
mechanisms involved in its removal. 
 
To conclude, monitoring was carried out at three operational plants. Data was collected on 
the concentration of APIs throughout the aqueous wastewater stream. Salicylic acid and 
caffeine were detected at the highest concentrations in the influent; however, they had the 
highest removal efficiencies. Propranolol, carbamazepine and diclofenac were present at 
lower concentrations in the influent, and their removal efficiencies were low and variable. 
A significant positive association was identified between propranolol and the TSS, which 
supports the rig findings that propranolol, has an affinity to the solids. The behaviour of the 
APIs in full-scale plants, largely agrees with the findings from the laboratory rig 
monitoring, which will be discussed further in Chapter 7.  
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Chapter 7 General discussion 
 
The presence of APIs in the environment has become a global concern over recent years, 
due to their ubiquitous presence and pseudo-persistency. Furthermore, their bioactive 
nature has sparked concerns over possible negative effects on flora and fauna. Toxic 
effects on a range of species have been demonstrated in the laboratory at environmentally 
relevant concentrations. Pharmaceuticals have been reported in most types of aquatic 
environment, i.e. sewage, the sea, rivers, lakes, groundwater and even drinking water. The 
terrestrial environment is not free from contamination either due to sludge spreading from 
STPs and run-off from farms. It is crucial that we understand the fate of these compounds 
in the environment, in order to mitigate their impact. If these problems are not tackled 
soon, the growing global population, along with fast rates of development in countries such 
as China and Brazil, will only contribute to the contamination already seen in the 
environment. Therefore, compounds that were once detected at high ng l
-1
 to low μg l-1 
concentrations, might soon be approaching sub mg l
-1
 levels. 
 
The overall aim of this thesis was to investigate the fate, behaviour and removal of APIs in 
BNR sewage treatment. There has been little research conducted into the removal of APIs 
from BNR, furthermore, BNR does not feature in the fate aspect of the ERA for APIs, even 
though it is a widespread type of sewage treatment in the UK. This research set out to 
investigate the fate of APIs during BNR sewage treatment, to understand whether the 
processes involved in the removal of nutrients, could also offer superior removal of APIs. 
To this end, five APIs were selected for study. Literature reports indicated a range of 
recalcitrance for the selected compounds during sewage treatment, so any marked 
differences in their behaviour during this work, could be attributed to the SBR design, 
BNR or both.  
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Radiochemistry methods were developed for the analysis of four out of the five APIs in the 
laboratory, and LC-MS/MS and SPE methods were developed for the five APIs in full-
scale STPs. A SBR, capable of BNR, was built and operated in the laboratory in order to 
monitor the fate of the APIs under controlled conditions. The laboratory system enabled 
the dosing of radioactivity, so data could be collected on the distribution of the compounds 
throughout the system. This generated detailed data on the fate of the APIs, which cannot 
be obtained from monitoring full-scale plants alone. STP monitoring was conducted at 
three STPs, all of which employed different types of BNR activated sludge treatment. Grab 
samples were collected to gain data on wastewater constituents, API concentrations and 
removal efficiencies from systems similar to the laboratory STP rig. A comparison of the 
datasets allowed the laboratory system to be assessed for its ability to reproduce field 
conditions, and for behaviours in the rig to be investigated in full-scale plants.  
 
7.1 Comparison of rig to full-scale STPs 
7.1.1 Wastewater parameters  
The influent feed to the laboratory SBR was collected from Totnes STP, one of the STPs 
included in the full-scale monitoring work. Feeding the SBR with real wastewater, created 
conditions in the SBR that were more analogous to a full-scale plant. The SBR removed 
TSS, BOD and COD within the same ranges as the three full-scale plants. Budds Farm and 
Ringsend STPs performed slightly better than the SBR rig for removing these three 
parameters, and Totnes STP marginally outperformed the rig for removing COD and TSS, 
but not BOD. NH4
+
-N was equally well removed from the SBR and the full-scale plants, 
and all removal efficiencies were > 90%. Similar to operational plants, no removal of 
NO3
-
-N was achieved in the SBR rig, even Budds Farm STP, with its anoxic zones did not 
produce any net removal of NO3
-
-N. This is because NO3
-
-N is present at very low 
concentrations in the influent.  
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The SBR rig produced an average total-N removal that was lower than Budds Farm and 
Ringsend STPs, but higher than Totnes STP. Totnes STP is a NAS plant only; therefore the 
higher removal of total-N in the rig would be expected. The rig, however, did not perform 
as well as the SBRs at Ringsend STP, which like Totnes STP are also designed to nitrify 
only, however, the SBRs at Ringsend STP also seem capable of removing NO3
-
-N, due to 
the absence of any detectable increase in NO3
-
-N concentrations in the aeration tanks. 
Comparable to the three STPs, the SBR rig did not remove total-P to a high level; removal 
was similar to Totnes STP, but slightly lower. The removal of PO4
3-
-P displayed the same 
behaviour in the full-scale STPs and the SBR rig, as no treatment system produced any 
removal.  
 
Overall, the SBR rig operated under similar conditions to the full-scale plants, and with 
some degree of confidence, it can be suggested that the dosed pharmaceuticals would be 
subjected to comparable biological processes in the laboratory and field.  
 
7.1.2 API concentrations 
The pharmaceuticals dosed to the SBR were at the same concentrations as those reported in 
the literature; however, some concentrations dosed to the SBR are out of the range of those 
detected in this field monitoring study. The nominal concentrations in the influent of the 
SBR rig for each compound were as follows: 11.46 µg l
-1
 (salicylic acid), 7.77 µg l
-1
 
(caffeine), 8.74 µg l
-1
 (propranolol) and 6.95 µg l
-1
 (diclofenac). The concentrations of 
these compounds in the influent of the full-scale STPs ranged from: 6.3 – 57 µg l-1 
(salicylic acid), 20 – 162 µg l-1 (caffeine), 0.06 – 0.42 µg l-1 (propranolol) and 0.03 – 
5.1 µg l
-1
 (diclofenac). The concentrations of propranolol dosed in this study, are an order 
of magnitude higher than those detected in the STPs monitored in this work, which are at 
low μg l-1 levels. Diclofenac concentrations dosed to the SBR are at the higher end of 
concentrations reported in the full-scale plants. Whereas concentrations of salicylic acid 
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and caffeine, are lower than concentrations reported in the full-scale STPs in this study. 
However, significantly, the concentrations dosed to the SBR would be classed as 
environmentally relevant, unlike some of the concentrations used in ERA fate tests, which 
use mg l
-1
 levels. Furthermore, concentrations dosed in the laboratory needed to be above 
LOQs for the HPLC and LSC instruments. 
 
Primary effluent and activated sludge collected from Totnes STP were used to feed and 
inoculate the SBR. Therefore, this wastewater is likely to contain a whole host of 
chemicals, including the APIs in this study. This is important because, microorganisms can 
become acclimated to organic compounds, by widening their enzymatic capabilities in 
order to degrade ‘foreign’ chemicals. Furthermore, if the microorganisms are acclimated to 
the APIs, then they are less likely to be affected by any toxicological impact the APIs 
might cause.  
 
The concentrations of the APIs in the primary effluent at Totnes STP were < MQL for 
diclofenac and propranolol, 4.8 µg l
-1
 (salicylic acid) and 14 µg l
-1
 (caffeine). Propranolol 
and diclofenac concentrations were detected in the primary effluent, but concentrations 
could not be reported because they were < MQLs. Propranolol was > MQL in the activated 
sludge tanks. Both propranolol and diclofenac were dosed at much higher concentrations in 
the reactor. If the biomass within the SBR rig had been pre-exposed to higher propranolol 
and diclofenac concentrations then removal may have been improved. This has been 
suggested in an OECD modified 302B study carried out at Astrazeneca using propranolol. 
Activated sludge biomass was acclimated to propranolol, and was then dosed with 
14
C-
propranolol and 
14
CO2 production was measured. The percentage of applied radioactivity 
mineralised, was higher in the acclimated vessels, compared to non-acclimated biomass 
(AstraZeneca, 2012). 
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Salicylic acid and caffeine were present at higher concentrations than propranolol and 
diclofenac in the primary effluent, and due to the reduced concentrations of both in the 
activated sludge tanks, the microbial biomass at Totnes STP is clearly able to degrade 
these compounds. This might be because the biomass has been exposed to these 
compounds at high concentrations, or their chemical structures are more easily 
biodegraded than those of propranolol and diclofenac, which have more complex structures 
perhaps less familiar to microorganisms.    
 
7.1.3 API removal efficiencies 
The full-scale monitoring work showed that propranolol and diclofenac were poorly 
removed from all three STPs, and negative removal efficiencies were obtained at some 
sampling points (Table 7.1). The chemical dosed to the SBR rig was the parent compound 
only, whereas the influent to STPs is composed of the parent compound and a range of 
metabolites, including glucoronide conjugates. These conjugates can be cleaved during 
sewage treatment, releasing the parent compound. Therefore, the removal efficiencies will 
vary between STPs, depending on the concentration of the conjugates, and the presence of 
the deconjugating enzymes. In the SBR, no removal was obtained for diclofenac as little 
14
CO2 was recovered during batch and semi-continuous dosing (Table 7.1), and the 
majority of the effluent appeared to be composed of the parent compound. A slightly 
higher removal of propranolol was observed, as there was more mineralisation, and 
primary degradation was occurring (Table 7.1). There seems to be little difference in the 
removal efficiencies between propranolol and diclofenac in the full-scale STPs, both seem 
to be poorly removed, with no discernible concentration reduction for diclofenac, and an 
increase in concentrations of propranolol in the activated sludge tanks.  
 
Salicylic acid and caffeine both had considerable removals from the SBR, indicated by 
14
CO2 production during batch and semi-continuous conditions (Table 7.1). Furthermore, 
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there was no detectable parent compound remaining in the SBR effluent for either API 
during semi-continuous dosing. This sizeable removal rate for salicylic acid and caffeine is 
in agreement with the high removal efficiencies achieved in full-scale plants (> 90%).  
 
The removal of APIs in the SBR was similar to the removal from full-scale plants, but 
crucially the laboratory system had the added benefit of allowing the construction of mass 
balances, which the ‘black-box’ studies of full-scale plants cannot easily achieve. 
 
Table 7.1  Comparison of the removal data obtained from the laboratory batch and semi-
continuous studies (shown as % mineralised) and the three full-scale plants (shown as % removal 
of parent compound).   
API Batch (rig) 
Semi-
continuous 
(rig) 
Totnes STP 
Budds 
Farm 
STP 
Ringsend 
STP 
Salicylic acid 63 25 97  99 98 
Caffeine 83 15 99  99 98 
Propranolol 29 3.7 - 21 -6.8 
Diclofenac  3 0.2 - -39 -0.9 
Carbamazepine - - 44 -6 -19 
Batch and semi-continuous data represents the total compound mineralised (no replication). Totnes 
STP (n = 1) and Budds Farm and Ringsend STPs (n = 3). Carbamazepine was not dosed to the SBR 
rig. 
 
Although the removal end-points measured in the laboratory rig and full-scale plants differ, 
Table 7.1 shows that the trends in removal are similar. For example salicylic acid and 
caffeine have the highest removal efficiencies in the SBR and the full-scale plants out of 
all the compounds, followed by propranolol, which is considerably less removed than the 
former two compounds, and then the lowest removals are seen for diclofenac, which are 
negligible and there is no removal of the API from the full-scale plants.  
 
7.2 API removal mechanisms 
Based on the mass balance data from the SBR rig, the main removal mechanisms for each 
API can be determined. In terms of salicylic acid and caffeine, this appears mainly to be 
biodegradation, due to the substantial level of mineralisation produced under batch and 
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semi-continuous dosing conditions. Furthermore, in the full-scale plants significant 
removal occurs for salicylic acid and caffeine during activated sludge processes, however, 
it is not known what these removal mechanisms were. Based on the literature and data 
collected from the laboratory SBR, sorption appears to be an important removal 
mechanism for salicylic acid and/or its transformation products. Sorption does not seem to 
be as important for caffeine in the SBR or in literature reports.  
 
The main removal mechanism for propranolol from the SBR seems to be sorption to the 
activated sludge biomass, although a small amount of biodegradation was occurring in the 
SBR during batch and semi-continuous dosing. In the full-scale plants, little removal was 
observed for propranolol, with effluent concentrations similar to influent concentrations, if 
not slightly higher. The full-scale monitoring data, demonstrates a positive correlation 
between propranolol and concentrations of TSS. The increase in propranolol 
concentrations in the activated sludge tanks in all three STPs shows that propranolol might 
be accumulating in these systems, which supports the findings from the laboratory SBR.  
 
Diclofenac does not appear to be removed by sorption or biodegradation in the laboratory 
SBR, with little mineralisation recorded during batch or semi-continuous conditions. 
Additionally, there was little indication from the SBR rig that diclofenac sorbed to the 
biomass. In the full-scale plants two sampling points at each STP showed positive removal 
efficiencies for diclofenac, with a removal efficiency of 65% on one occasion from 
Ringsend STP. However, there was one particularly low removal efficiency at Budds Farm 
and Ringsend STPs, with effluent concentrations more than double the influent 
concentration. Therefore, when the average removal efficiencies were calculated they are 
low at -39 and -1% for Budds Farm and Ringsend STPs, respectively.   
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7.3 Importance of BNR for removing APIs 
An important finding in this work was that the anaerobic/anoxic zone within the laboratory 
SBR did not seem any more adept at achieving improved removals of the two recalcitrant 
APIs; propranolol and diclofenac. Removal of propranolol and diclofenac by 
biodegradation processes was inadequate, and not substantially improved. Similarly, the 
monitoring of full-scale BNR plants, did not show any great improvement in the removal 
of the persistent APIs: propranolol, diclofenac and carbamazepine. This is supported by 
other studies that have investigated the fate of pharmaceuticals in BNR plants (Gabet-
Giraud et al., 2010; Lacey et al., 2012; Rosal et al., 2010). There are some suggestions that 
anaerobic/anoxic conditions might increase the degradation of pollutants, due to the 
different degradation pathways microorganisms may be capable of employing under these 
conditions. However, oxygenated conditions seem to be most important for the degradation 
of APIs.  
 
An important plant operating condition for the removal of APIs, is the length of time the 
pollutant spends in the aerobic tank. This must be sufficiently long to achieve the 
maximum contact time between pollutant and microbial biomass. Xue et al. (2010) 
suggested that a HRT of 5 h in an aerobic tank, should be sufficient for the elimination of 
most biodegradable target compounds. Furthermore, nitrification is a key aerobic process 
that can improve the degradation of APIs; hence the SRT needs to be reasonably long to 
allow nitrifiers to grow. The HRT and SRT are important operational parameters that effect 
the removal of APIs, therefore CAS plants that typically have short HRT and SRTs, would 
not be as efficient at removing APIs; however, a nitrifying plant with a sufficiently long 
HRT and SRT is likely to perform as well as a BNR plant that biologically removes 
PO4
3-
-P and NO3
-
-N. Nevertheless, BNR plants are essential systems for the removal of 
nutrients detrimental to the environment. Therefore, as long as the aerobic zones within 
these plants have suitably long retention times, then BNR treatment should always be 
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preferential over CAS plants, but not necessarily nitrifying plants that might grant longer 
HRTs in the aerobic tank. The HRT rather than the SRT is likely to have the greatest effect 
on the removal of APIs, as the latter can sometimes have a negative impact on removal.  
 
The anaerobic/anoxic zones might not have a positive effect on biodegradation rates, but 
sorption may be improved under these conditions. Anaerobic activated sludge might have 
different sorption properties to aerobic activated sludge. There have been some reports in 
the literature that suggest this (Drillia et al., 2005). The sorption of propranolol and 
salicylic acid in the SBR was quite significant, and it showed that propranolol, in 
particular, was accumulating in the system. The SBR configuration might influence the 
amount of propranolol sorbed to the biomass, because sludge wastage rates from SBRs are 
lower than from CAS systems. Therefore, the sludge is retained in the reactor for a longer 
period of time and equilibration between the API and the activated sludge can be reached. 
If the anaerobic/anoxic conditions are generating biomass that is more favourable for the 
sorption of APIs, this in combination with the SBR sludge wastage rates, could be 
producing sludge heavily contaminated with organic compounds. This sludge may require 
different treatment as it could pose a greater risk to the terrestrial environment. 
 
7.4 ERA and BNR 
The ERA fate tests, in particular the biodegradation tests, are key to estimating the 
environmental exposure, as a result of consumer use, of pharmaceuticals, and their 
subsequent release into the environment through STPs. As the STP is the entry point into 
the environment, it is important to characterise those mechanisms which contribute 
significantly to the removal of APIs during sewage treatment, and potentially have the 
greatest impact for reducing concentrations prior to entry of treated effluents into surface 
water (Ericson, 2010). While the extent of environmental testing required for 
pharmaceutical registration in EU countries has increased in recent times, the development 
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of new biodegradation methods to support these assessments have lagged behind (Ericson, 
2010). 
 
The current ERA guidelines for APIs do not include a sewage simulation in the suite of 
fate tests employed. However, such a simulation is used for other regulated organic 
pollutants. The OECD sewage simulation in use is based on a CAS design, with no anoxic 
or anaerobic zones, and no requirements for nitrification (OECD, 2001). Whilst BNR has 
been shown to have little benefit on the biodegradation of the APIs studied here, it is 
important that ERAs should include test conditions that are similar to those the APIs face 
in the environment. APIs have such a broad range of physical and chemical properties that 
some APIs might be more affected by BNR than others, for example removal of estrogens 
has been shown to occur under anoxic and anaerobic conditions (Joss et al., 2004). 
Furthermore, as already mentioned, BNR activated sludge might possess properties that 
favour the sorption of APIs, compared to aerobic CAS systems.  
 
Therefore more realistic fate tests are needed in the ERA procedure for pharmaceuticals. 
Currently the OECD 301 ready test is the one prescribed to determine removal from STPs. 
It is a stringent test that is useful as a screen for chemicals, to determine whether they 
would readily degrade in the sewage treatment process, however, more often than not 
pharmaceuticals do not meet the criteria for ready biodegradation (Ericson, 2010). 
Therefore research effort should focus on a suite of pharmaceuticals with low to mid- 
removal efficiencies from full-scale STPs, and assess their removal from a range of STPs, 
including those employing CAS, nitrification, nitrification and denitrification and 
nitrification, denitrification and bio-P removal. If higher removal is observed in the BNR 
systems then extensive laboratory experiments replicating these systems can be 
undertaken. Furthermore, data needs to be obtained on the use of BNR in the UK, in order 
to determine exactly how widespread B R is for treating the   ’s wastewater. 
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7.5 Outcomes and applications 
What this research clearly shows is that biological treatment does not fully remove 
pharmaceuticals, even from the most advanced types of biological treatment such as BNR. 
Biological sewage treatment is a good pre-treatment for the removal of easily degraded or 
highly sorbed APIs; however, additional treatment is required if complete removal of these 
pollutants is desired.  
 
There has been a slow move towards the regulation of APIs in the environment. The 
European Commission is required to review the WFD list of PSs every four years, and as a 
result, pharmaceuticals were proposed for inclusion on the list, however, their inclusion 
was rejected, but they have been placed on a ‘watch list’. A UK wide study conducted by 
the Chemical Investigation Programme, investigated the presence of 70 hazardous 
chemicals in STP effluents (Gardner et al., 2012). It was discovered that a number of APIs 
exceeded the existing or proposed EQS in over 50% of STPs monitored. Propranolol and 
diclofenac were two of these APIs, which have been prioritised for further consideration. 
Gardner et al. (2012) concluded, that additional management options have to be considered 
in the cases where there is insufficient dilution to reduce concentrations below the EQS. 
Their proposed measures include source control, substance substitution, tertiary/advanced 
treatment, and the optimisation of existing processes.  
 
For persistent APIs, the only viable option, to reduce concentrations entering surface 
water, is advanced treatment, and to a lesser extent the optimisation of existing processes. 
The optimisation of existing sewage treatment processes is unlikely to greatly affect the 
removal of persistent APIs like propranolol, diclofenac and carbamazepine. Therefore, 
decisions need to be made on whether STPs discharging APIs above the EQS level, pose 
enough risk for decisive action to be taken. This could involve the installation of advanced 
technologies capable of removing these recalcitrant APIs. However, these treatments are 
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expensive, are often logistically impractical and can be damaging to the environment in 
their own ways. Research should focus on which advanced treatments are most capable of 
removing a set of ‘problem pollutants’ whilst also having the smallest environmental 
impact. Advanced treatments may only be necessary at STPs with large industrial 
contributions and little dilution. Carbamazpeine has been identified as one of the most 
recalcitrant APIs during biological sewage treatment (Behera et al., 2011; Jelic et al., 
2011). However, Table 7.2 shows carbamazepine can be removed from wastewater, by 
advanced wastewater treatment processes. However, advanced treatments such as ozone do 
not remove all APIs to the same high efficiency. Ibuprofen for example, has a low removal 
by ozone (Monteiro and Boxall, 2010). A trade-off needs to take place between API 
removal and the economical cost and environmental impact of the wastewater treatment. 
 
Table 7.2  Removal of carbamazpeine from advanced wastewater treatment technologies 
(Monteiro and Boxall, 2010). 
Advanced processes Removal efficiency (%) 
Chlorine (1.2 mg l
-1
 free chlorine) 0 
Activated carbon: 5 mg l
-1
 74 
Activated carbon: 12 mg l
-1
 99 
Ozone: low dose (0.2 – 0.3 mg l-1) 99 
Ozone: medium dose (1 – 5 mg l-1) > 98 – 100  
Ozone: high dose (> 5 – 7.1 mg l-1) > 99 
Ozone/H2O2: low (2.1/1.0 mg l
-1
) 98 
Ozone/H2O2: medium (3.6/2.5 mg l
-1
) > 99 
Ozone/H2O2: high (≥ 7.1/3.5 mg l
-1
) > 99 
 
7.6 Future work 
As a result of time and cost restraints there are experiments that could not be conducted in 
this research. However, the following section considers the future work that will build on 
the data already collected in this thesis: 
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 The fate of radiolabelled carbamazepine should be investigated in the SBR, in order 
to expand the data collected in the full-scale plants, which highlighted the low 
removal efficiency of this compound. 
 
 To gain a better understanding of how BNR operating conditions affect API 
removal, a number of variables could be manipulated in the SBR, such as extending 
the SBR cycle and altering the length and order of the react phases. This extended 
dataset could be inputted into a suitable model to enable the optimisation of the rig 
for removing APIs. This model could be taken forward as a test system for 
inclusion in regulatory environmental fate assessments of pharmaceuticals. 
 
 Conduct a more detailed sampling regime at full-scale STPs. More samples should 
be collected and a larger number of wastewater parameters measured, in order to 
improve the PCA, and discover more specifically what mechanisms are affecting 
API removal. 
 
 To investigate the sorption of propranolol to activated sludge, in more detail in 
laboratory batch tests and operational plants. A sludge extraction method should be 
developed to distinguish between the extractable and non-extractable residues. This 
method could then be applied to field samples in order to generate Kd values. 
 
 There has been little research into the influence of biological treatment 
configuration on the sorption of APIs to sludge. To investigate this, the sorption of 
propranolol, as well as other APIs possessing high Kd values, could be analysed in 
the solid fraction of different operational plants.   
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 Investigations into the community structure of the SBR microbial population would 
add support to the chemical analyses of wastewater constituents. DGGE could be 
employed in conjunction with sequencing techniques, to identify some of the 
dominant microbial populations in the SBR. These techniques could then be 
applied to full-scale STPs to determine how comparable the microbial populations 
are at laboratory and full-scale levels. 
 
7.7 Conclusions  
The behaviour, fate and removal of five APIs in a laboratory BNR rig, and in three full-
scale BNR plants was investigated. The APIs in this research were chosen because they 
were highly consumed in the UK and possessed a 
14
C radioisotope. The APIs came from 
four therapeutic classes and possessed different physical and chemical properties. In order 
to quantify these APIs in sewage matrices, a robust LC-MS/MS method was developed and 
validated for quantifying five APIs in full-scale STPs, and a radio-HPLC method was 
developed for analysing four 
14
C labelled APIs in the laboratory. 
 
A SBR rig was developed and operated in the laboratory, and achieved high removals of 
wastewater parameters including: TSS, COD and NH4
+
-N. The SBR generated detailed 
fate data, not easily obtained from full-scale monitoring. It showed that different 
mechanisms were responsible for API removal in the rig.  
 
Three full-scale STPs were selected, based on their differing BNR treatment configurations 
and population equivalents, in order to investigate further, the behaviours observed in the 
laboratory rig. Comparable wastewater constituent removal was achieved in the laboratory 
and full-scale systems, furthermore the behaviour of APIs in the laboratory and field were 
similar. Salicylic acid and caffeine were well removed, whilst propranolol and diclofenac 
were more recalcitrant. Carbamazepine was found to be ubiquitous and persistent in the 
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operational plants, therefore future work requires a detailed investigation of its fate in the 
laboratory rig. The rig revealed removal by sorptive processes, appear to be important for 
salicylic acid and propranolol, the extent to which might be affected by the biological 
treatment configuration, i.e. SBR, MBR. The sorptive behaviour of propranolol was 
observed in the full-scale plants, because aqueous concentrations were significantly higher 
in the activated sludge tanks compared with other sample locations. This indicates that 
some retention of the compound was occurring in the tanks containing the high suspended 
solid concentrations. 
 
Anoxic and anaerobic zones in BNR plants, do not appear to improve the removal of 
recalcitrant APIs, any more than aerobic nitrifying tanks. However, BNR is preferential to 
CAS systems for API removal. Further research needs to focus on the ERA process for 
pharmaceuticals, and assess whether the fate assessments accurately reflect the conditions 
APIs experience in the ‘real-world’. 
 
This research showed biological wastewater treatment is inefficient at removing 
recalcitrant APIs. Instead, if complete removal of these compounds is desired in full-scale 
STPs, advanced wastewater treatment needs to be considered. 
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Appendix 
 
Appendix A 
Composition of mineral salts: 
Solution A 
Potassium dihydrogen phosphate (KH2PO4) 8.50 g 
Dipotassium hydrogen phosphate (K2HPO4) 21.75 g 
Disodium hydrogen phosphate dihydrate (Na2HPO4.2H2O) 33.40 g 
Ammonium chloride (NH4Cl) 0.50 g 
Dissolve in water and make up to 1 l. The pH of this solution should be 7.4 (± 0.2).  
 
Solution B 
Calcium chloride dihydrate (CaCl2.2H2O) 36.40 g 
Dissolve in water and make up to 1 l. 
 
Solution C 
Magnesium sulphate heptahydrate (MgSO4.7H2O) 22.50 g 
Dissolve in water and make up to 1 l. 
 
Solution D 
Iron (III) chloride hexahydrate (FeCl3.6H20) 0.25 g 
Add 1 drop of concentrated HCl acid. 
Dissolve in water and make up to 1 l. 
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Appendix B 
 
Summary of literature studies investigating the fate of pharmaceuticals during wastewater 
treatment: 
 
APIs in full-scale STPs 
APIs in laboratory 
BNR STP simulations 
Radiolabelled APIs in 
laboratory STP 
simulations 
Radiolabelled APIs in 
laboratory BNR STP 
simulations 
(Batt et al., 2007; Behera 
et al., 2011; Carballa et 
al., 2005b; Carballa et al., 
2004; Castiglioni et al., 
2006; Comeau et al., 
2008; Drewes et al., 
2002; Gabet-Giraud et 
al., 2010; Gao et al., 
2012; Gardner et al., 
2012; Ghosh et al., 2010; 
Gros et al., 2010; Gómez 
et al., 2007; Hedgespeth 
et al., 2012; Jelic et al., 
2012; Jelic et al., 2011; 
Jia et al., 2012; Jones et 
al., 2007; Joss et al., 
2005; Kanda et al., 2003; 
Kasprzyk-Hordern et al., 
2009; Kosma et al., 2010; 
Lajeunesse et al., 2012; 
Langford and Thomas, 
2009; Lin et al., 2009; 
Lindqvist et al., 2005; 
Lishman et al., 2006; 
Lubliner et al., 2010; 
Martín et al., (2011); 
Martín et al., 2012; 
Martínez Bueno et al., 
2012; Maurer et al., 
2007; Nakada et al., 
2006; Okuda et al., 2008; 
Paxeus,  004; Radjenović 
et al., 2009; Roberts and 
Thomas, 2006; Rosal et 
al., 2010; Santos et al., 
2009; Scheurer et al., 
2010; Sim et al., 2010; 
Spongberg and Witter, 
2008; Strenn et al., 2004; 
Stumpf et al., 1999; 
Stülten et al., 2008; Sui et 
al., 2011; Sui et al., 2010; 
Tarcomnicu et al., 2011; 
Tauxe-Wuersch et al., 
2005; Ternes, 1998; 
Terzić et al., 2008; 
Thomas and Foster, 2005; 
Van De Steene et al., 
2010; Vieno et al., 2007; 
Xue et al., 2010; Ying et 
al., 2009; Zhou et al., 
2009; Zorita et al., 2009) 
(Clara et al., 2005b; 
Kosjek et al., 2007; 
Lesjean et al., 2004; 
Serrano et al., 2011; 
Suarez et al., 2010; 
Suarez et al., 2005; 
Zwiener and Frimmel, 
2003) 
(Bouju et al., 2011; Cirja et 
al., 2007; Junker et al., 
2006) 
This study. 
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Appendix C 
 
Mass balance table for the distribution of radioactivity during dosing with 
14
C-salicylic acid, figures are reported in Bq (n = 3): 
 
SBR cycle Applied radioactivity  
Gas/ 
mineralisation 
Effluent WAS: solids 
WAS: 
aqueous 
Reactor: solids 
Reactor: 
aqueous 
Remaining in vessel 
1 103673 14102 25185 2336 2381 46723 47620 59669 
2 103673 18061 31950         113331 
3 103673 18061 31950         166993 
4 103673 23993 38715 6679 3860 133587 77200 197419 
5 103673 30170 34695         236227 
6 103673 30170 34695         275035 
7 103673 31027 30675 12271 3129 245413 62580 301607 
8 103673 34443 29423         341414 
9 103673 34443 29423         381221 
10 103673 32591 28170 14790 3192 295807 63840 406151 
11 103673 24704 30990         454130 
12 103673 24704 30990         502109 
13 103673 22760 33810 15636 3924 312718 78480 529651 
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Mass balance table for the distribution of radioactivity during dosing with 
14
C-caffeine, figures are reported in Bq (n = 3): 
SBR cycle Applied radioactivity  
Gas/ 
mineralisation 
Effluent WAS: solids 
WAS: 
aqueous 
Reactor: solids 
Reactor: 
aqueous 
Remaining in vessel 
1 45928 8794 4995 857 428 17148 8560 30854 
2 45928 4421 14355         58006 
3 45928 4421 14355         85159 
4 45928 10682 23715 2797 2253 55938 45060 91640 
5 45928 2327 23408         111834 
6 45928 2327 23408         132028 
7 45928 4462 23100 1272 2252 25444 45040 146870 
8 45928 7292 25065         160441 
9 45928 7292 25065         174012 
10 45928 8167 27030 1547 2673 30947 53460 180524 
11 45928 8605 26310         191537 
12 45928 8605 26310         202550 
13 45928 9447 25590 2183 2588 43662 51760 208670 
 
 
 
 
 254 
 
Mass balance table for the distribution of radioactivity during dosing with 
14
C-propranolol, figures are reported in Bq (n = 3): 
SBR cycle Applied radioactivity  
Gas/ 
mineralisation 
Effluent WAS: solids 
WAS: 
aqueous 
Reactor: solids 
Reactor: 
aqueous 
Remaining in vessel 
1 32207 146 3690 1078 354 21566 7080 26939 
2 32207 851 7566         50729 
3 32207 851 10346         71740 
4 32207 595 12675 3625 1214 72492 24280 85839 
5 32207 1343 13930         102773 
6 32207 1343 14919         118718 
7 32207 1479 15105 4970 1427 99402 28540 127944 
8 32207 1510 15969         142673 
9 32207 1510 16155         157216 
10 32207 1599 16635 6182 1599 123634 31980 163408 
11 32207 1481 16772         177363 
12 32207 1481 17452         190637 
13 32207 1377 18345 7072 1776 141439 35520 194275 
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Mass balance table for the distribution of radioactivity during dosing with 
14
C-diclofenac, figures are reported in Bq (n = 3): 
 
 
 
SBR cycle Applied radioactivity  
Gas/ 
mineralisation 
Effluent WAS: solids 
WAS: 
aqueous 
Reactor: solids 
Reactor: 
aqueous 
Remaining in vessel 
1 35719 47 22395 1191 2162 23812 43240 9925 
2 35719 39 26363         19243 
3 35719 39 26363         28561 
4 35719 43 30330 1251 2933 25019 58660 29723 
5 35719 65 30015         35363 
6 35719 65 30015         41003 
7 35719 67 29700 1173 2933 23457 58660 42849 
8 35719 47 29963         48559 
9 35719 47 29963         54268 
10 35719 57 30225 1504 2970 30081 59400 55232 
11 35719 83 38325         52543 
12 35719 83 38325         49854 
13 35719 113 46425 1310 4530 26205 90600 33195 
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Appendix D 
Method 1 – Preparation of wastewater samples prior to analysis by LC-MS/MS 
1. Wastewater aliquots (100 ml) were spiked with IS (100 ng) 
2. Samples were filtered through 0.7 µm GF/F Whatman filter papers 
3. Samples were then acidified to pH 2 with formic acid 
4. Samples were extracted by SPE using Oasis MCX (6cc 150 mg) SPE cartridges as 
follows:  
 Cartridges were conditioned with MeOH (6 ml) followed by ROW (6 ml) 
 The samples were then passed through cartridges at a flow rate of 
5 ml min
-1
 
 The cartridges were washed with ROW – formic acid (98:2, v/v) (5 ml) 
 The cartridges were allowed to vacuum dry 
 Analytes were eluted with MeOH (2 x 3 ml) followed by MeOH – ACN 
(94:6, v/v) (2 x 3 ml)  
5. The extracts were evaporated to dryness at 40ºC under a gentle stream of N2. 
6. The dried extracts were then reconstituted with H2O – MeOH (80:20, v/v) (1 ml) 
7. The reconstituted extracts were filtered through Chromacol 17 mm RC syringe 
filters (0.45 µm) into amber HPLC vials. 
 
Method 2 – Preparation of wastewater samples (from the rig) prior to analysis by radio-
HPLC 
1. Wastewater aliquots (100 ml) were filtered through 0.7 µm GF/F Whatman filter 
papers 
2. Samples were extracted by SPE using Oasis MCX (6cc 150 mg) SPE cartridges as 
follows:  
 Cartridges were conditioned with MeOH (6 ml) followed by ROW (6 ml) 
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 The acidified samples were then passed through cartridges at a flow rate of 
5 ml min
-1
 
 The cartridges were washed with ROW – formic acid (98:2, v/v) (5 ml) 
 The cartridges were allowed to vacuum dry 
 Analytes were eluted with MeOH (2 x 3 ml) followed by MeOH – ACN 
(94:6, v/v) (2 x 3 ml)  
3. The extracts were evaporated to dryness at 40ºC under a gentle stream of N2. 
4. The samples were reconstituted in the HPLC mobile phase starting gradient 
solvents (mobile phase A – mobile phase B) (95:5, v/v) (1 ml). 
 
Method 3 – The LC-MS/MS method used to analyse wastewater samples from the 
operational plants 
 
The liquid chromatography conditions employed for analysis of APIs in positive and 
negative ionisation mode: 
 
Method parameter Negative Positive 
Column Agilent Zorbax SB-C18 
column (3.0 mm x 50 mm, 
particle size 1.8 µm) 
Agilent Zorbax SB-C18 
column (3.0 mm x 50 mm, 
particle size 1.8 µm) 
Mobile phase composition A: HPLC water and 0.05% 
acetic acid. 
B: MeOH and 0.05% acetic 
acid 
A: HPLC water and 0.1% 
formic acid  
B: ACN and 0.1% formic 
acid. 
Mobile phase gradient 0 min 90% A 10% B 
10 min 0% A 100% B 
16.5 min 0% A 100% B 
16.7 min 90% A 10% B 
0 min 95% A 5% B 
15 min 0% A 100% B 
16 min 0% A 100% B 
16.5 min 95% A 5% B 
Flow rate (ml min
-1
) 0.2 0.3 
Injection volume (µl) 3 3 
Column temperature (ºC) 15 15 
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Mass spectrometry conditions optimised for the five analytes and ISs: 
Compound name MRM 1 CE (V) MRM 2 CE (V) 
Fragmentor 
voltage (V) 
ESI (+) 
Caffeine 195.2 > 138 16 195.2 > 110.1 20 125 
Carbamazepine 237.3 > 194.1 16 237.3 > 179 36 130 
Propranolol 260.2 > 116.1 12 - - 120 
Caffeine-
13
C3 198.2 > 140 16 - - 130 
Carbamazepine- d10 247.3 > 204.1 20 - - 140 
Propranolol-d7 267 > 116.5 12 - - 125 
ESI (-) 
Salicylic acid 137.1 > 93.2 16 137.1 > 65.2 36 100 
Diclofenac 294 > 250 8 294 > 214 20 86 
Salicylic acid- d6 141 > 97.1 16 - - 70 
Diclofenac-d4 298 > 254 8 - - 81 
 
 Drying gas temperature (350ºC) and flow (10 l min-1)  
 Nebulizer pressure (275.8 kPa)  
 Capillary voltage (4000 V) 
 Collision gas (N2).  
 
Method 4 – The radio-HPLC method used to analyse the four 14C labelled APIs in the rig 
 
 Sample analysis was performed on an Agilent HPLC 1200 series connected to a 
Mirastar radio-detector 
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The liquid chromatography conditions employed for radio-HPLC analysis of the four 
14
C 
labelled APIs: 
Method parameter Negative 
Column C18 Gemini-NX column (50 x 3.0 mm; particle 
size 3 µm) 
Mobile phase composition Mobile phase A consisted of H2O containing 
0.1% acetic acid and 100 mM CH3COONH4. 
Mobile phase B consisted of MeOH – ACN 
(60:40, v/v) 
Mobile phase gradient 0.00 min 95% A 5% B 
2.00 min 95% A 5% B 
11.00 min 0% A 100% B 
13.00 min 0% A 100% B 
13.10 min 95% A 5% B 
17.00 min 95% A 5% B 
Flow rate (ml min
-1
) 0.25 
Injection volume (µl) 100 
Column temperature (ºC) 40 
UV wavelength (nm) 280 
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Appendix E 
 
The 24 APIs generated after applying two selection criteria: (1) consumption figures and (2) availability of a 
14
C isotope. 
Therapeutic 
class 
Compound 
Prescription 
items (2007) 
Amount 
consumed in 
2004 (t) 
Molecular 
weight 
(g mol
-1
)
v
 
Water 
solubility 
(mg l
-1
 at 25°C) 
(WSKOW 
estimate)
w
 
pKa 
(literature) 
Log Kow 
(KOWWIN 
estimate)
w
 
STP removal 
(%) 
Analgesic 
Acetaminophen 16,287,400 3,535 151.2 30,350.0 9.4
a 
9.9
f
 0.3 
96
f 
92
g 
~100
h 
99.9 ± 0.1
j 
> 
99
l
 
Acetylsalicylic 
acid 
30,764,600 178 180.2 5,295.0 3.5
p
 1.1 81
d
 > 98
h
 
Codeine 
phosphate 
2,754,300 42 397.4 49,880.0 8.2
p
 1.3 42
h
 
Diclofenac 
sodium 
8,851,700 35 296.2 4.5 4.1
a 
4.2
e 
4.0
m
 4.0 
75
b 
69
d 
0
h 
< 
10
i 
21.8 ± 
28.5
j 
18
l
 
Hydrocortisone 7,546,200 - 362.5 219.6 12.6
s
 1.6  
Ibuprofen 5,885,500 330 206.3 41.1 
4.9
a 
4.9
e 
4.4
f 
4.5
m
 
3.8 
75
b 
55
c 
90
d 
96
f 
86
g 
> 95
i 
99.1 
± 1.8
j 
87
l
 
Morphine 1,664,500 - 285.3 26,420.0 8.0
u
 0.7  
Naproxen 1,311,200 34 230.3 144.9 4.2
e 
4.2
m
 3.1 
78
b 
66
d 
> 74
h 
40-60
i 
71.8 ± 
14.3
j 
88
l
 
Antibiotic 
Chloramphenicol 1,990,500 - 323.1 388.5  0.9 90
h
 
Erythromycin 3,763,700 49 733.9 0.5 8.8
a 
8.8
o
 2.5 
0
c 
> 50
h 
35.4 ± 
50.5
j
 
Metronidazole 1,960,300 - 171.2 25,730.0 2.6
q
 0 23
h
 
Antidepressant Fluoxetine 5,045,700 - 309.3 38.4  4.7 33.1 ± 28.9
j
 
Antidiabetic 
Metformin 
hydrochloride 
10,868,600 497 129.2 1,000,000.0 12.4
s
 -2.6  
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Rosiglitazone 1,173,900  357.4     
Antiepileptic 
Carbamazepine 2,373,800 52 236.3 17.7 
13.9
a 
13.9
f 
13.9
o
 
2.3 
0
c 
7
d 
< 0.1 
f
0
h 
< 10
i 
< 10
j 
< 1
k
 
Valproic acid 304,900 73 144.2 894.6 4.6
s
 3.0 > 99
l
 
Antiseptic Chlorhexidine 759,800 23 505.5 0.1 10.8
r
 4.9  
Beta-blocker Propranolol 2,621,400 - 259.3 228.0 9.5
n
 2.6 96
d
 
Bronchiolytic Theophylline 511,700 13 180.2 2,912.0  -0.4  
Keratolytic agent Salicylic acid 307,600 37 138.1 3,808.0 3.0
m 
3.5
n
 2.2  
Sex hormone Estradiol 1,138,800 - 272.4 82.0 
17α: 10.5r, 
17β: 10.7r 
3.9  
Stimulant 
Caffeine - 17 194.2 2,632.0 14.0
q 
10.4
o
 0.2  
Nicotine 5,917,000 - 162.2 1,000,000.0 
pKa1: 8.0 & 
pKa2: 3.1
t
 
1.0  
Tranquillizer Diazepam 4,722,500 - 284.7 58.8  2.7  
a 
Wu et al. (2008)    
u
 Morgan and Johnson (2000) 
b
 Stumpf et al. (1999)    
v
 NCBI (n.d.) 
c
 Castiglioni et al. (2006) (median values)  
w
 EPA (2009a) 
d
 Ternes (1998) 
e 
Urase and Kikuta (2005) 
f
 Yamamoto et al. (2009) (log Dow at pH 7) 
g
 Jones et al. (2007) (mean) 
h
 Kasprzyk-Hordern et al. (2009) 
i
 Gagnon and Lajeunesse (2008) 
j
 Radjenović et al. (2009) 
k
 Heidler and Halden (2008) 
l
 Yu et al. (2006) 
m
 Marchese et al. (2003) 
n
 Lacey et al. (2008) 
o
 Viglino et al. (2008) 
p
 Watson (2005) 
q
 Wall et al. (2007) 
r
 Brittain (2007) 
s
 DrugBank (2005) 
t
 Yang and Smetena (1995) 
